var title_f2_41_2704="Osteochondritis dissecans of the elbow";
var content_f2_41_2704=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F85769&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F85769&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Osteochondritis dissecans of the elbow",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 227px; height: 427px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Frontal radiograph demonstrates lucency with surrounding sclerosis (black arrow) in the capitellum in keeping with grade 4 osteochondritis dissecans (OCD).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Kotnis NA, Chiavaras MM, Harish S. Lateral epicondylitis and beyond: imaging of lateral elbow pain with clinical-radiologic correlation. Skeletal Radiol 2012; 41:369; with kind permission from Springer Science + Business Media B.V. Copyright &copy; 2012.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_41_2704=[""].join("\n");
var outline_f2_41_2704=null;
var title_f2_41_2705="Corns PI";
var content_f2_41_2705=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F83520&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F83520&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 535px\">",
"   <div class=\"ttl\">",
"    Corns",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 515px; height: 197px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Corns can appear on the feet when something repeatedly rubs or presses on the skin, such as shoes that don't fit well.",
"    <br>",
"     Picture A (on&nbsp;the left) shows a corn on the outside of the fifth (pinky) toe.",
"     <br>",
"      Picture B (on the right) shows a corn on the bottom of the foot.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_41_2705=[""].join("\n");
var outline_f2_41_2705=null;
var title_f2_41_2706="Calculator: Ideal body weight (method of Devine) and dosing weight for adults";
var content_f2_41_2706=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"IBW_Devine_form\" name=\"IBW_Devine_form\" onkeydown=\"clrResults();\" onkeypress=\"return validNumberField(event);\" onkeyup=\"IBW_Devine_fx();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: Ideal body weight (method of Devine) and dosing weight for adults",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_main\">",
"     <center>",
"      <span class=\"medCalcFontIO\">",
"       Input:",
"      </span>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"      <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"       <tr>",
"        <td align=\"right\">",
"         <span class=\"medCalcFontOneBold\">",
"          Sex",
"         </span>",
"        </td>",
"        <td align=\"right\">",
"         <span class=\"medCalcFontCCTab\">",
"          Female",
"         </span>",
"        </td>",
"        <td align=\"left\">",
"         <input checked=\"checked\" name=\"Sex_radio\" onclick=\"IBW_Sex = 45.5; IBW_Devine_fx();\" type=\"radio\" value=\"Female\"/>",
"        </td>",
"       </tr>",
"       <tr>",
"        <td>",
"         &nbsp;",
"        </td>",
"        <td align=\"right\">",
"         <span class=\"medCalcFontCCTab\">",
"          Male",
"         </span>",
"        </td>",
"        <td align=\"left\">",
"         <input name=\"Sex_radio\" onclick=\"IBW_Sex = 50; IBW_Devine_fx();\" type=\"radio\" value=\"Male\"/>",
"        </td>",
"       </tr>",
"       <tr>",
"        <td align=\"right\" width=\"42%\">",
"         <span class=\"medCalcFontOneBold\">",
"          Height",
"         </span>",
"        </td>",
"        <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"         &nbsp;",
"         <input name=\"Height_param\" onblur=\"IBW_Devine_fx(); minMaxCheck();\" onchange=\"IBW_Devine_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"        </td>",
"        <td align=\"left\" valign=\"top\">",
"         <select class=\"medCalcFontSelect\" name=\"Height_unit\" onchange=\"IBW_Devine_fx();\" style=\"width:80px;\">",
"          <option value=\"0.393700787401575|0|cm\">",
"           cm",
"          </option>",
"          <option selected=\"selected\" value=\"1|0|in\">",
"           in",
"          </option>",
"         </select>",
"        </td>",
"       </tr>",
"       <tr>",
"        <td align=\"right\" width=\"42%\">",
"         <span class=\"medCalcFontOneBold\">",
"          Actual Weight",
"         </span>",
"        </td>",
"        <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"         &nbsp;",
"         <input name=\"Actual_Weight_param\" onblur=\"IBW_Devine_fx(); minMaxCheck();\" onchange=\"IBW_Devine_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"        </td>",
"        <td align=\"left\" valign=\"top\">",
"         <select class=\"medCalcFontSelect\" name=\"Actual_Weight_unit\" onchange=\"IBW_Devine_fx();\" style=\"width:80px;\">",
"          <option selected=\"selected\" value=\"1|0|kg\">",
"           kg",
"          </option>",
"          <option value=\"0.45359237|0|lb\">",
"           lb",
"          </option>",
"         </select>",
"        </td>",
"       </tr>",
"      </table>",
"     </center>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <center>",
"      <span class=\"medCalcFontIO\">",
"       Results:",
"      </span>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"      <table bgcolor=\"#eeeeee\" cellspacing=\"4\" summary=\"MedCalc 3000 Table\">",
"       <tr>",
"        <td align=\"right\">",
"         <span class=\"medCalcFontOneBold\">",
"          Ideal Body Weight",
"         </span>",
"        </td>",
"        <td nowrap=\"nowrap\" valign=\"top\">",
"         &nbsp;",
"         <input name=\"Ideal_Body_Weight_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"        </td>",
"        <td valign=\"top\">",
"         <span class=\"medCalcFontOne\">",
"          <select class=\"medCalcFontSelect\" name=\"Ideal_Body_Weight_unit\" onchange=\"IBW_Devine_fx();\" style=\"width:80px;\">",
"           <option selected=\"selected\" value=\"1|0|kg\">",
"            kg",
"           </option>",
"           <option value=\"0.45359237|0|lb\">",
"            lb",
"           </option>",
"          </select>",
"         </span>",
"        </td>",
"       </tr>",
"       <tr>",
"        <td align=\"right\">",
"         <span class=\"medCalcFontOneBold\">",
"          Dosing Weight",
"         </span>",
"        </td>",
"        <td nowrap=\"nowrap\" valign=\"top\">",
"         &nbsp;",
"         <input name=\"Dosing_Weight_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"        </td>",
"        <td valign=\"top\">",
"         <span class=\"medCalcFontOne\">",
"          <select class=\"medCalcFontSelect\" name=\"Dosing_Weight_unit\" onchange=\"IBW_Devine_fx();\" style=\"width:80px;\">",
"           <option selected=\"selected\" value=\"1|0|kg\">",
"            kg",
"           </option>",
"           <option value=\"0.45359237|0|lb\">",
"            lb",
"           </option>",
"          </select>",
"         </span>",
"        </td>",
"       </tr>",
"       <tr>",
"        <td colspan=\"3\">",
"         &nbsp;",
"         <br/>",
"        </td>",
"       </tr>",
"       <tr>",
"        <td align=\"center\" colspan=\"3\">",
"         <span class=\"medCalcFontOneBold\">",
"          Decimal Precision:",
"         </span>",
"         <select class=\"medCalcFontSelect\" name=\"decpts\" onchange=\"IBW_Devine_fx();\">",
"          <option>",
"           0",
"          </option>",
"          <option selected=\"selected\">",
"           1",
"          </option>",
"          <option>",
"           2",
"          </option>",
"          <option>",
"           3",
"          </option>",
"         </select>",
"        </td>",
"       </tr>",
"      </table>",
"     </center>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <center>",
"      <span class=\"medCalcFontOne\">",
"       <input name=\"reset\" type=\"reset\" value=\"Reset form\"/>",
"      </span>",
"     </center>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_hints\">",
"     <span class=\"medCalcFontOne\">",
"     </span>",
"    </div>",
"    <div id=\"calc_notes\">",
"     <span class=\"medCalcFontOneBold\">",
"      Notes",
"     </span>",
"     <ul class=\"medCalcFontOne\">",
"      <li>",
"       <b>",
"        Ideal body weight",
"       </b>",
"       (IBW) is estimated by the following equations [1]: Males: IBW (kg) = 50 kg + 2.3 kg for each inch over 5 feet. Females: IBW (kg) = 45.5 kg + 2.3 kg for each inch over 5 feet.",
"      </li>",
"      <li>",
"       IBW may be useful for calculating an initial dose of certain medications distributed primarily to non-adipose tissues, such as penicillins, cephalosporins, digoxin, rocuronium, vecuronium, and aminoglycosides (use IBW if overweight, but non-obese) [2,3].",
"      </li>",
"      <li>",
"       <b>",
"        Dosing Weight",
"       </b>",
"       is calculated using the formula [3]: Dosing Weight = Ideal Body Weight + (0.4 * (Actual Weight - Ideal Body Weight)).",
"      </li>",
"      <li>",
"       Dosing Weight (DW) is a calculated weight that accounts for the increased distribution of certain drugs to non-lean body tissues in obesity. It is only applicable for patients whose Actual Body Weight is greater than or equal to 125 percent of Ideal Body Weight. This calculator reports N/A when Dosing Weight is not applicable.",
"      </li>",
"      <li>",
"       Separate calculators are available for estimating lean (non-adipose) body weight in adult males and lean body weight in females.",
"      </li>",
"     </ul>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_refs\">",
"     <span class=\"medCalcFontRef\">",
"      <b>",
"       References",
"      </b>",
"     </span>",
"     <ol>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        Devine BJ. Gentamicin therapy.",
"        <i>",
"         Drug Intell Clin Pharm",
"        </i>",
"        . 1974; 8:650-5.",
"       </span>",
"      </li>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        Hanley MJ, Abernethy DR, Greenblatt DJ. Effects of obesity on the pharmacokinetics of drugs in humans.",
"        <i>",
"         Clin Pharmacokinet",
"        </i>",
"        . 2010; 49:71-87.",
"       </span>",
"      </li>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        Erstad BL. Dosing of medications in morbidly obese patients in the intensive care unit setting.",
"        <i>",
"         Intensive Care Med",
"        </i>",
"        . 2004; 30:18-32.",
"       </span>",
"      </li>",
"     </ol>",
"    </div>",
"   </form>",
"   <script language=\"JavaScript1.1\" type=\"text/javascript\">",
"    &lt;!--",
"",
"with(document.IBW_Devine_form){",
"IBW_Sex = 45.5;",
"",
"}",
"//--&gt;",
"   </script>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_41_2706=[" ",
"",
"",
"function log(i){",
"return Math.log(i) * Math.LOG10E;   ",
"}",
"",
"function ln(i){",
"return Math.log(i);",
"}",
"",
"function sq(i){",
"return i * i;",
"}",
"",
"function sqr(i){",
"return Math.sqrt(i);",
"}",
"",
"",
"function power(x,y){",
"return Math.pow(x,y);",
"}",
"",
"function eTo(x){",
"return Math.exp(x);",
"}",
"",
"",
"function fixDP(r, dps) {",
"if (isNaN(r)) return \"NaN\";",
"var msign = '';",
"if (r < 0) msign = '-';",
"x = Math.abs(r);",
"if (x > Math.pow(10, 21)) return msign + x.toString();",
"var m = Math.round(x * Math.pow(10, dps)).toString();",
"if (dps == 0) return msign + m;",
"while (m.length <= dps) m = \"0\" + m;",
"return msign + m.substring(0, m.length - dps) + \".\" + m.substring(m.length - dps);",
"}",
"",
"function alertNaN(){",
"alert('This field is improperly formatted. You may only input the digits 0-9 and a decimal point.');  ",
"doCalc = false; ",
"clrResults();",
"}",
"",
"",
"function validNumberField(event) {",
"var field = event.target;",
"",
"if(field && field != 'undefined' && field.attributes.type.nodeValue && (field.attributes.type.nodeValue == 'number')) {",
"var val = field.value;",
"var charCode = event.charCode;",
"var key = String.fromCharCode(charCode);",
"",
"if(charCode == 0) {",
"return true;",
"}",
"",
"if(key == ' ') {",
"alert('Numeric field cannot contain spaces.');",
"return false;",
"}	",
"		",
"if(val.length == 0) {",
"if(key == '+') { return true; }",
"if(key == '-') { return true; }	",
"if(key == '.') { return true; }",
"}",
"		",
"if(key == '.') { return validFloat(val, key); }",
"",
"if(isNaN(parseInt(key))) {",
"alertNaN();",
"return false;",
"}",
"	",
"return validFloat(val, key);",
"}",
"return true;",
"}",
"",
"",
"function validFloat(val, key) {",
"var currentVal = parseFloat(val + key);",
"if(isNaN(val + key) || isNaN(currentVal)) {",
"alertNaN();",
"}",
"return true;",
"}",
"",
"var currenttimeout;",
"",
"",
"var calctxt = ''; ",
"var xmltxt = ''; ",
"var htmtxt = ''; ",
"",
"",
"",
"function IBW_Devine_fx() {",
"",
"currenttimeout = self.setTimeout('minMaxCheck();', 2000);",
"",
"with(document.IBW_Devine_form){",
"",
"",
"doCalc = true;",
"param_value = parseFloat(Height_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Height_unit.options[Height_unit.selectedIndex].value.split('|');",
"Height = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"param_value = parseFloat(Actual_Weight_param.value);",
"unit_parts = Actual_Weight_unit.options[Actual_Weight_unit.selectedIndex].value.split('|');",
"Actual_Weight = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"dp = decpts.options[decpts.selectedIndex].text;",
"Ideal_Body_Weight =  (2.3 * (Height - 60)) + IBW_Sex;",
"",
"unit_parts = Ideal_Body_Weight_unit.options[Ideal_Body_Weight_unit.selectedIndex].value.split('|');",
"if (doCalc) Ideal_Body_Weight_param.value = fixDP((Ideal_Body_Weight - parseFloat(unit_parts[1])) / parseFloat(unit_parts[0]), dp);",
"",
"",
"",
"Dosing_Weight =  0.4 * (Actual_Weight - Ideal_Body_Weight) + Ideal_Body_Weight;",
"",
"unit_parts = Dosing_Weight_unit.options[Dosing_Weight_unit.selectedIndex].value.split('|');",
"if (doCalc) Dosing_Weight_param.value = fixDP((Dosing_Weight - parseFloat(unit_parts[1])) / parseFloat(unit_parts[0]), dp);",
"",
"if (isNaN(Dosing_Weight_param.value)) Dosing_Weight_param.value = '';",
"",
"if (Actual_Weight < (1.25 * Ideal_Body_Weight)){ Dosing_Weight_param.value = 'N/A';};",
"",
"",
"}",
"",
"}",
"",
"function minMaxCheck(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.IBW_Devine_form){",
"",
"if (Height_param.value && isNaN(Height_param.value)){ Height_param.value = ''; alertNaN(); }",
"if (Height_param.value && Height < 60) {",
"Height = 0;",
"Height_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Height is 60 in.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Height_param.value && Height > 108) {",
"Height_param.value = \"\";",
"clrResults();",
"Height = 0;",
"doCalc = false;",
"alert(\"The maximum value for Height is 108 in.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Actual_Weight_param.value && isNaN(Actual_Weight_param.value)){ Actual_Weight_param.value = ''; alertNaN(); }",
"if (Actual_Weight_param.value && Actual_Weight < 30) {",
"Actual_Weight = 0;",
"Actual_Weight_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Actual Weight is 30 kg.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Actual_Weight_param.value && Actual_Weight > 300) {",
"Actual_Weight_param.value = \"\";",
"clrResults();",
"Actual_Weight = 0;",
"doCalc = false;",
"alert(\"The maximum value for Actual Weight is 300 kg.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"",
"",
"}",
"",
"}",
"",
"",
"function clrResults(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.IBW_Devine_form){",
"",
"Ideal_Body_Weight_param.value = '';",
"Dosing_Weight_param.value = '';",
"",
"",
"}",
"",
"}",
"",
"",
"",
"",
"var IBW_Sex;",
"",
"",
"",
"",
"",
"",
"",
"",
""].join("\n");
var outline_f2_41_2706=null;
var title_f2_41_2707="Calfactant: Drug information";
var content_f2_41_2707=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Calfactant: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/35/41522?source=see_link\">",
"    see \"Calfactant: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F144833\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Infasurf&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F144840\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Lung Surfactant",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F144837\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/35/41522?source=see_link\">",
"      see \"Calfactant: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention or treatment of RDS in premature infants: Intratracheal administration",
"     <b>",
"      only",
"     </b>",
"     : Each dose is 3 mL/kg body weight at birth; should be administered every 12 hours for a total of up to 3 doses",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15682418\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15682419\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F144823\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, intratracheal [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infasurf&reg;: 35 mg phospholipids and 0.7 mg protein per mL (3 mL, 6 mL) [production involves products derived from bovine sources]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F144811\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F144825\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be administered intratracheally through an endotracheal tube. Dose is drawn into a syringe from the single-use vial using a 20-gauge or larger needle with care taken to avoid excessive foaming. Dose should be administered in 2 or 4 equal aliquots.  After each aliquot is instilled, the infant should be positioned with either the right or the left side dependent. Administration is made while ventilation is continued over 20-30 breaths for each aliquot, with small bursts timed only during the inspiratory cycles. A pause followed by evaluation of the respiratory status and repositioning should separate the aliquots. Do not dilute or sonicate.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F144824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention of respiratory distress syndrome (RDS) in premature infants at high risk for RDS and for the treatment (&ldquo;rescue&rdquo;) of premature infants who develop RDS",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Prophylaxis: Therapy at birth with calfactant is indicated for premature infants &lt;29 weeks of gestational age at significant risk for RDS. Should be administered as soon as possible, preferably within 30 minutes after birth.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Treatment: For infants &le;72 hours of age with RDS (confirmed by clinical and radiologic findings) and requiring endotracheal intubation.",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F144838\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Cyanosis (65%), bradycardia (34%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Airway obstruction (39%), reflux (21%), requirement for manual ventilation (16%), reintubation (3%)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F144815\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Transient adverse effects: Transient episodes of bradycardia, decreased oxygen saturation, endotracheal tube blockage or reflux of calfactant into endotracheal tube may occur. Discontinue dosing procedure and initiate measures to alleviate the condition; may reinstitute after the patient is stable.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Administration: For intratracheal administration only.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Monitoring: Produces rapid improvements in lung oxygenation and compliance that may require frequent adjustments to oxygen delivery and ventilator settings.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Trained personnel: Rapidly affects oxygenation and lung compliance; restrict use to a highly-supervised clinical setting with immediate availability of clinicians experienced in intubation and ventilatory management of premature infants.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298945\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6218819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323037\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Infasurf Inhalation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     35 mg/mL 0.9% (3 mL): $455.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F144821\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Following administration, patients should be carefully monitored so that oxygen therapy and ventilatory support can be modified in response to changes in respiratory status.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F144814\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Endogenous lung surfactant is essential for effective ventilation because it modifies alveolar surface tension, thereby stabilizing the alveoli. Lung surfactant deficiency is the cause of respiratory distress syndrome (RDS) in premature infants and lung surfactant restores surface activity to the lungs of these infants.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F144827\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No human studies of absorption, biotransformation, or excretion have been performed",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bloom BT, Kattwinkel J, Hall RT, et al, &ldquo;Comparison of Infasurf&reg; (Calf Lung Surfactant Extract) to Survanta&reg; (Beractant) in the Treatment and Prevention of Respiratory Distress Syndrome,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1997, 100(1):31-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/41/2707/abstract-text/9200357/pubmed\" id=\"9200357\" target=\"_blank\">",
"        9200357",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hudak ML, Martin DJ, Egan EA, et al, &ldquo;A Multicenter Randomized Masked Comparison Trial of Synthetic Surfactant Versus Calf Lung Surfactant Extract in the Prevention of Neonatal Respiratory Distress Syndrome,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1997, 100(1):39-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/41/2707/abstract-text/9200358/pubmed\" id=\"9200358\" target=\"_blank\">",
"        9200358",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8834 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-FD3AE0A3B5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_41_2707=[""].join("\n");
var outline_f2_41_2707=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144833\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144840\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144837\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682418\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682419\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144823\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144811\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144825\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144824\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144838\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144815\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298945\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6218819\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323037\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144821\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144814\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144827\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8834\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8834|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/35/41522?source=related_link\">",
"      Calfactant: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_41_2708="Isolated intest transplant";
var content_f2_41_2708=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F79079&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F79079&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 554px\">",
"   <div class=\"ttl\">",
"    Isolated intestinal transplantation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 534px; height: 529px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAIRAhYDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKr6he2unWU13f3EVtawrukllYKqj3JoAsVgeLPGGheE7bztd1GG2LDKRfekf/dQcn69K8P8AiT8ep5ml0/wQpii5VtRlX5m/65oen1PPsK8LuWvNTu5Lq/nmubmU7nllcuzH1JPJoA948T/tHMHaPwxoqkA8T37Hn/gCH/2avNdY+LvjvV2bdrU1rGc4S0RYcfiBu/WuYhsQByKtx2qjotAFK81fXtSfff6tqN03rNcu5/U1XFrNId0jMzHuTk1trbe1SCDHagDGjguYgfJmkjz/AHWIrY0/xD4o00KLHxBq0CLyES7k2/8AfOcU7yaRoT6UAdNpfxd8eadtB1VLyMHO26gRs/8AAgA3612GlftD6tEQNY0CznHc2srRfo27+deSmI+lMMPqKAPo7SPj/wCFbrC6jb6jp7cZLxCRPzUk/pXoHh3xl4e8R2v2jRtVt7mIHaeSjKfQqwBH4iviqW1Vh0p+i6hfeHNUjv8ATXKyLw6H7sq91Yen8uooA+8UZXGUYMPUHNLXkvhzXItU0W21KxdxHPHvXnBUjgqfcHIP0rnvF/xjl8L6g2nWUUuo3kQHnb5AsaEjOMkEk+oH50Ae90V83WP7R99HgX/hiGUZ5aG7KED6FDn9K63Sf2hPCt0AuoWup6e+eS0QkQfipz+lAHslFcZpnxR8E6iqmDxJp8e4Zxcv5BH134rpbDWNM1BVaw1GzulboYJ1cH8jQBeooooAKKxNY1Q2V+kIBO6MN+pH9KpXOvSRJuCn86AOoorF8Nas2qLcbxgx7f1z/hW1QAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRWd4h1my8P6NdapqkwitLZN7t3PoAO5JwAPU0AVfGPijS/COiy6nrU/lQJ8qIvLyt2VB3J/wDrnAr5D+IfxC1nx/qJNyxttKjbMFlG3yr6Fv7ze5/ACqnxA8Yaj498RPfXxMdqhK2tsDlYU9Pcnue/0wBn2lsFAAFAEEFoABkVo21ozY2rWhYaeZSOK6zTdIRFBYUAcvBpMjAHbV2PR27iuyWCGJegqCe4hQHpQBzLaWQOlV5LEr1Fblzfxc4IrIur9ecGgCqbUCj7OuO1QSXuT1qI3nvQBZa3X2prWy1V+1n1p4u/egBZLUdqrS2e5cEVaF0DThOpoA7n4N3Lx22paTI3yqwuoQT0z8rge3Cn8TXH/EHTmh8bauZOTJMZQfZgGH6Gtr4eXAi8YWbIfvpJG3+7t3H/ANBqt49Vl8YaqJvvecSP90gFf0xQBxzW6/3RUL2qHqtajgU0KKAMWTTkboKrPppBytdJ5aml8laAM2x1jxFpv/HhreqW2Bj9zdSJx6cGul0/4t+PdOwF1qSdAMbbiFJM/iVz+tZTQCoXgX0oA7T/AIXlrlzcxS6tpdhOY1CZg3REj3yWGefSultfjLoN9CI721vbKXuSokQfiDn9K8dktkPaq8lkjdBQB9W/CzxHpWq6jcxadfwTl49wRWw3B/unn17V6ZXwAsMtrKk1vI8csZDI6NhlI6EEdDX218NtQvtU8B6He6qS17NbK0jHq/ox+owfxoA6WiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK+VP2jvHJ13xGPD2ny507TXPnFTxLP0P4Lyv13e1e+fFfxUPB/gbUNTRgLsr5FqD3mbhT745bHopr4ntEeeZpZGLOx3MzHJJPc0AX7KHABxW3YwbmHFUbdcEVtWIwRQBvaZGkYBOK1JL1Ik4rC+0bF4NUrm7ODzQBo32qHnBrDudRdifmqpcTls81Sdy1AFmS7Y96gaVmqOigBdxpMmiigAzRk0UUAGT60ocjvSUUAdb8LlMvjfT8nhRIxH/bNh/WpPilcxv4wuEh6xRpG7f3mC/0BA/CrHwcgMni15cZWO3Zc+jMy4/QNXL+I5Wn8QalK5JZrmQ8/wC8aAKPmGlEhqMCnAUASCU07zjUOKNpoAm86mtLUWKCKAFLZptOVeMscCtLw1oV94o1VLDTEwBgyzN92JfUn+negCXwboZ8Qa5DDKrDT4nVrlxx8ufug+p/+v2r7Rt4o4IIooEVIY1CIq9AoGAB+FeR2fhq08OaTFY2C/Kgy8hHzSN3Y/54r0zw1eC90a3cnLoPLf6j/IP40AalFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRUdxNHb28s0zBIo1Lux6AAZJoA+X/2pvEhv/FVh4fgfMOnxebMAesr9AfooH/fRryqxj2Rim69qsniTxZqerzZ3Xlw8oB/hUn5R+AwPwq3GuFAoAsW45rXtuFrNtUyRWkTtjoAJpsZ5rPmmznmlnkJNUmYk0AK7ljTaAKXbQAlFOC0u2gBlFOIpDQAlFLSUAFFFFAHpfwWt2aXVblQSV8pQfpuJH6iuK8VmB/E+qtaNvga6kZT7Fia9Q+C9uV8N3TKQJLi5dkJ7YVVH6qa8g2MHYPncDzn1oAYBTgtSBaeqUARBKdtqXbikVCx4oAg2E9BTZCkQyxyalkc71ht1aSRyFVVGSxPQAV7T8MvgyZPJ1XxpGc8PFp38jL/APE/n3FAHCfDv4bav42mS5lD2GiA/NcuvMg7iMdz79B79K9qsPD9l4SnbTdMh8q2XDKx5Z8jqx7ntXpMMccMSRQoscaAKqKMBQOgA7CsHxhZl7aO8jHzQnD/AO6f8D/OgDGvFE0R47U3wnf/AGDU2tpTiGc4BPZu359KksnWVADWfq9mVbcv50AekUVheFtYGo2vkzt/pcQw2f4h/e/xrdoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK4L46az/AGJ8LddmR9k08QtY+cEmQhTj/gJY/hXe14J+1xqRi8OaDpakg3V085x3Ea45/GQflQB86aRHxurYXrVHTF2wir69aANC0HNT3DYXFQWtOuGoApSmowOakfrSKKAExS4pwFOAoAZikqTbRtoAiIppFT7aaVoAgIop7CkxQA2jFOxShaAPW/Dd/wD8I/8ACyO/jA+0qXMWf77OcH8M5/CvLAS7FmOWY5J9TXpmt2LL8JrDnaEWCZh6kjBH5tn8K84RaABVp2KXFSxxgDfJ8qD9aAIgmRknAp1la3eq6hDp2k28lxdzNtSOMZJ/wA9TwKv+H9D1Txdqw0/RLcu3V5G4SJf7zHt/M9q+mvh34C03wXYbbcfaNRlUCe7cfM3sv91fb880AY3wu+F9l4Tjjv8AURHd64w5k6pBnsnv/tdfTFek0UUAFNkRZY2SQBkYEEHuKdRQBwF5ayaTqLQsSYz80beq1eBW5hwetdHq+nR6laGJ/lcco/dT/hXGp5tldNb3K7ZFP4H3FAFOeGexuVuLVikiHIIrr9C8R29+qxXBWC66FWOA3+6f6VktsmTnrWZdWCsTgc0Adjq+vWWmLiWTzJu0UfJ/H0rmp/G9wWPkWUar/tsSf0xWNHp+Cc082WOgoA1IvHVwp/f2UZH+yxX/ABrb03xbp16wSRmt3PaTp+f+OK4W5tiM8VnPGUbI4oA9rVgygqQQeQR3pa838Oa5PYMqMxeE9UJ/l6V6JbzJcQpLE25HGQaAJKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK+Vv2r7sz+OtIsgxKwWAcjsGeRs/oor6pr48/aIuWu/i/qMTdLaGCFfoY1f+bmgDjLNdsQq0g5qGEYQVYi60AXrfhabMeaSM4FNc5NAETDmlUUvenKKAACl206lAoAZil21IFqRI2boCaAK+w0GPNXDbuByuPrTWUKOSKAKbRUzyTVlpYx3zUDTr6igCMpik5wcDntQ06Dqc1LpMb3upQJHG7rvUvtGTtzz+OKAPYPF8Tw/DtrZhl4BDu9xkDNeVQxtJ90fjX0FZWdn4u8OanZ2zxG7a38qOOUlSjnoWGM4BA7GvPtV+EWuaPod3qGoalY7IAp8u3LuWBYA8kLjGc9+lAHBSmG3HzMHf0Fd34J+Fms+KHiutX8zS9JOCN64llH+yp6A/wB4/gDXW/Azw5paahrDXdpBc39m0RimlXcyBg3IB4ByvUDNe2UAZnh3QdN8O6aljo9qltbryQvJc/3mPUn3NadVdUYrpl2ykhhC5BHUHaa+Pvhp4l1RNI1GZ9Sn1ZJvCeoyXMAvp7pIZow7K90khKoWUBVCEcfU0AfZdFfM8nirWtCm8Q6tokIa6/sDQy2Iy6WySBg8oT0UH6DqcgGvVPg54m1XxF4b1O41S9sNVltrt47e4s3U+ZHsVlVyvybwSQdvHTgHNAHolFfLOmeONe1jxBp+tHVo73xBDoOsT/2ZDa7BYXCKCkLL95jlR97n8637v4y6ze28snhmW3vhD4btL2dhaO3kXT3IjncqMFlRSTtHHB9DQB9D1ma5pSalb/LhblOY3/ofavDtS8U6i/ijwPc2nxFjvdFk1K7tJ7+K0EcDN9nRkikCsEkJLEKexYY+ZTX0JQB5/bu6M0cgKyIdrA9QatH5hVrxTbiDUYZ0GBMpDY9R3/Ij8qrQfMKAGiMUjIKtBOKhkFAFOaIMOlZF5bYyQK3SM1Vu48oaAOZLmOSu58EanuZrSRuG+ZPY9x/n0rhr5Crk1c0S6a3uI5EPzIQRQB69RTLeVZ4I5U+66hh+NPoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAr4l+K0/2v4seJJN27F20ef90Bcfpivtqvg/xDMLvxtrtwG3CW/nk3euZGOaAFXoKliqIVNFQBNnFGaYxpAaAJBTxTUUt0FXIbb5dzkKPegCBVJqeOEt14HvUU93DDwnzGrmg6F4g8UTCPRdOuJ0zgyBdsa/VzwPzoAiaS3gHzNuPpVeTVivEQCivW/D3wDuZtkviPVliHVoLRdxx/vtwD+BrBn8KWGm+Ib+ztoQ0dvO8SNL8zEA4BPv8ASgDzxWv7s5iilceoU4/OrNtoWpXTEExxn0Z+f0r12PRQ1twnAFcZ4jEelLLPcOI4YxuZj2oA5t/Dy27xi+vlhMjhFG3G5j2GTya6LSvBOm3GN91I7ehYCr3w58O3Hi3WvN1aRred4HFksibxajGcsuRlj35GBwD1JsWWhNdPqKLIIZ1lETeVM33o3wzDI43KBx2x1Oa2o0JVm4w3M6tWNJXkWoPAdpbfPBbwyH/bG/8AnWZq+hvHKJDEY5FPEkfysK3ft2oaFJcT3UnmWSusUMeMyucdQo6kk4AGT8ue/HTWOoWOqwgSBQxHIOMioqU503yzVmOE4zV4u5xOmale2Wy4ujMDARs1G3BDRZ6B8djjvwa9El8ZQ6x4S1Cx1kLvmtnSK8gGY5G2nbkDlTnHt9OlVIbW50SaW40vy5IJV2ywSLujkX0YViS6TFJLJd+ElNteE7rjRJmyko7mA+v+z+XvBZr/AAruRa+M5I2wqalYKyn1kjPT8mY/hXq+r6lZ6PptxqGqXMVrZW6GSWaQ4VR/nt3rwj+27W105degdbW50mUSvDL8pBztaPHXLZK465PrXoPhRZfHslr4l1uNY9NhkL6bpRYN5TAkedcY4MvonIT3Y5ABq+HJNX13U11y9a503SQpWx01hteVT/y2uARkE/wx8bRy3JwvWUUUAFFFFABRRRQAUUUUAc94yx9ltT383+hrKsDk1f8AGknz2UYPdmP6Y/rWfp/UUAaBFVphVxhgVVnoAqnrUcoypqRqaelAHN6nHgtxVCzfbIBWxqqZzWDD8s340Aer+ELnz9KEZPzRNj8DyP61uVxfgefbdPETxIn6j/62a7SgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAGyuscbyOcKoLE+wr8/wC2k8+9mmxje5bH1Oa+89fV20LUljDFzbSBQo5J2npXwjp0WPrQBep6NinLC7dBT1tifvMqj3oAYWzU9vEX5PApjm2hHL729q3vDHg/xH4ukUaPp8i2hODdTfJCv/Aj1+i5PtQBlyXUNsuF+Zq2vC3g7xJ4zkB0y1ZLPOGupvkiH4/xfQZr2vwP8FtG0Upda6w1e+HIV1xAh9l/i/Hj2r1WNFjjVI1VUUAKqjAA9AKAPKvB3wT0PSNk+tudXuxztcbIVP8Au5+b8Tj2r1O3gitoUht4kiiQYVEUKqj0AFSUUAFeJarbBPGmrh+9yzfnz/Wvba8d8RgL471Qf7aH/wAcU0AbIWKHTpJZWSONELM7EAKAOST2FeIa6zeINSTVJEZNKjbdYxOMGY/892Hp/dB7fN3GPSVVvGryW8Z/4pizcrcOOmoTKceWPWJSDuP8TDb0DZ53xwuybgYA44oA6H4Qn/ioLQ9yHH/jhrH8PuF8V6rED8rXsv8A6Ga1Pg82fEFn/wAD/wDQGrF0Tjxjf46fbZv/AEM12Ze7V18/yObFq9J/11Ov1+JbKDe31HtXm+qoNK1KCWx2RteHJaWR90hzzhjuDEZ+7kdeB1r0n4ifLpqHuQK8v8UTSC8sNjlSkClSD0OTXp4y0sJzyWtzhwqar2Wx12g+KHjYQ3fTpzXRXNlb6lEJ7Vtso+YFTgg+1cLomnXfiC3uTFbk3Vsgkcp/Ep4zj/CpdM1W60i4Ec27YD3rwD1yXxSLq1vItVNuJb6BlMzFQROq9GYf3xgfN3+ozXReDfEkWi30epW7/wDEg1FgLqPPFtKekg9ux9ue1Xo57XWbTI2liK4a9t28NaoY5E3aRfExyJ2RjQB9Lg5GR0orgfhTrby2c2g3su+609QYXJ5ltz90/Vfun8K76gAooooAKKKKACiimTSJDC8sh2oilmJ7AcmgDjvFEvna1sB4iQL+PX+tOsE4BrLSc3t1JcEHMjFue2a37OPEYJoAkk6VUnq5JzVO4NAFVqa3SnHrTJDhTQBkamRzXPnietvUW61hrzLQB13hKTZqVsfVsfmMV6LXmvhof6da/wDXVf5ivSqACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK8s8WfBPw/rV5NeafNPpVzKxZxCA0RJ6nYenPoQPavU6KAPnq5/Z+1FGxaeIbaRfWS3ZD+QY1b0/9n05U6l4iYjulvbY/8eLf0ruPjb4u1Dwb4Y06+0qa1t5LnU4LOSa5hMqRRvu3PtDAnGM9awPC3xS1m40ewivdGXUta1HVLqx0w24NnDfQQJvNz+8JKKVzxzkigDovD3wk8IaKyyf2d9vmH/LS+bzf/HcBf0rvkRY0CRqFRRgKBgAV5jonxaTxBe6NaaD4d1G+n1Gwa/ZRNDH9nVLjyJA+9gDtYH7uSeMDnjI0H4uavJ4HXWtZ0C1W6l1KSxghjvFjE21pAdq/O5ZdgUgA5JyABnAB7NRXlHg34kXPi/xh4YNij2uj6no93dyWsqqXWaK4EX3uuAQ319K1fEPxOtdE8U3Hh6fTLl9S+0WUNpGHUfaxcFhvX0CFH3Z9KAPQqK8jtfjNa6nrN1YWWkXy2ebuGHUFIfEkCMSzJj5VJUhSScnGQM1XHxguLTQ7FrfQr7WrgeHY/EF1MZ4YNsBZlcsOm4bCcKDnNAHslfPvxGlk1n4janpGmTFLYeWNQuo25QbFzChHR2HU/wAIPqRXp+reIrzV7DSbPwrHJHfaxbJdC7ljyljbMATK3YvzhUzy3J+UGuI17Q7Pw54hhsNPRlhFujl3bc8rktukdurOxyST1JoA6nQreC00ZLW0iSG3hjCRxoMBVAwABXm/j2P5yfevStHObNh7V5/49TgmgB3wil2eILPP94j81IrN8ObpfFd2x+8buVj/AN9mrPwtJXX7L/rsv86i8EAyeJrxvS4k/wDQjXZgP46fr+TObF/wn8vzOq+JjbbK3Q9wK8u8UjGoW49Ik/lXpHxUlBltYgecDIrzbxYf+JvjsqoP/HRXo43TBQ83/mcmG/3iXp/keq/A/H2+99TAP/Qq6jxt4It9Xie5sI1ju+pQcB/8DXJ/BDP9p3XPy/Zuf++lr1y7uoLOLzLmVY09WPX6eteEeofOK/bNAvykiuu1sMrDGPrXTXItfEujS27kB3XAPdW7H866jxkdO8QAeTbSCZePOwBuHpjvXLWPhyWxl8yKeTHoV4oA5vQNYn0e5sNUcMLnS5vIu0HV4ScOP6j3Ar6RjdZY1kjYMjAMrDoQe9fPuueH7ttSubu1VHiuYwssRO0k4xkZ4rrvhL4kuba3tdC1oPGQPLtmlGCMcBD7EdPy9KAPVqKKKACiiigArmfG+oCKzSwjb97cn5sdkHX8zx+damt6vb6TbeZMd0rf6uIH5nP+HvXDx+fqF293dnMsh7dFHYD2oAtaVB93iukVQsYFUtOt9gBIq/IcLQBWfvVG4PNW5DgGqEpyTQBHUNw2ENTGqN7JhTQBkag+c1mwjL1NeTbmIos03SCgDqPDEW6/th6OD+XNehVx3hG33XofHEak/j0/rXY0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAZXiLw9pfiOC0h1m1+0xWl1HeQjzGTbMhyjfKRnGeh49RUfifwxpHie2gh1q1M4t5PNheOV4ZImwRlZEKsvBIODzWzRQBz+jeDtA0XULS90rTY7W4tLE6bAY3YKluXDlNucHLAHcRu9+aypPhd4QeN0/sqRFa7N8PLvZ0Mcx3ZaMq48sHc2VXAOeR0rtaKAOZ8PeBPDfh2fT5dH077PJYQS21sfPkfy45ZPNdfmY5y5zk5I6DA4q1qHhPQ9Q8Uad4jvNPjl1rTkaO1uSzAxqwIIwDg/eOMg4ycYrcooA5Nfh34XTVLnUI9OeKe5eSSVI7uZIXd1Ku/lB/L3EMfm255z1p0Pw+8MQwPDHpmIn0n+wmH2iXmyyT5X3v9o/N97nrXVUUAV9Os4NO0+2srOPy7W2iWGJMk7UUAKMnk4AHWvMviSSPGdt/wBeif8Aob16rXlvxOXHiqxbubUD/wAfb/GgC9orZtmHtXFeOx+7b612OiZ8lvpXIeOR+5b60AZ/wzO3X7HP/PdP51J8NEabVbuZhy07E/8AfVVPABK6zZkdROn/AKEK3vhhbkSzvjrNIf8Ax413YBe/J9kzlxb9xLu0VviO5k1+GIc4IFcF4lO7WJ/aQr+XFdz4m/0jxioPRTk1wGpuZr53xy7k4+pruzR8tClA58Er1JyPSvhXqA0y6uJ2RnzbFFA6FiykZ/I12kVvc6tcm4u2LE9B2A9BWB4O0j7NYwLIuHIDP9fT8K7+Ax28I6dK8M9Ihg0yOJBwKjuIo1GABTLvUwoOCKyZNVDMeaAHXojXIKistreG4dd8anacqccg+oPanXVz5h4PWrdjEPLBPWgCaa61IHdFf3Cn/ez/ADqeDxFq8HEi29yvqylG/McfpSYBoWEN2oAsy+LbspiPTo1f1abIH6Cq9x4h1W4XbEYbcHui5b8zx+lOFpk9KnisRQBkR2rzTGadmllbq7nJNbNla4xkVbhtAvarSoqCgBY1CCoZ3GaWWUetUZ5etADZ5OwqoTk0rtk1GzYoAbI2AaxdSnwDzV27nCqea568n3sRQBVJ3SVraZESwJrPto97Cuq0Kwa4uI4lHB5Y+g70Adb4YtvJsTIww0pyPoOn9a2KREWNFRBhVGAPQUtABRRRQAUUUUAFR3E0dtbyzzuEhiUu7HoqgZJqSsrxZ/yKus/9eU3/AKAaAMhPiJ4WdVZNVDKwyCIJSCP++ad/wsHwx/0E/wDyXl/+JrV8J/8AIq6N/wBeUP8A6AK1aAOV/wCFg+GP+gn/AOS8v/xNH/CwfDH/AEE//JeX/wCJrqqKAOV/4WD4Y/6Cf/kvL/8AE0yb4j+FIV3Tauka5xloZAP/AEGutrzX4t6gJJrDTI2yVJuJQD07L/7NQBtr8SvCL/d1qJvpFIf/AGWh/iV4RQZfWolHvFIP/Za5Xw033Kk8WfNavQB0A+KfgonA1+2z6bH/APiadJ8UPBsbBZNdt1YjcAyOCR6/drwuIY1I+vatHXr1dR1mxkQMDFZxwOCOjKW/pg/jQB7H/wALP8G/9B2D/v2//wATSN8UvBS/e1+2H1R//ia80SMGBc1z/iQYhIFOwj2uP4peC5WCx6/bOScAKjnP/jtTyfEbwpHjzNXRc9N0Mg/9lrwzwMsn9oW7xDLRyLJ+AOa9ihiuNXuzcXbZJ6DsB6CkM0B8SPCR6axGfpDJ/wDE0v8Awsbwp/0Fl/78yf8AxNX7exihUcCmXBjUYGKAG6V428O6tqMNhp+pxy3c27y4tjqWwCTjIHYE/hXR151eEHxx4Rx/z9z/APpLNXotABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV5d8T8jxRYHt9mH/obV6jXmnxSXGt6Y/YxMPyb/69AE+hLmH8K5Lx6u2Jq67w+f3P4Vynj/mM0Ac54Fz/AGxa4/57J/6EK9B8D2qwR3TqAEDuR/30a858KzC0vo5yMiJxJj1wc16Zobmz8K3E8h+YoSSe5Nehg4vkm11sjjxT96K9WcFcz+frepXB5CI2KxfCmm/2l4ijLrmKH94317D8/wCVXbMl7TUpj/Gdv6103w608RWMtyV+aZzg+oHA/XNb5xL97GC6IjL17jl3Z2lnthQCku74Kp5qC5fYOTisi5lLnFeQd4k9w8zMc4Uckk8VmjU7PzdvmMwzt3qvy5+tV9fuChSyiBZ2Xe4H6D+v5Unh+GJ0eO4jG4cMjCgDXfgBlOVPQ1oWc/yYNV7eCNIFgRdoA496gYPC5B6UAb8UobvVmM+lc9DdYPJrShugRyaANZZcVMlxistZwe9SCUetAGn9q4pj3JPes8y01pfegC3JNVZ3zUDTD1qCS4Ud6ALLPiqVzchAeaqXN8ADzWPdXRfPNAE17dlyQDVBVaRqWJGkatWzs+hIoAk0215HFekaBp/2K13SDE0gyfYelZvhnR9gW6uFx3jU/wA66agAooooAKKKKACiiigArK8Wf8irrP8A15Tf+gGtWsrxZ/yKus/9eU3/AKAaADwn/wAiro3/AF5Q/wDoArVrK8J/8iro3/XlD/6AK1aACiiqup6ha6ZZvdX0yxQr3PUn0A7n2oAi1zVbbRtNlvLxsRoOFHV27KPc14rqcs93cXGo3/F1dNu2/wB0dl+gGBW7rOpTa7fLf6gDDYQ5+z25PP8AvH3NcvqN688kkscZcqOABwoJxk+2SKAOp8NjhKs+Jxmzk+lVfC+RGgY5OOTV/wAQpus5PpQB5KCU1EkdQeK6KC3tdXjBjcQ3i/8Aj1c/IoOp7T0z2rSvYUtbm2Qu3mTQiYOi9PmZcEd/u9fegDUjN3Awt7i3dmPCtGM5/D/Cuc8UB4y0cqMjjqrAgj8K6CW4vTosoikMk00iWyNGcsAwYnHuduPxNY2q2Zu9WstNjYvsVICwOc7R8x+nX8KAOj+GuklNOFxIuGm5Gey9vz6/lXqVkUt4h2rB06FLW3REAVVAAA7Cp7i82rwaAL19qW3POKw59UYscGqNzO08pGeKxZdU/fmKziEu3q7HAJ9v8aANy0uTP458J57XM/8A6SzV6vXjOgXP2jxv4WDxNFKtzPuUg8f6LNXs1ABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV518Vk/03RpPUSr/AOg16LXn/wAVT+/0Ye8v/slAEfh7/U/hXLePOUNdT4f/ANQfpXK+Oh8poA4/RRun2D+I4r0nxLL9i8ILGODJxXnvhOIzasi4yAc123xFl22dnajqQOK9zLqfuwXdt/ceXi5e/LyVjlYIPL8PFiOXbdXe+FIBFpFoo7RqfxIya5bUohDoqRjstdx4aQfZYV7BQP0rz8wqe0xEpHZhYctKKHX8I8vcRWAMGfnhRya7LVoQIDgdq4e8ysd0fSNv5GuM6DPsEW6uZruReZGyM9h2H5Yq/Jbq1zFOhKMFw23+L0rE05LiaISebthHVV4NbtuoMbCNmZRwSeooAZeXDm4hSMue7BBk4q5Dcpd5jkRo3HQtxmq8aKkjlOGIAJpiRxmJw2GyTk9/zoAnnt2jPAqJZXTrUllOyKySymZF6Ej5h+PepI2trssLeVGYdVB5H4UAMW9x3qVdQx1P61UnsmB+WqUsEy9jQBt/2gP71MfUB61gNHMPWoyk3vQBtSaiPWqk9+T0NUFt5W7GrUOnO/3qAK7zs5qSC3kkI4NalvpgUjIrotL8P3FxtYR+XH/ffj8vWgDDsbDkcEk+1dtoegiPbNeKM9VjP9f8K1NM0m3sACo3y/32H8vStCgAooooAKKKKACiiigAooooAKyvFn/Iq6z/ANeU3/oBrVrK8Wf8irrP/XlN/wCgGgA8J/8AIq6N/wBeUP8A6AK1ayvCf/Iq6N/15Q/+gCtWgArzT4mTXlpqkFw0ST6eB88bqCcYHKnqD97+tel1Wv7G3v4fKu4hInvQB4mtnf63rB07TP32MMZDwiIRkMx7ZHau017w3a+H/AF7Fb5lnZonmnYfNId6/kBngV3FhYWunxeXZwJEpxnaMZwMDP4AD8Ky/HKhvCWpg/8APLP6igDgPDB4X6Vf14n7K/0rP8MD7v0q94gOLR/pQB5TM2NRYjrmtS9kzrWmqeotFH/kR/8AGse5OL0n/aq9cOW8QWXtAo/8eNAHYNmG3ZoiULDDFTjI96z/AAnaCfX552GRCmB9WP8AgDWrMoNqPpTvBUXz3j/3psfkB/jQB0042R5xWPdSkk54rpHhJiJI4xXM6gP32PegDM1qZrfT1SMZmuDtHsvc/wBPxrMsoJbOeO4nGYnIBOPumr924k1YiQgRwqFGfoCf5/pV7dFPE8QIZG4IoAmsMN448KOuMNcz9P8Ar1mr1uvH9LKjx14URcfLcz8Dt/os1ewUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXn/xY4Ojn/bk/ktegVwHxaH7nSW7iVx+goAi8PYNufpXMeNVyjV0vhk5gb6Vg+MVzG9AGN8NbPzdRaQjgNWh4ykF34rggByseM1f+HNsILGS4YYwC1c6kxuvEV7cHouQK+lwq9nq/sx/E8Ws+d6dWXdf/AOPDj0rsPB0wksbZs9UU/pXJ68n/ABLx9KvfD+/32CRk/NExQ/zH6EV83JuTbZ7KVlZHoOqLutj9K4W4i8xp4yPvKy/mK7yVhLa/hXF3w8q6JHrSGcv4bkD2qbsZAxitCOQwXdxHbAENhtpOOtY0VrPb6ncwQMo+clQ/AIPIwauhpbUs8mWuWG0KBnntigDSt2K5Mzrvc8DNF+omjVQdshYAMvUjvn14qkkzRwiO9tpEGMZZcj86faRxJmWMkcYyaAJZLZYIHMTOGIwSTnNcjLbSS36JEzAD5ywODXUzi4nXYJIFVv4iT/Ks9Izay/vIyxAA3LyGoAiuNW1DTXVROZFx92T5v1616ufD1tNZxXMVx5aSIrgSgHAIz1rxnUWa4kjiIIlJ2gMME56V6HGLi7SMTuzhFCIpPCgDAwKANf8A4RuSTPkTWsoH91+f5U3/AIRe7z/qU/77FZxs5oiJIiyOOjKcGul8N6480i2d+f338D/3vY+9AFKLwtcnr5KfVv8AAVft/C6A5nnJ9kGP1NdJRQBStNLtLXBihBYfxNyau0UUAFFFFABRRRQAUUUUAFFFFABRRRQAVleLP+RV1n/rym/9ANatZXiz/kVdZ/68pv8A0A0AHhP/AJFXRv8Aryh/9AFatZXhP/kVdG/68of/AEAVq0AFFFFABWH43/5FTU/+uX9RW5WN4yGfCuqf9e7H9KAPPPDH8B9qu+IVLWj4qh4UbhK09cP+jPQB5BfDbeH/AHqvRYfX7X2jA/U1U1RcXx+tWbbjXbY/7FAHdSYNuPpVjwX92Yf9Nm/kKrgboD7CmeCZ8XN3ET92Xd+Y/wDrUAekmMfZenauK1ZMXR+tdzEd9r+FcdrSbbon3oA42WBbjWrtJmbaGGMHHYVq2myOaODaqEgkNjGRWbesIPE024/LKiOPyA/pV68nVvs+08h+vtigC/pw2+O/Co4/4+Z//SWavXa8Z0VSPH/hjdIzt9om69v9Fmr2agAooooAKKKKACiiigAooooAKKKKACiivL/2gXmHhXT1g1+20YG+QuLySaK3u0CsTDLLF80an1yAcY7igD1CivlZ9U1/UvDfg7/hFor3Sb5tdvDbwjUJp7e9MMPmKI2kOTA7IQAxIyW7VLYweNNTX4tLc6nqEPiLTTpusW1slwzLbO0ck7W6gHBAU+XgcMVB5oA+pK4D4t5+zaUO3nN/IVzfwx8Uaj4jt/EfxC+w6pd2Fy8Npp+mQsCywxACaRFLBWJdn6cny8DtWp481rTvEGg6XfaRdJcwC5aNiAQ0bheUdThkYd1YAjuKAJvDB/dH6Vk+MB+5krT8MH93+FUfEy+bcQQjq8gz9Bz/AIVth6ftKsY+ZnVnyQci1pw+weFJG6EpXFaUMRu5+9LL+g5rsvF8wsvDiRDgsK4q0k2XVnb/AN1N7fVj/gBXt16nLhak/wCZ2PLow5q0Y9jf13A08fSuX8Jal9j11oGYBJxxn+8On9a6fxAP9AH0rzC+ZkuldCQysCCOxr549g+hLO73wDngisjVIyzkgVm+FtV+1WUUjcFhhvZu9dG8ayr65oA5HUbNrgpNDgXEYx/vD0rKt7+RriVJ1ZWU42sMEV2c1mQTtFZt3p8dxgTxZI6MOGH0NAGe19EsB55xUen3InidieMnGaivvD8jf6i5Ye0i5/Uf4U2306+hTy1WMgdw/wD9agA05EM8jE4O4gDsBU13NFGwVm+9xmq8Ogam0zsJYEVjn7zE/wAq2LHwmJJUkvppJypyEA2r+Pc/nQBnaDYtf6oLt1/cRZCE/wATeo+ld1boIscU6CxS3jAVQqqMAAYAFQ6hcrBAzE4xQBvW8cU0GMDNc3rELWtyskXyuhDKfQitbQrkTWysD1puvw74d1AHT6fcreWMFwvSRA2PQ9xViuY8CXJfT57dusEvHsG5/nmunoAKKKKACiiigAooooAKKKKACiiigAooooAKyvFn/Iq6z/15Tf8AoBrVrK8Wf8irrP8A15Tf+gGgA8J/8iro3/XlD/6AK1ayvCf/ACKujf8AXlD/AOgCtWgAooooAKy/FX/Isat/16S/+gGtSsvxXz4Y1b/r0l/9ANAHmPhM/wCrrU144tnrI8KHhK19fGbWSgDyjVzm9B96ntj/AMTe3P8Asiq+rf8AH0PrU9t/yGYB6ID/ADpgd/bjNsT7Vz2jXX2PxMYycLOCPxHI/rXR24xZn6V594ine3vhNEcSRuGH1BpAe76Xch4ACe1Y3iBMsWFZ3hbVo72yimib5XXIHp6itW/BmX3oA4fxDbCT7NdEHCfu3IPIHY/z/Okjto40EsTtNkcBjyDW3NCNrxyLuRhgg965+/sLm1mSSDdLbLzxyy/Ud/rQBe8NxSr498MyzSKS9zP8gB+X/RZu/evba8Q8L3HneO/C4yDi4mOR/wBes1e30AFFFFABRRRQAUUUUAFFFFABRRVLU9Us9NiL3cypxwvVm+goAu0Vwd/4tvrpyunRrbxdnYBmP9BWc+qazG3m/bZSfTIx+XSgD02iuR8PeLPtMq22pBUmPCyKMBj6H0NdapDDIoAWvI/jb4dt3ksNV00/2frEkux7uJeJgF+VZV6SAds8jsRXrlcB8X/+Qbpn/Xz/AOymgDjvB3iQ211DpviOFdPv5cJBLuzb3R9I3PRv9hsN6bhzW3IBd+KNg5WBQD9Tyf0xTNPsbTUtNktNRt4bm0lTbJFKoZWHuDWH4G07VNN1JprSZbzQ5nc7buRjParzt2ucmReAMN8w67j0rvwKs5VLbL8WcmLd4qHf9C18Qrr7RqltYxnIGMiuP027+0eILlwcosmxfovA/lW3PL9t8UXdwTlYgcVyOiPsv7hhxidv/QjXXmj9nTp0V6mOCXNOVQ9D105sc9sV5hqHM/410Gr+JGu4rOO13IEvHgulIyVAVwM+gJ2Nn0IrlTJNIqz3CeWkrt5WeMqDgH6nr+IrwlOLfLfU9mWFrRpqs4vlfU9v+FemRap4Qu43IWVbjMb91Oxf0q2ss1jctbXalXQ4Of50z4HEnSdQGePMQ4/A13uq6Va6nHi4T5wPlkXhhVnOcnG6yDOaeYlbsKq6no2oaUS6Az24/jQdPqO1UYtU/v5FAGuLNHqaHT488gVmJqSHo1SDVMdGFAG4lpEo6CnHy4x2rn31g4+9VG51Zm6MaAN+9vURTyK4vxFqO62nfJEcaM7n+6oGSx9gAT+Falnp+paywFvEwiJ5lfhR+Pf8K61fCFkPD+o6e5Mkl9bSW0sxHO11KkAdhzQBzPhjUoPLt4Y5C7yF0QBT8xThh+GKualr9o1jYS5PkXsxt45WICqwDHLdwMoR9SK4Tw7pGJoBvy9vdSzbTnDBwdynnpuO78AK318ORWWnrEW+RLlrpCAAyMZDJgH+6CenpXP7e+yPTeXcrtKRa+F2v/bvEN/ZtF5W+2EwB670kZJF99rd++a9SryDTo2stQkurA+TM4YFlAz8xy35nmtuHXdYtiGM/mqOqyKCD/WtottanDWUIytTd0eiUVi6R4itL9FWRhBP0KOcAn2PetR7qCP/AFssceem9gM1RkTUU2ORJV3Rurr6qcinUAFFFFABRRRQAUUUUAFFFFABWV4s/wCRV1n/AK8pv/QDWrWV4s/5FXWf+vKb/wBANAB4T/5FXRv+vKH/ANAFatZXhP8A5FXRv+vKH/0AVoS3MEJxNPFGfRnAoA81+Mmp+KrK80WLwybp9PIll1KLTJLcX5RQNjRiYMCoJ+bCk9BxmuBn+K2vW9x4L1PRbu/13QZtNnvb+3lsoo7m4VZ/JzhFOHQsudhAbYT0Ne5+IPDHh/xOsB17R9O1QQ5MTXMCylM9dpI4BwPrirNvoelW13a3Ntp1pDPawG1geOJVMURIJRcdF4HA44oA+ftB+IXjq08IzeIfEepJImieLZNM1mBLaIILTESHBCZ+R2JBByd3JOBXf+D/ABPdeKPCXinUr/UImgvvtcuk2WEV0sYwY1kwAGIZlY5ORyMGu8/4RrRPsGpWP9lWf2PUpnuLyHyhsuJHxudx3JwMk+lYnjnwlo914Jmto7RLQaZaSGwktf3T2uIyMIR0GBgr0YcEEUAcV4T5CVr69cwRYglkCyyqzIp/iC4zj8xXB+DNcm0u5t7HxHsj81gltfqNsM57K3/POQ+h4PY54HaeJbeK9uLKF1zLHKJ0YHBQgEZ/EEj6ZrWjSdaagjOrUVOLkzyi/vfOMNw8LwwtbrdMz8CNW6Z/Jv8Avk1dgbGrWrZ4MY/ma7Pxlo+m2mjpEIOZQN8avsEgBLBWPpuYn8T6mvONNuXkvYGkkEhUFfMX7j/Mfueqj7oJxnbnvW2Jw/sUpJ6Mzo1vaXT3R6zF/wAeWfavOfFA/fvXe2kwfTs56CuA8SSBp3ArkOg1/h1dTCQ2kYZ92XUDtgZP6D9K9OtLhZoxk815x8IOPF+n49X/APQGr1TxJoslpM17YITCeZI1H3T6j2/lQBTntlfmqUtkwOVqa1vVfAY81eV0YUAc5Z2wh8eeFZNih2uZwWAwT/os1et15tMF/wCE18I4/wCfuf8A9JZq9JoAKKKKACiiigAooooAK57xL4otNGPlMfNuiMiFTyPcnsK1NZvl03Srq8fkQxs+PUgcD868IgnkvL6W6u2LyyMWYnuTQB2k3iHVdQzicwRt/DF8uPx6/rVcWbRuJ5MuScsSck1Us50VR6CrtxqIaPaOlAFuS1VoxNaYB67exqlcXBZdgBB6YPXNP0+5eBX3I5UnI6cetWm8i+QlNqzAcHHIoAz4bAudzcmr1vqmpaY48i5dkH/LOQ7lP59PwqFLh7ZykylW/Q1XurgyyfKMk9BQB6ToOrR6tZCVRslU7ZEz90/4Vy3xdUHRrA9xdjH/AHw1YVncXmnu0ltM8bMMMF6VF4r1C91rSIYX2ySwSiUHGGYYII/X9KAIxcG20G4dfvGPYv1bj+taMTDTvDWehKVzNrcfbktbcdN+9vw//XWt43ufJ0pYU6kYAr3MBSvTiv5nf7jy8XP335I5TTW/0eWU/enlA/DrXI2yK893DIW2vK6naSD1PQjkV1UR8qWxtu6oZG+p/wD1VzVim/U7oD/ns/8A6FXBnFe9acl00PSybC+2lTpP7T/D/hjotK0RTpc97cMXkwAZGADPgYBOAK5HV4i586K1kuZImBRmm2xx9s4z1OeoBNeieJrkaf4WggXhpK811fYlkjzx3w3sFWW2ZsKfRlU5P5ED2r5unpVilufo2MtLL60paR6L02Pd/gWSdM1HP96P+TV6fXl/wJXbpWoDkgNGMk5PQ16hXrn52FZ1/omn35LXFshc/wAa/KfzHX8a0aKAOSuPBFqxzb3U8X+8Aw/pVf8A4QZs86nx/wBcP/sq7WigDkY/BFsMebeTt67VC/41q2PhrSrQhlthI4/ilO79Dx+lbNFAABgYHSiiqOr6nb6XbebcEknhUXqx9qAPLrbFlruoo3AjncAf8CNXbq4uL9fLjUqn6mqt873l/cXMcQTznLlevX3pIrqW2YbwQPXtWUKSjudmIxkqukdEOazuIecn8au2EMtwjbmCgHb6k05bprpQq/M3t2+tOuLz7CiW8GGumHAI4X1J/wAK1OMj1SHyIY0jTBdsA/1qkbEsmc81Ymil2eZMzPJ13E1inVjBqMdvI2BJnbnvigCaG/vtEuxPZzMMfeQ8q49CK9a0bUYtW0yC8g+7IuSueVPcfga8m1ba8Oe5Fdb8Jpi2k3sJJOyfcB6ZUf4UAdzRRRQAUUUUAFFFFABRRRQAVleLP+RV1n/rym/9ANatZXiz/kVdZ/68pv8A0A0Aed6bruo3fh3SoVc2luLSJQE4LfIOrf0pVsVKlmYknvTfCbxyeHtOtpwp/wBFix7jYKs3cM1uCFDPH2I5I+v+NAFew1O60e43W0p2Z+aMn5W/CvQtJ16y1CNP3yRzN/yzdsHPoPWvPba3WQhnOSf0qa8tFVO1AHqdZfir/kV9Y/685v8A0A1y3hLW5LW6WzvJS1s/CM5/1Z7c+ldV4jdG8N6qysGX7JLnBz/AaAPIfD9rb3unPbXsMc9tKpWSOVQysvcEGq+hWWqaXrcK2qzanoTyCJBJLmeyXOB8zH95GPc7lH97s/R51h09juCluASf89s10+l3EEOnGWOWNsxeYu1gdynoR7e9engqVoOp1eiOHFT95Q6HK+Ors3WrpBGGcRg/KuMn6Z4/OvPi5a8ilMt1JvBObmIRMOTxgKvHvj8a6O9uy97czk/MflU+5P8AhmsnxAAup2wHTyFP6mts2agoUV0ROBTfNN9SzPrE8lvLYxESWt1A8G9BkxSjOQ3sQfw2+4rCvBJEv2nUJ44Fgt1TZv4kc/ex69BjvyfWu08JaXFd3jzvGo2qC5A+8QO9Yev3Ecd9IyTQW6Rv/rZl3InbJGR/OvlKmJmp3Wx+i4TJcPLDunUXv2u32vsvkdF8F2Eni3TmIIyJCAwwR+7avoevm/4KNnxXYBLpboh3zINuPuN0x7V9IV6R8U1YwdZ8NW18Wlt8W9we6j5W+o/qK5K803VdMyZYWeIfxp8y/wD1vxr0uigDyTT7s3HjnworDBW5nP8A5KzV63XI+J4Yk8Z+DJEjRZGvLgFgoBP+iTdTXXUAFFFFABRRRQAUUUHpQBgePIml8JamqDJ8rd+AIJ/QV4jbTKgwSM16t8UtYay0qPT4DiW+yjH0j/i/POPzrzq20a2eLmNWOOuKAGJepHH85IBIGfT3q7DKUbDdaZp2io0d5GYsx4xj2IOayrS9EV7Jptyx+0Q5Ebt/y0Uf1FAHbafIjqN1F4io4eI7XHQisKzu2Q4zV6a4LgAHk0AasF1DdxbLkKGBxg/0pslmltmSIEqevfH/ANaobC2VxyBz61fUNb4ViTH2z2oAS3WORcHGazL4CGX5Rmtd7cOu+D5W9OxrKeN2uWWVSCOMGgDO0+CK2vnnPCu27HpVTxRIb2+gRQfLzwccGumFlG6e9Z1xD5Te1ejhsxlRa5ldI462DjUu07NnCpcCbxBKwOVVti/Qcf0qjoyZ1W5J6G4P/oRrVvNI/s/VEmgJNvIcjuVPoao6CudSmJ7zuf1ryMbNyi5Pq/1Po+H6aWLj/dT/ACsTePJI9Rnhs5UWSDbtZHGQR9K4fVNJihuFi0+5u7NE52pKXTPsj5UfgBXX6u3ma1u7CuevjuvHJ7tXHg7yqNn0HEVqWDpwS1b/AA3/ADPU/g1J4qstNvmsINK1aAOm9JJXtJcYPQgOrH67RXq2g67c6lcyWt9oWqaVcxpvP2lY3ibkD5ZI2ZT16Eg+3Bri/gV/yC9R/wB6P+TV6hXpHxB4ZonxH8Tf8Jj/AGf4pf8AsO4lnnS30240l/IuI1Vihhuw+HbgEkgKeQMcVy+kfHnxPe6b4Xgk060j1S51GGPUZjE3lfZpmXyTH833mDOOpwYm45r2zTfhv4U07UY7210tvPiDiHzbqaVIN4w3lo7lYyRxlQKsHwH4aOhaXox0wf2dpc0U9pF50mY3jJKHdu3NgseGJHNAHnl38XriH42ReHQ+nf8ACN/a10l33f6R9sMe4EDd9zcRH065r2quLvPhx4L/ALJktLrSLdbY3RvWlaZxL5xfeX87dvzu5+97dK1L3xZptuSsTSXDf9M14/M/0oA6Co55o7eJpZ3WONeSzHAFchJ40kLHyrEbe26Tn+VYuv67PqjRLJH5MKfwBsgt6mgDo77xlbxuVs7d58fxMdg/Dv8AyrlNc1WfVLwTyx7EVQqqDnApLSFXIJ6VoS20XlcCgCrp0sRHOKkuo1uG8uNQWI9Og9aSx0lJHaV9wjP3QGxk+v0qXUZ0061CWyqJHO0cd/WgCYzWunQJGGVWA6dT9cCsqy2SX0srk7mYkZ9O1La2TyKZGJZm5LHvVe8BgbP8S80Aa97IoiIBzxXm/i8mKGG5Xhop1IP1OP612L3Ae2DA9RXC+OblfKt7VTmSSQEj2HP+FAG09951pGO+2vVPhxpj6f4eWSZSst03mkEchei/pz+NeQQJ5dnDIh+ZcHNe/wCk3X23S7S64HnRJJgdASAaALVFFFABRRRQAUUUUAFFFFABWV4s/wCRV1n/AK8pv/QDWrWV4s/5FXWf+vKb/wBANAHlHhcSHR9LkBUFbaPA6/wCt5b2SJsXCfIf4l7VzfhC4xo2nA9Ps8f/AKCK6SeVHhI4oAbNbsP39mQynkpn+VUp7l5DsIIbptp1rdNbzFVy0Z/hHatNTDdocDbIPUcigDLS0LLlzub9BRmaKOWEu6pIhjfacZUjBFaEW6GTEi/4GmamyFNydaAOJuvD4nYWs8rGDDhOTn5l27uD1AJH41a8Uac+nafPcWdw8JuDEkigllEMZLbADkjJLfdx941rBXLKzAkr0qvrqy6hbxoihSnYnrXs4PE0VGEJO1jzcRRq80pLU85sr03sUTMhSTefMU9mHBHvg5H1Bqxr67tYtB2MCj/x5qbeRm11FojF5W1sbcY/H8an1Ub9Xsj/ANMP6tXm4+s6lSdS/wDSPUy2gpTp0n1a/FnWaRINP8N3dweGZSBXndrqEdy91LZ3to1zEWO1mDgEdQVBB9q67XLho/D0cK8ButcVrenWc9lAtzaQSuedzxgkfj1r5+EVUnGB+j4mrLC4ariFu/8Ahkdv8EQ7eKtPMqRxyZkLCM5Gdjd8CvoHV9V0/RrM3er39pYWgIUzXUyxICeg3MQK+Z/hLoPmeKLJdN1XU9LlPmBZLeUSBTsb+CUOuPwr0b4p+FtUvtP0J7ufW9T1LT7qWe21HSrS3LW5KqAJYHYLIDzyuMY6DNeyfmx6ZZ+INGvfsf2PVtPuPtoY2vlXKP54X7xTB+bHfGcVLHrGmS293PHqNm8FmzLcyLOpWAr94Oc4UjvnpXzy/gPx3rk/gq5u7e30rXLCK9uUvIoEijimMsbRmZIiVDSKGDBcj5j3zVfTfh/4q0vwb4h8HaZpk0sereIgr3V1IY45LNERnkZwGIEhTbwD948UAe2a/cwXnibwNcWc8VxbyXdwySxOGVx9km5BHBFdhXhHwx0vXvDl94d8N+IbH7Omma1dixljcyRSW8lrM4COQC20lhkgduK93oAKKKKACiiigApDzgUtBOKAPKPi+WXXdOLH92YCB9dxz/SuctdTiiUJuBaum+Ls8d1q2m2CqC8KNI5/3iAB/wCO5/EVT07TI0t1YQoOP7tAF/Ro2ls5JyMCUcfTFcV4v0ndcyOSY5N5eKReCD7V6DpLjyZIT0QED6GqVxGLi6myuQGwKBnm1hrirIttqZENz0WTokn+B9q6RHYbWJyCOtQ+LNCt7u2dZYx09K4jwjrMtlr39iXtwZLaTKws55R+wz6Hp9aTdhxg5aI9dsJ/kUg1pS3CPDg9a5SKSS2bBzVt74mMADk0yTb0+6QTGIsPUZ7+1X7yzE2HQ844rC06NR878k9609+xcxuV+hoAY9vcIDswf0rHaGaedhNlcHBFbUGpEuY5F3AfxDqKknQSrvADH++vX8aAMv8As1BHkDgVnyabbPL8kKiT+8owa3JPNWMjBI9qr2gWJyZOppNJqzLp1J05c0HZ+RjSeHbPeZXt9zHuWP8AjWDrHhC0uDvtna3l64PzKf6ivQJ7hGQgYrIYebMB2pRhGPwqxdXE1q9vazcrd3cPh9ez+GbG7ikgWaSZl2kPwMA+3vXQTeJdXuCfK8uFf9hMn9az7eOJOoq/BJCq8gZqjEpyXuqy/fvbgewcr/Kmx6lqlqdyXs5x2Z9w/I1aupkb7oqlI6kHNAEV3fXOqTmS7lLMOgHQfQVJbWqMwBqvbK5lbZE7c8YUmtS2tLh8NhUz6mgB7WsSqAAM1QvIUww4xWo9oyjM1yqL/nvUGNPiO52M7j2JH+FAFCxiuViUiBip+62QAa0mjEcfmX0iog/hB/z+VR3OtJDGTHAwc8AtjAqmkZuZRJOxdj69qAH3OqTSgpZoYoum8jk/SsO4DpMHdmY55JOa6jy4xCRgVzep8TEDpQBt2V5i2C47Vl6pLuc+tMsp9kQ3HtWRr2rw6fay3c+dqjCqOrE9AKAILzUlsNN86dsIvCjux7AVzFnpt3rl417MCGJ+Vf7o9KrW0d5r13Hc3nyQqcRRDoo/x969J0SOGytguV3EUAYEUUwKWYUtKzBFA6kngCve9EtTY6RZ2jHLQwrGxHqBz+teHa5hbkSIcHOQR2r2/QLxr/RLG7f78sSs3+9jn9aAL9FFFABRRRQAUUUUAFFFFABWV4s/5FXWf+vKb/0A1q1leLP+RV1n/rym/wDQDQB4R4aukfQ9NlgcNGbeMZB/2RXQpdZi6159p9pqGkaZaXdjAWieCNpIGPyt8o5Hoa39C1i01VGWBzHOv3oX4ZfwoA7DTlDHJNbLW4KBo+GHQiua0242naxxW9BdFUx1FAFiGRZQY5APcH+dVNQsnjKuDmMHkHqKgkvNlwpQZbPT1rbjmgmhCuSPTcKAMy3WPGGAqtqEcajIIFazWCNkxt+RrK1DTZBIr72ki7+xoA5vWtPi1K34H+kR8xuB+h9q5y9027XUIZTA5jSEKWAzg5P+Nem21rEUAwKrXCKsnloBk1M488XHub4av9XrRqpX5Xc8/wDEZL20Eag8Cud1hWxHlSML6V7MmnfLuwAfpVDULKGaNo7mJJUPGGGa5qWF9nPnbPZx+e/W8P8AV1C3ne/n2OW+DZ/4q7TyPVx/441fRleGaDpUekarHfaYXjdMlVPzAEgjv9a6aWfU70/v7qYj0DYH5Cus+fPR5ru3gz51xFHj+84FV01bT3fat7blvTzBXnf9msBl8montFA4oA6zxQwbxd4KKkEG8uMEf9ek1dXXj+lh18eeFUZiVW5nwCeB/os1ewUAFFFFABRRRQAUhGSPY0tFAHiPia4+0eN9TkfnZL5Y/wCAgD+lbVvqUQtwhIBArl/ENtPP4x1aOF9o+0uS3XqatQeH9oDPLKW9SxoA6rSEMrPIPuvnH4VE8q217OrkDLZ/OtDSCBZx5ADAeXx9axdUhF7dSSHoCVX6UAUNeuo5EYKR0ryvSdGttR1HVZbxWdgwihVeu7qT+HH513Ot20kETsjHCjODTfh5ZKNKa9K/vLmZ3BPYA7f/AGWscQ7QO/LY3r3fRBa3Op6ZbImsWsl3bqMC4TBlUf7Q7/Xr9auW17YalEW0y6jmZOWTo6/VTyK6wWn7rL8g9q47xJ4atzcDUdOkFlfxfMsq8A+xHcVhCvKOkjtrYGnVbdPR/gatjfbRsk7Vee4Uxkg1xlrrSeYsGrxixuiOHbiKT3DHp9D+tbihtvByD0IPFdcZKSujx6tKdJ8s1Y1tPcEZ6961UlULlTtb2rlrO4a3kw/TpWtHcxuODVGZpR36K+2cDB7ipWuLRzgMT7bTWDdyDORWhZTIANwBoAvB7M/eQZ+gH9KsRLbsp2RLg+oFUpZInQ8Csi6meJ8RuygnnBxmgDovssDN/q1/Mig2tsD820fV6wbeTcOSSa0Ld41HzdaALzLYoOdn5Z/rTRLZIcqce4UCqcsqtwBVWQ4WgDYe9sY4t5kDHONoOWNUZr+aY4iAij9uv51g3Bw+R1HIrRhkBQZoA07e3RxukJYnuTmmXcSIMrUEdwUGM8VFPcZ5Y0AUNWbEYHerVm5MCnvisjUJjM+B06VNHcPHGFNAGtJMQhGax7r97OAKXz3c4GaxPEV5LEg0/T2DapdDaoHJiU9XPp7e/wBKUpKKuy6dOVSSjEdqmrWenYjlnElwfu28XzOx+g6fjXC6nd3er68be/hNuICNsB7Z5yfU4r0jwz4TsNDtlZEEt0eXlfkk1i+L7BB4u025UANPEVb3Kkc/k36VhTrOcrHficFGjS5k7s2ND0lBaR7wOmcVLfaeYxuiyuPStywhVAqN2UfyqW4ReR1GK6DzThLkySSqhyzdAB3r3nw1avY6DY20v+siiVWHoe/614rqLNZX8NxDgPE4dfqDmvdrSZLi2ini/wBXKokX6EZoAmooooAKKKKACiiigAooooAKyvFn/Iq6z/15Tf8AoBrVrK8Wf8irrP8A15Tf+gGgDyuwtA3hfTSwHNrF/wCgCvJfHCf2Zq8FxZApcq4ZSvrmvUNN1VG8N6bGDyLWIc/7gritSiW78YacxTzRGTLs65K/d/8AHsVM3aLZth1zVYpdzqtGvItX06O9tOGPEsZ+9G/dTWilxKikHPFZkHhu4SZr21ufsd43URjKt7MOhqK+1+fSn8rX9PZYzwLu2G5PqV6j8M/SsaddSXvaHZiMunBt09UdHphDtvfBatpZlxgiuTimEZSa3dZIJAGR1OQwPcVpxX4ZeeDXQebsX3uXScCBip6mtGOYyjL/ACMf4h0P1rnILgNdHmtmKfaMEZFAE5tjklCBn06GqptZEl3soJ7c0S3LRHfGce1Txam0qjbACT/tYoAQyy7f9S/5VQnt7id/lifn2rXFxKoz5Ix9Qf6UJqCbsPtj+q0AZ0cZtwAyEEeoq1FdbDnbVs30GceaCPbNO+1wE4BZvoKAKsl00gIVSfwqqUmY8ROf+AmtZrtVHyxufqcf1qu+oDP+oX8TQBj2sMsfjzwo0ihQbmfHIP8Ay6zV6xXl63oufG/hJBHtK3U56/8ATrNXqFABRRRQAUUUUAFR3MogtpZm+7Ghc/QDNSVR17/kB6jj/n2k/wDQTQB4roEplvnuJjl5GLsfUk5NdZNPEUAGM1wOhpPM5WFtozyxFdNHpjDBe4lLfWgDptNXECc8M279azrdRkBq17ZcQQ47IOK5/VpWtLyRB0zuGPegDO8XKosLjb12Gqfw+dW8KacQc43g/UO1VtavDLaTBuSVNVPhXdCbQrm2J+aC4YAf7Jwf5k1hiF7p6GXO1Vruj0e6kAiGPSuf2i9v/Lcbo4uSD0J7VfLkxkE9Kp6KwN5c567hXE3dntwjyRbLt3ptteR+VcQJKvowzXP3ngrysvo15cWLf3EbKZ/3TxXbgiNAcc0guVH3gK0Ssc7k5K1ro8run8QaHOG1mOO+048PNDHiRPfA4P5Vu2Tx3dus9hOk8J6Mhz+B9DXdtHb3SFXAIPY1yuqeBrJ5muLJprOc9ZLZyhP5VrCrKO+px1cNTqv3fdf4FVkmdcFTRHNLb8MDxVK78MapsKx67fDHq3P51hW3h7VY7ppLfW7w3SHDR3DmRGHuCehq/rMexmsrm02pI7NNRUjnrUc06y1gtPf2q41PTJMjrLaHep99p5H60v8AbemIMPcTIe4a2lB/9BrRVYPqcksJWi7OL/M24pmT8KtR3ikcmuUk8RrgppOnXl/L2Owxp+Z5/SmW2q69tH23w2Wz/FDPjj6EH+dDqwXUqOCryV+U7E3a44NQS3RYe1c8mr3A+9oGog+gKkfzqT+0NWmGLXRDExHDXEwAH4Ac/mKPbQ7gsFXbtymtglXkcgKFJJPAApxMkSDHIxwa5m48P6r4jeW11bU/JhXG63t12ofr3P4k1bsfBWo6NFt03XbiOEdI3UOg+gOQPwrP6xG+x0/2ZNLWSuarXMvoacrSyDLDCjqTVF11aJ44XvLdnfgMsGCPfripl8NG+wNXv7m7TvHkIh+qrgGh4iPQUcsqfaaSMe58WaJb3jRGaWcpwWgjLrn696b/AMJdazHbY6Xqdw/bMQVT+Oc/pXa2ej6dYxhLe0iVR/s1LPeWloP+WaewFZuvI6o5fS82craQ69qn/LKPSrY9wd8uPqeB+VaFp4YtrEF4Xm+0Ny0zPudj6knrV9tZ3H91bzuPUJxTDrDg/vLS4C+uzNYym5bs7KVFUvgjYhaS7suJ/wB9D/fUcj6isbWpVu/F2lQIQ2yAycf7Tf8A2NdLBqFrdHbG4391PB/KubFmsPxKQg/JJZq6j+78xGP0/WtKC985sxb9jax1GsyGznhIBw8YOPpxWd/auch1I963tYRXurcEZG0gfnVC6sY2Q7kruPAOc1dxIgI5r2Twa5fwrpZbr5Cr+XH9K8W1CJ4X8vqM8V7rolobHR7K1b70MKo31A5/WgC7RRRQAUUUUAFFFFABRRRQAVleLP8AkVdZ/wCvKb/0A1q1leLP+RV1n/rym/8AQDQB47ZWCv4c00462sX/AKAKxvCduJPFeoOefs0IQe24/wD2NdZp00f/AAi+lrxn7LF/6AK5fwfJt8X63D3kiRwP90kf+zVnW+BnVgv48T0Ozt1aLe1U9Vjt5IHS4VWjxzuHFXraZRbbe4rG1FjLcQw9nbn6CuB7HvwTcnc5KPStR03zJ9Ei82wZtxtJTjPqUParEGtWRYJdGSxl7pcrs/8AHun613sMPyBVFNu9Gt72IpcwRyA9iM1rTqSjocuIw9Gq7vR+RyuM7ZYWDKehU5FX7e/4Cv1FZWq/DqBS02jzz2Nx1BicgZ/CqUOpy2TfZ/EkDW068C5RCYpPc4+6f0+ldEKyej0POq4GUFzQfMdTLOJE4NJp9yE4zyDWOl5p7ruTU7MoRn/Xr/jUM2p6VA4H9rWAdu32hP8AGtbo5PZy7HaLdkiqN+29SR1rJW8li68j1pxvTJ1pkFi0kHGa04JQpyOawQ2Wyvep0nkjxkZFAG69yzDgYqB26kmsz7b2wc01p3b1xQBY05g3j3wrj/n5n/8ASWavXq8Z0QN/wnnhZm6faZ//AElmr2agAooooAKKKKACsPxrdmy8K6jMv3jH5Y/4EQv9a3K5H4pbv+EOuCucLJGT9N3+OKAPPPC0aqw3CunudnGzrXD6RqIhIUKzv6LXWaHO15eATRPGqjdz3x2oA2zL5EJJ/wCWaj8fT9ax5E81izjczck1o6kcREf3nGfyqGLYEyetAHLeJ4I4tOmkCjIUmuT+G0M39m3dzbxv5rXJ24HylQB1P1z+VdR49ulh0W5P+wa1fDenrpWh2VkijMcY3+7Hlj+ZNc+Ifu2PRy2P71z7FKW7uIhmaCRR3IG4D8qbolwv9pyAEESKGB+h/wDr10gtmYHK1i6rpjQSLd2iYmQ5IH8Q7iuJprU96NSMvdOmLhoQO9c/qKyWVylypY2uSJFH8Gf4vpkVoaZdpdW6up4P6e1TzICpyAVPBBq3qYR9x2IIJiACDlTyCK0ILs9M5HvXLySSaPKiKnm2UhO3n5kPp/hWnHKHjWWFtyNyDSUrDnTTNSbaxyOhrn9ag+zypeRj7hw49V/+tWxDKHX3pt5EssDqwyCMGm9RU3yMZDtmgVxjBFVJoY9xDxqQeDkVW8P3OwNbSnlCVB+laV4nGRU7ou3LKxm2BW1la3YD5eVPqvathFVwCCK5/VBIsH2iIAvF1B7r3qO11aVNqmJyx6BTnNJOxcoOSujpvLA9Kr3K4xxVe0uJrk5C4A65PI/CrcoIQZqjKzi9THRxDrZPQSRj9DWjd3S7OuB61ja4XjureSNgpwRk1Xgs59RG+aZhF2xxuqb9DflTSkya2lS41QvnhVwme/rWsswB5qoNCtQg+WQMOjBzkVVnhuY544Em3q+eWHzAfWjYHyy2LstzLdSGO2OFU4eTsPYepqa2sI15WMFu7tyT+NWbK2WONURcKK2ILdUUF/yq1G5zzqqOiMxbU4pGhK9q1JZUHCKKrl92elNpEKcmY1zZwXLYljAYdHHBH41xt8L3TPiJYy3ZLWksIihlPRgMkg++TXoM6Y5FYniuxOo6BP5Yzc23+kQkddy84H1GR+NVSlyyM8XB1aTSNvUGP7mXqFP6GiWVZIxgVFoMv9paLazNyJIhmsz7f5UjxspZVJG4c5rvPnjP8QRgHIr1zwjenUPDen3Lkl2iCsT3K/KT+Yrx3WrlZlypyK9S+Gpz4Osh6GQf+PtQB09FFFABRRRQAUUUUAFFFFABWV4s/wCRV1n/AK8pv/QDWrVDxBbSXmg6la24DTT20saAnGWZSBz9TQB4ZphuF0HTztJH2aPGP90VzmiXrWnxD3N9yaFo3PoOD/NRXeWOleKrfSbW0fwlcl4oUjLC9tsEhQP+entXM2vgrxpF4nbU5PDEjRBGVU+22+ckY5+f0zUVFeLSNsPJRqxb2udyJFVuDwazriUDVrY54JI/Q1VGi+M402xeG7kgdFa7tsD6fvaa2i+MmkidvCs4dGDcX1t/8XXD7KfY+hWLw6+2dran91kdagmvlhfEj7WxkZ71St/+EpiTB8IXh+l7a/8AxyqmpWPiS+gaN/CN6CfusL21yp9f9ZV+znbY5ViKHNrI6CG+DcNg0+4tbS+jKuiNnswzXM21r4uWFBN4TujIBglb22wff/WVcjHipcf8Ulef+Btr/wDHKahPqhSrUU7xkVL7wfpLO26xhye4Fc5qXhHSrWVS9mjW7Ha3H3T612jSeKHXDeEL0n1+22v/AMcqpeWviW6heN/CF5hhg/6ba/8AxypdGXRGtPHU18Ujm7fwxcWUQ/sa+eOHqIJh5kf0GeR+BFNYa1bnEmmW0/vFOU/Qg/zrf0208W20Ajn8J3bkdCL22/8AjlTTW3ih/u+EbwfW9tf/AI5VxVWK0Mqk8JUl71jkzca/PK8VnplrbOOC00pkx74AFJF4d8UmVrhtfKSN/AIlKD6KRiujk0/xWbiOWPwndBgNrZvbbkf9/KuxxeKVGH8I3h+l7a//AByhqq9wU8HBe7b8/wAzmhpnihD/AMf1jJ7vBj+RFPOmeJHH73UbWIesUAJH/fWa6bZ4m/6FC9/8DbX/AOOUx4vE7KQPCN7/AOBtr/8AHKLVRKphL7L7jE8MaVLY/EDwxNcX1xdSSXE4Pmtwv+jTdB0H4V7jXlegaT4hn8X6HdX2gzWFpZyyyySyXML/AHoJEAARyerjtXqldFJNR1PNxcoSqtw2CiiitDmCiiigBrniuf8AiEqN4N1QSdPLBH13DH64roH6Vx/xZlaLwfKq/wDLSaNT9M5/pQB5r4XtFHbJPeuttx5E0bAYIIrnfCbhVUv3rpZ3DMNtAF65j82KRRywG4fhXOz3zoD5cLvit27lIt5AvDZ25+prOji3igDz7xldSy2375HVN6ZBHbcK9KtlzcYNcZ47tS+j3AUfMF3DHqOa6nSrtbq1tLtfuzRJIPxANc2I6M9TLXpNG5POsQCADNV2KyryKparM8arKibxn5h3xUNteq6bkO5e47iudy1PRjS926E+wtBdGW3O1WPzp2PuPeryZZSGqNLqNupxTzPHjg1Ohb5nuUr63FzazQn72Nyn0I6Vk6XcG3ZWf/j2m4bP8Letal5dCCGWU9hwPU9hVLSLdZLQxT4O4YxSe5qtIu5o5MUnHSrisJI6yLV3Ae1mz58PQn+Nexq1ay4OCaaZMomNLZzf2ncNauA4Iba3Q8etatjdNODFOhSZeoNWBbk36TJjDLtb+n9a0XslUGQ43Y60KIp1VomYssY3lW+6wwRWDZgxX8UTdYpCn8xW/fHEgxWJejy9ZVum4xt/T+lSzanqdfDGPJD4qC8OEq5Ac2YqhfthRVvY5YayMPWI/tElsg7titqyiVVUKMKowBWccPeQ/wCypb+la0R2RZqUbTeiRJOcLxWRD+81OZj0jUKPx5/wqe8ugo+ZlX6nFUtJlElzclXD5cHIOeMUN6hCLUWzoLfCYJp9xeL64FUb25WCAsxwAM1kJBcah80rukZ6Ipxx71V7aGapKXvM07rU4IlJeRV+ppukXLTxvK54dsqM9B2qtDoNuDl4lJ9WGaupplvGQUjVSO4GKWpb5ErIuOAy1UhOJSp6HtVpF2rjOaok4uaGRHqit4fk+xeHrm2Q8wzPAv8A30R/KkS1BUkDmq9vlZdTTsLoN+a5/rWzGgEOfavSi7pM+aqLlk0cXrcBilBHAPWvYvAdsbXwlp0bfeZDJ/30xYfoRXlniWPgMK9a8ISmbwxpjMcn7Ogz9BimQbFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAB6Vx3xZhMng6Zh/yylRz+eP612NZfiiw/tPw9qFmPvSRHb/vDkfqBQB4doV4EQDOSO1dRZTTvKjyR7YwQSCeSK5Lw7Cqz5cc579q7tUHlA0ATXv3JCOhINQQTpEp3EVZCeZajJ4xiudube5klePeFVTjI5JoAZrU8U8cinkEEVR8BXu7TZbCQ/vrJyFz3jJJU/wAx+Aq0+lEodzOxPqa5bV47vQbyPVLFSWiG2SM9JEPUH/PWs6kOeNjowtb2NRSex6PLcnyidpYAcgCsQ2t1c3Hm2qvAF79z/wDWqxourW+pWUV5ZPvikHIPVT3B9xWxFcqR2rz2u59HGVlePUwzLfwnbParJj+JcrmnC7uCuEtMN7t/9at8zJjmqGoX4i2xwpvmfhVFFilNy0sVIbKW5cS30gwOVQDAFV4ZWt9XeNzkEAqfpVkWFzcYNzO6/wCxHwB+NV7rRGDK8U8iyL038ikUmtmzS1SBpEjurcgTR8j3HoarLKs8YngBHZl7qfSqlpez20jW12MEjg54NR6dHcSXU8ts4QA42sMhz70XBRaWps216AcMcGrMt+Cn3s1kORz9pglgcdSBuU/iKYz2w4E6n2707sn2aepYZjNNntWNeGS5uZZ41/doQAx77fT9a1FjluUKW6vHGRzIwwT9BUC77UiC6QBTwrr0P+FSzSLSOisZg9uNp4IyKp375cLTrECOABeFUcVXP72fJ6CrvoYKKUmyvFg38g/uqBW1CQ0YFcnb3nl6jLO/+pmOM+mOlbqXIUZBGKSZpUgye8tFkBbYrY9RWaLXyXa4tVCygfMg6OP8a2rC5ErbCODVa6j8q6IHQ02upnGbT5WZk0ovriFFOYwvmN9ewrbtUCx8CsaxhEep6gvpsYD2OT/PNb1qu5QBQh1XZWKF5eSWxyYndO5UZxU1nfw3KbkcGr09vujJK1gXVgRL51txMOqjgP7Gm7omLjNGtLOqqcHmqMOZJ81zkfjHQpBh7yRJBwUaByQfTgYq5aa1/akqWmjwzDzfla5kXaEHsOpNUqc5PYwliaNOLfNc1bG2+0W9/KnPmzFlPrt4pbWcNHtJ5HFbltbxabZIg/1cKkfXpXLXVvMZnuImC7iW244Fd6VlY+flLmbfcq+I3Hl4r1PwQpTwppgPUwg/nzXi+p3LzOI2Hz9MV7zpFsbPSrO2OMwwpGceygUyS3RRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVHchjbShPvFDj64qSj2oA+ctIn2TYPBzXXpeBYRuauV8V2LaJ4ovbbBEYkLx/7p5H86NMuXuZBuyRnAoA9DsHje3Xa6txyAeh9KgvIhHPkdG5FZ1tG8KrJESGH61phxdQAng9PoaAI44i4yOlZms2ST27xuAcjFaDzNbqQ/GK53UdVkkcrbI0nqR0oA4Hw59p8PeKbm2WTFvIhbYfuscjFej2+p28gHm7oW/2un51yeo6Tc37CbaI51+6c9fY0+2lvtPULdwmSEdT1xXHiIPm5ke9llam6fs29TsWu7ZV3G4Qj2bNSaNGJy90w+aQ4XPZRWUDZTWYlt1XzW4AHrXS6dEILaNR/CoFcy3PQqe7HQ0UWOKPL9aa7RyrjAFZ93MSRzVPTb2SVPLhXeQ7bnJ4UZ/nV83Q51SbXMV9etS8bbfvp8yH+lO0EAWsR7sNx+prRv1BAJ61Q0bAQr/dZgPzNT1N1K8LGqZUL7DjNSbEHO0flWRdHy9TiPZ1K/j1/wAatXN2I4CzHgD86dyHDaxbJB6VWuYI7iJo5VyppdNSQxGSbIZ+dv8AdHpTpThqBLR2Rj200kDyWkhyyHg+o7Gm6nMYrfyUP76bjjsven6orpewSQpukdGXHrjBH9azkJE0jXGftH8W7t9PapZvFX1HSrtjjt4kDytwq1p2uiwQRr5xMkp68nH4CotFjAVryTlpOEz2WtiBTI249KaRNSbWiLVhbJEAVUKBVa8O+6yKszTiOPA61jXty6/JbgPcv90enuapvSxhBNyuzOW8CeIZmLYhk/dZPQEdP1zXQWlx5bYzyKxoPDyNDi4lkdzycHAzSzpc6ew3lpoR0b+JR7+tTsbyUZ6I6d7remOKzWbdcDFVIZ/OjDRtkHuKp61epZ2rW6Sr9tnG1FzyoPG4+mKtXm7I558tCLkzkfDOiRXmq6hfSKGjkuJGj47Fia9C023SK6gWNQuGB4qhotrDZ2UcUZU4HUV0GmwFZBM/U/dH9a9FHzTd3ck1x9tp7MwB/E5/pWc23yRj0q34hmWS0eGHDSbgc9hjtXNDUCkbRyAq47UCK2mRxy+MdPSRQyG4UFT9a9zrxbwLbtqHjW1cDKQbpn9gBgfqRXtNABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAee/Fzw8b/T11W1XM9quJQP4o+ufwP6E15toGFIz2r6GuoEubaWCQZSVCjD2IxXz1LBLo+p3FncArJC5U+/ofxHNAHeWBRoMN6VXWYQXQGflY4NZdhf8A7nrzVO/uzLcRxRn5mPWgDtZoYrq2eOYZBBGe4rHi0swttCB1HQr/AIVJYicqN0sjE+9aMZuE54b/AHhQBXit4gMSR7T6EYqjqlnGELRge4rdF1HINky7Cex5U1n6jbBEZoiSO6Ht7igDiXjGm3kdzEP9HZsMv9w+tddBcqbcbT1Fc/foskE0R6Mpx9aTR53a0TJ6DFcNaChLTqfRYGq8RS9/dGpd3GyJ3J5A4qxpIEFkkffGSfU1jOTcTALzGhyT6mrEt6YlWKNS8jcBR3rC/U7pQ0saF7dKCATxUOluBAGzyxLfmc1CmkXV3zcSlNw+6g6fjT5tKubVP3EzPgfccdfxp67k+5bluSahmSEyKfniO8H6VFbOt/cw7TmNBvI9+39ao3N4ZrU20YYTudrjH3R3rS8Nwj964HV8fgOKW7Ka5Ys6SKICEk+lZs/3615TtgrGmOZa0kclJ3bYyaPN1Z+uW/8AQay/EMGIvOUYdOPqDWyuGvox/wA84yT9Sf8A6xqprag20oPTFQ9jeDtJEaARw28Q6KgFaSyCOIcHp2FZsxxMhHTAxWtDh4xTRMzKu7maXPkRN/vPwBRoEOYvPkO6WXlmP8qt6iwjgkPsQKfpkXlW8ansoFHUbl7hcHFUbxvmxVyR9orNlbzJsChkQWpxvjZ7mLU9NtdMnkt3nV2l8ptuRkAHj8a1tG0OOCHdJ88rcs78kn61UKjUvGM0g5jtVECn3HLfqSPwrskjRYeetd9KNoo8DF1HUqy10INE06JLwkplQpOM8ZrWupSo2p99+/oKNPi8uEseGf8AQVnPexyXcnlOGCnaMH0rQ5hJ49vBrltd3eYqxAl2OAB1PtXR3c2ELMaxtDgbV/FljCgyiyiR/wDdU5P8sfjQB3vw58Ny6LYy3N8u29ucZXvGg6D6nqfwrsaKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK86+KvhtrqAaxZJmaFcTqP4k7N+Hf2+lei0EAjB5BoA+bba4ZCMnirumOJdS3t2GBXbeM/AJ8x7zQlHzHL2xIGPdD/T8vSuEhinsbvbcwyQv/ddSp/WgD0CwKhRWkuCM8Vy1je/KMmtSO9GOtAFy6VXBGKyfthR/JkPGflb09qnnvBg4rAvpgS3PNAEt3APPHZGzn2rC0WTzrdhuOwscDpxW4rfa7VFclS4Kkg47Vz7Wc+iyEcyW/Zu4+tcuJi2k0ezlFSEXKEnq7WNuWRbaIKoy7cKBW94f0YqfOnG6dup/uj0FZPheza9nW6mGUH3M9z613Tyx20GFxnFYQjfVnfiqzi/Zx3I5hDbRjgZrNupklQ7cZrP1bUSz7FOWJ4pLB98EjHoDjPqaJSu7EQo8q5nuYmqAW+rRyKBiVfm+o/yK19DIjtY/Ukn9TVC5gF7qKqS22NMnBx1P/1qcbSe1GbZ2cL/AAP/AENZrc65WceVnSzygxjHSs1fmlJPQc1Ba3ouY8dGHBB6g0mpTfZrFth/eSfKv9TVN31MYw5dCTT5C7yyn/lo2R9BwKq61IXxEvJbr9KksW/doFxyoxV6OxjDNIfmdh19KW6KuoyuzNDeZaxMOoGD+FWrS5wAKrzQS2jsUXfE3JX/AAqANHI37t9rf3W4NIqykjYdYp9pc9DnFSmaOMdRWOFuOgGaR4JFUvPIsaDqzHAFO5DgurLdxdbzhKz9X1BdKsjIcNdS5WGPuzev0Heqtxrdpb5i08fbrroBH9wH3b/DNRaPot1d351DVn825b7qAfKg9AOwrenRcneWxwYrGwpx5Kbux/hW2EFruY5lYlnJ6knrXV20BbDycIOee9W7G0SCHaUUyMcnA6VDqMoiKRZwX5P0rtPDI7u5MgKR5Cdz61gXkYtpfPTg98d62ZHXZgVzmv3Y2eWnJNAFbU9T8xdkZyT6V6N8OPDsmlWb3t8m29uQMKRzGnofc9fyqbwp4OsNMhtru4iaXUNiuxkORG2Odo6cevWutoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAGSJvGK5Xxv4bOs6Xm3A+2wZaI9N3qv4/zrraMUAfOsV5JA7RShkdDtZWGCCOxq/DqXH3q9P8V+CbDXHa4jP2a9PWRRkP/vD+ted3/gXWbJyFi89B/FF82fw6/pQBA17lfvVTZ3nkCoCc1BeWx0yRV1BzAx5COpDH6Cqlzq3mp9nsY2jRuGlbgke3pWc6kYbnTQwlWu1yrTuJf63cw3ohskWW1h+Vs/xt3IPb0rodDlk1wrFscQrjzN45HtnvWboukNdsqIu2MfefHT2HvXo+kafFY2yrEoVV5+p9a5VUlJs9mphqFKKsveX9alyC0isrVVQBcDAA7Vhaxe7AQG5q1q+pCNSqtzXNu+4tcTk7B0HqfSonLojShRfxzGBXLKeTPKcKP7o9a2ZNllYhCcKo5qpYjyEN1OCZZOgAzgegpIUl1K63yoUgjbhD1ZvU/SoOh677ItaPbsQ0jr+8kO4j09B+VXrmA4zjBq9aQrCgZqZcyiZuOlXy2RzOo5T0Oavo/s7i6TgAgSD29aIbf+0G8+YtgjCKDjC1d1FAYpE7MCKraBJmOMH0xUdTo5vduivIrWcgjyducox/lWnYXwJAcfUGtC709ZoMsAwPasGbT5oTmFsgfwt/jRZxJUo1VqdMfs0yfKwBPasPUrKMKWCgiqlvczJKEeFw/pkc1qXTk2hLDBxTbUiYwdN7nn3jWe6sJ9MayurqGK43IyxSsoyMeh9/0rV0jwrbXka3GoTzTStziRyf51W8SwG7v9DtwM7Wklb6fKB/WupWPy7cfSu6ivcR4WOf7+SuT2ej2linyIqAe1WxKU/490/E1j6bPJI7rI5bacDPYVqxzbByK1OMHuZyCDIwHoOK57U7mSK6SQuxxxyc8VrXdyqAknmudMMusatBZ2xHmTOEBPQepPsBzQBbvNVVY+G5xWj4A0GXWtVXUr2M/YLdty7hxI46D6Dqfyre0f4b2sMqy6tdNdYOREg2L+J6n9K7uGFIIkigRI4kGFRRgAe1AElFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRWdqusWmmRsZ2Z3UZ8uMbm/+t+NAGjRXkXibxrrt7lNIVLSD1Q5lP4kcfhzWPp/xC8QaaypdOtynpMvJ/4F1oA91ppUGvO9K+KdhMVTUbWWBj1ZDuX8u1dfp/iTR9Qj32uoW7D0Z9p/WgA8R6BY6/p5tr6INjmNxwyH1Bryu78HSWOpfZ5ZoniHO5PvY9COxr0HVvEqODDprg54MwP/AKD/AI1kQ+XGDJI25jySe9cdZxm9D2sCq1GPvbPp/WwadYx2sKgKFRRwKr6tqgjQohqDVNU4KofyrIjhkuWLyZ2jmsXK2iO6FLmfPUI8mdmllbbGvJJqtDIby+UMuyFPuKe/v9aexNzcLGVMdup4B7+5q/d2sTQDyzjHII6g+tQdLdjWimiKAHAxTlnggBK4HOeK560e5ZMNJGxDFSGXB/MVc+yXTjh4kB7gE07mLgurLl3qW6M7TtX1NFg7sN2CQe54ptjpKBxJK7TSDu3QfQVpuiQr1yapJ7szcor3YmbqBIwT1rN05thdRxtdh+uatXchmnCqeKz0kjF9cxxSxtIr8oHBYcDtUs1jZKzOosr0ABXOVqa4eB+V4rm1nK9QakFySOM1XNpYzdHW6NR44XIJxx0qneSLIBFGc+tU7i5EURkuZUhiHVnbArEmln1km3sd8NieJLhhhpB6KOwpwg5uyM61aFBXk9exc0tU1HWJr5fmtolEMJ7EDqR+Oa0dQuBHGVFRRvBp9okFuAEQYFY2oXRkJyeK9CK5VZHzs5ucnJ9TQ02XDuw71auL0KOuK56G6YDZECzHoFGSa2dP8La9qzjFq9vEeslx8gH4dT+VMkyr29eaQRx5ZicADkk16T8PPC0mmIdR1JMXsgwkZ6xKfX3P6fnWh4X8H2Gg7Z3/ANJvsf61hwv+6O316104JPUY9qAFzRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFePfE53h8Ws8bsjeSmCpwR1r2GvHfip/yNR/64J/WgDno9WuVP70pOMY/erk/n1/WpTe2c4AngeLAI+Qh15/2W/xrLqrcXXlqpiQy5dVbaOgJAJ/DOfwNTKcYfE7G1HD1aztTi36GzLo9jcqDazRluOFfYc/7rdfwqhdaJd20uY2O7OBuBRsevp+tRmQry6FV9e1WNN1WU24ezuGMDZAHVWwcZAPBHHXvShUjPWLKr4WrhmlVja5BHd6jZtl920d3H9R/jWlDr820CVm/mKkj1ONhi5tlJ/vRNs/Tkfyp7WmmX5/dyKszZ+WRCh6e2R70SpxluiaeIqU/hkXNHu7bULxInmjVmONzttUfXPSvW9F0i1sLcGPbK7jmTqCPb2r5o12ZbF0S0DAtzufnv2r2/wCCU8s/gSF55Hkfz5BuY5PWphRjF3RrWxtWtHlk9Df1TwxZXmXiHkSHuo4P4Vzdz4R1CEnytkq/7LY/nXoVFEqMZBSx1amrJ3XmeSXWk31jIz3FtKsJ4d9pIX0OfShJJYhhhkdjXrdUZ9JsJv8AWWsf/ARt/lWTw38rOyGZ3/iR+482F86DgGonuJ5s8ED1rd+JOlmx8K3V3ow+zXMLISw+b5CQD1z6/pXj/wBl1DVUC6jqE80R52bsKfwHFJYeXVlPMqa+GOpsa/4nhsg9tpTC61Bht3JykXuT3Pt+defyaDfNmcsWkJ3E55z616Npnh+3t0BjjGfWtI2CgY2iuiFNQVkebXxE68ryOP8AD+qGW3S0mvJ7a+QbcM52ye4zxmtWT7dnEl/cgf7J2/yqLXNDhnUny8N6iq/hSwvv+EgsNPN1J9mmmVGBAbC55xnpxVcq7GftJpWuy9BbW3miS4WS4kH8UrFj+tajXb+WFij2qOgAr1GPwfo4JPkOP+Bmr9r4f0u2IaOzjLDu+W/nTIvc8r0nw/qusuDDCUhJ5lk4Uf4/hXoWjeC9LsI1NzCt5Pj5mlGV/Ben5104ozQBXtLG0s1xaW0MA/6ZoF/lU+RS0UAIBj2paKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK8Y+J5z4tn9o0/lXs9eM/FAEeLJjxzEh/SgDidQuI7a2ZpSyq3y7gpIH1wOPqanuL23sLW3cFCh4bd0GaS4UtCwXr1H4c0kmn2eo6eWnVHA6qTivMxt+deh9hw64ewlf+b9NCx/aEN3aC2CoCejf0qOSA2kqRHG1kBUDtVPStDgtme4shtGMlTyB9M9KcLwTX/lSeYZFXAPltt/76xj9aywzl7RWO7N40vqs77L8+hbq1pYzfwA/3qq1Z0z/j+h+v9K9g+BOU8Ug+Za8/wn+le6fAz/kQYf8Ar4l/nXhfij/WW/Q/Kf6V7p8Df+RBg/67yfzoA9AooooAKKKKAKesWKanpd3ZSHCzxNHn0yOteFaTbvFLJBOu2WJyjqexBwRX0DXk/jqw/s3xU06LiG9XzRjpvHDD+R/GgCW1iURDinPCMHiq1pcDAqzJMCpoAydRRQDTPBFt9q8baeAuVhDyv7AKQP1Io1OT5TXS/CbS2AvNXlUgS/uIc91Byx/MAfgaAPRaKKKADFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV438UY3XxVI7KQjxJtJHB4r2So54IriMx3EUcsZ6q6hgfwNAHzjVDUbWV4JTZP5c7DC5wVBPcj2617tqngLRr0s0Mb2kh7wn5f8Avk8fliuR1P4cajAS1hPDdJ2Dfu2/Xj9aidONRWkjfD4mrhpc1KVmefJ9qjQpG6hDx1IzUsSbEwTk9Sa0NS0m/wBMbbf2k0HOMsvyn6HoapVFPDwpu8TpxWaYjFw5Kj08lYKsad/x+xY9ar1Z0z/j+h+v9K2PPOT8Uk+fbDuFJP5//Wr3f4IAj4f2pPRppSP++q8H8TjFzCAB/qzwPqf8a98+Cgx8PbIf9NJf/QzQB3VFFFABRRRQAVyfxJsPtXh83KDMto4kB/2Tww/r+FdZVbU7YXmnXVsek0TR/mCKAPGrGTIHNW5psDrWHa3It4lEzBGyRhuDkdana9hcgeauTwOaAL+nafLrurw2MWVQ/NK4/gQdT/T6mvZLS3itLaK3t0CQxKERR2ArifhZCPJ1K428mRYw30Gcf+PCu7oAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigBGUMpVgCp4IPesHUvCGiagS0tkkUh/jhOw/kOP0rfooA831H4Zqctpt+R6JOuf/Hh/hWCvgvW7K/i32vmx7vvxMGH+P6V7NRQB5ZoXwsgnuILzxG28xji0jbg8/wAbd/oPzr0+3gitoI4beNIoYxtREGAo9AKkooAKKKKACiiigAooooA8+8U/DmLVb2S4s5o41lcyPDKpKhj1II6Z9KyLH4W3EV2jvPZRKp+/Hvdh+BwK9YooAo6LplvpGnx2lqDsXks3JZj1Jq9RRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Isolated intestinal transplantation is performed in patients who have only isolated intestinal failure and no associated liver disease. The arterial inflow is usually from the recipient infrarenal aorta and venous outflow to the portal vein. In patients with mesenteric thrombosis, the venous outflow is created to the inferior vena cava (systemic drainage).",
"    <div class=\"footnotes\">",
"     SMA: superior mesenteric artery; SMV: superior mesenteric vein.",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Khan FA, Tzakis AG. Intestinal and multivisceral transplantation. In: Transplantation, Ginnis LC, Cosmi AB, and Morris PJ (Eds), Blackwell, Malden 1999. p.422.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_41_2708=[""].join("\n");
var outline_f2_41_2708=null;
var title_f2_41_2709="Hemochromatosis (hereditary iron overload)";
var content_f2_41_2709=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Hemochromatosis (hereditary iron overload) (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?2/41/2709/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/41/2709/contributors\" id=\"au6887\">",
"       Bruce R Bacon, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/41/2709/contributors\" id=\"au5720\">",
"       Stanley L Schrier, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?2/41/2709/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/41/2709/contributors\" id=\"se4110\">",
"       William C Mentzer, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?2/41/2709/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/41/2709/contributors\" id=\"de4624\">",
"       Stephen A Landaw, MD, PhD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?2/41/2709?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      HEMOCHROMATOSIS OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Hemochromatosis is a condition that causes excess absorption of iron from the digestive tract. Over time, the excess iron accumulates in tissues throughout the body, leading to iron overload. Signs of iron overload may include sexual dysfunction, joint pains, weakness, changes in skin coloration, liver damage (cirrhosis), heart failure, diabetes mellitus, and rarely, thyroid disease or liver cancer.",
"    </p>",
"    <p>",
"     Early identification and treatment of hemochromatosis can prevent complications. Treatment typically involves regular phlebotomy (removal of blood) since blood cells contain an abundance of iron.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      HEMOCHROMATOSIS CAUSES",
"     </span>",
"    </p>",
"    <p>",
"     Hemochromatosis is caused by the excessive absorption of iron. The exact process is still being studied. As a general rule, a number of chemical events take place that regulate how much iron is absorbed. Central to this process is a gene called HFE. Mutations in this gene cause excessive amounts of iron to be absorbed. The most common mutation is referred to as C282Y.",
"    </p>",
"    <p>",
"     Hemochromatosis is most often seen in people who have two copies of this mutation (one inherited from their mother and the other from their father). However, other mutations causing hemochromatosis continue to be discovered. Furthermore, for unclear reasons, a majority of people with two copies of the C282Y mutation do not develop iron overload.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Risk factors",
"     </span>",
"     &nbsp;&mdash;&nbsp;Hemochromatosis is usually inherited and most often affects people who are white. In the United States, about 5 in every 1,000 people who are white have the condition, although some are unaware of its presence. Family members of people with hemochromatosis should undergo testing since they may be unaware of the diagnosis. (See",
"     <a class=\"local\" href=\"#H20\">",
"      'Implications for the family'",
"     </a>",
"     below.)",
"    </p>",
"    <p>",
"     About 10 percent of people who are white carry one of the gene defects associated with hemochromatosis, although most of these people have no symptoms.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      HEMOCHROMATOSIS SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     Symptoms of hemochromatosis usually occur in people who have inherited two copies of the gene defects (the most common of which are called C282Y mutations) associated with the condition. However, the relationship between the gene defects and iron accumulation is still being explored; some people who have two copies of the gene defect do not have iron overload.",
"    </p>",
"    <p>",
"     In the past, hemochromatosis was often advanced by the time a person noticed symptoms and sought medical care. Today, most people with hemochromatosis are identified at a young age because of abnormalities on routine blood tests or because they undergo testing after a family member is diagnosed. As a result, about 75 percent of people with hemochromatosis are diagnosed before they have symptoms, and most people do not have complications at the time of diagnosis.",
"    </p>",
"    <p>",
"     Symptoms typically do not occur until after the age of 40. The symptoms tend to occur later in women than in men because women lose iron throughout their lives through menstrual periods, pregnancy, and breastfeeding.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Liver disease",
"     </span>",
"     &nbsp;&mdash;&nbsp;Accumulation of iron in the liver can cause liver enlargement, fibrosis (increase in scar tissue), and cirrhosis (extensive scarring) (",
"     <a class=\"graphic graphic_figure graphicRef64960 \" href=\"UTD.htm?39/54/40804\">",
"      figure 1",
"     </a>",
"     ). About 75 percent of people who have symptoms at the time of diagnosis have abnormal liver function.",
"    </p>",
"    <p>",
"     Cirrhosis can cause a number of complications and can ultimately lead to liver failure or death. People with cirrhosis are also at increased risk for developing liver cancer. Liver disease is often worse in people with hereditary hemochromatosis who also have chronic hepatitis (such as hepatitis B or C) or are alcoholics, so it is important to simultaneously identify and treat these conditions. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/45/31447?source=see_link\">",
"      \"Patient information: Hepatitis B (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/4/17478?source=see_link\">",
"      \"Patient information: Hepatitis C (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/3/44084?source=see_link\">",
"      \"Patient information: Cirrhosis (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Weakness and lethargy",
"     </span>",
"     &nbsp;&mdash;&nbsp;About 75 percent of people who have symptoms at the time of diagnosis have weakness and lethargy (a feeling of mental and physical sluggishness).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Infections",
"     </span>",
"     &nbsp;&mdash;&nbsp;Hemochromatosis can increase the risk of infections with specific types of bacteria. Accumulation of iron in immune cells interferes with their ability to fight off certain bacteria, and other bacteria grow well in an iron-rich environment.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Physical changes",
"     </span>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Darkening of the skin &mdash; Accumulation of iron in the skin, along with accumulation of the pigment melanin, can darken the skin and give a person a tanned appearance. About 70 percent of people who have symptoms at the time of diagnosis have darkening of their skin.",
"      </li>",
"      <li>",
"       Joint pain &mdash; The cause of joint pain in people with hemochromatosis is incompletely understood. One hypothesis is that the excess iron leads to the collection of calcium crystals in the joint spaces. These crystals can cause joint pain and, over time, joint deformity. About 44 percent of people who have symptoms at the time of diagnosis have joint pain. The joints of the hands, especially the knuckles of the second and third fingers, are most commonly affected.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Other conditions",
"     </span>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Diabetes mellitus &mdash; Accumulation of iron in the pancreas can interfere with insulin production and cause diabetes mellitus. About one-half of people who have symptoms at the time of diagnosis have diabetes. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?9/22/9572?source=see_link\">",
"        \"Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Reproductive problems &mdash; Accumulation of iron in the pituitary gland can interfere with the pituitary's control of sex hormones. In men, pituitary damage can lead to impotence, loss of libido (sex drive), and even osteoporosis (bone weakening) leading to fractures. About 45 percent of men who have symptoms at the time of diagnosis have impotence.",
"       <br/>",
"       <br/>",
"       In women, pituitary damage can lead to amenorrhea (absence of menstrual periods), although women with hemochromatosis seldom experience loss of libido or premature menopause. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?28/33/29205?source=see_link\">",
"        \"Patient information: Sexual problems in men (Beyond the Basics)\"",
"       </a>",
"       and",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?29/12/29891?source=see_link\">",
"        \"Patient information: Absent or irregular periods (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Heart disease &mdash; Accumulation of iron in the heart can cause enlargement of the heart, abnormal electrical conduction in the heart, and even heart failure. About 30 percent of people who have symptoms at the time of diagnosis have conduction problems, which may cause symptoms of rapid or irregular heart beat. Rarely, heart disease is the first sign of hemochromatosis.",
"      </li>",
"      <li>",
"       Thyroid disease &mdash; Accumulation of iron in the thyroid gland can cause hypothyroidism (poor thyroid function) in about 10 percent of people with hemochromatosis. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?14/54/15203?source=see_link\">",
"        \"Patient information: Hypothyroidism (underactive thyroid) (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      HEMOCHROMATOSIS DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     It is important to diagnose hereditary hemochromatosis early in the course of the disease because early treatment can help prevent complications. Diagnostic tests can help differentiate hemochromatosis from other conditions that mimic hemochromatosis, such as alcoholic liver disease. Tests can also determine the severity of hemochromatosis and the presence of complications.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Blood tests",
"     </span>",
"     &nbsp;&mdash;&nbsp;Three blood tests are usually recommended to determine iron levels in the body.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Iron levels &mdash; Most people with hemochromatosis have elevated levels of iron in the blood.",
"      </li>",
"      <li>",
"       Transferrin saturation &mdash; Transferrin is a protein that binds iron and transports it between the tissues. Transferrin saturation is calculated from iron levels in the blood. The transferrin saturation increases as the body's iron stores increase. This test is one of the most sensitive tests for detecting early hemochromatosis. A transferrin saturation greater than 45 percent should be investigated further.",
"      </li>",
"      <li>",
"       Ferritin levels &mdash; Ferritin is a protein that reflects the body's stores of iron. Blood ferritin levels increase when the body's iron stores increase; however, levels of ferritin usually do not rise until iron stores are high. Therefore, the results of this test may be normal early in the course of hemochromatosis.",
"       <br/>",
"       <br/>",
"       Ferritin levels greater than 300",
"       <span class=\"nowrap\">",
"        ng/mL",
"       </span>",
"       in men and 200",
"       <span class=\"nowrap\">",
"        ng/mL",
"       </span>",
"       in women support a diagnosis of hemochromatosis. However, ferritin levels can also be increased by many common disorders other than hemochromatosis.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Genetic tests",
"     </span>",
"     &nbsp;&mdash;&nbsp;Genetic testing can reveal the presence of gene defects associated with hemochromatosis.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H873345\">",
"     <span class=\"h1\">",
"      TESTS TO DIAGNOSE TISSUE IRON OVERLOAD",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Liver biopsy",
"     </span>",
"     &nbsp;&mdash;&nbsp;A liver biopsy is one of the more useful tests to determine if and how much of the liver is affected by hemochromatosis. In some cases, a liver biopsy is not necessary because other tests are able to confirm the diagnosis. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?4/39/4721?source=see_link\">",
"      \"Patient information: Liver biopsy (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Response to phlebotomy (blood removal)",
"     </span>",
"     &nbsp;&mdash;&nbsp;The body's response to phlebotomy (the removal of blood) can confirm the presence of hemochromatosis. During quantitative phlebotomy, a fixed amount of blood (which contains large amounts of iron) is withdrawn once or twice per week while iron levels are monitored.",
"    </p>",
"    <p>",
"     In people",
"     <strong>",
"      without",
"     </strong>",
"     hemochromatosis, four to five weekly phlebotomy sessions will cause iron deficiency and, ultimately, iron deficiency anemia. In people",
"     <strong>",
"      with",
"     </strong>",
"     hemochromatosis, 20 or more weekly phlebotomy sessions may be needed to cause iron deficiency.",
"    </p>",
"    <p>",
"     Quantitative phlebotomy is an option to diagnose hemochromatosis if a person cannot undergo or does not need a liver biopsy; it is also an option for people under the age of 40 who have evidence of hemochromatosis but normal results on liver function tests. Some young people with hemochromatosis, who have not had time to accumulate much iron, may only require four to six phlebotomy sessions to deplete their iron",
"     <span class=\"nowrap\">",
"      stores.",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H873353\">",
"     <span class=\"h2\">",
"      MRI methods",
"     </span>",
"     &nbsp;&mdash;&nbsp;Radiologic/MRI",
"     methods called T2* have been developed to provide useful information about the level of accumulation of iron in the liver and heart.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H15\">",
"     <span class=\"h1\">",
"      HEMOCHROMATOSIS TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     Treatment of hemochromatosis requires removal of excessive iron from the body, usually by periodically removing blood (phlebotomy). Treatment can help prevent complications and even reverse some complications after they occur. Treatment is usually continued throughout a person's life, although it may be temporarily discontinued in some cases, such as during pregnancy.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Therapeutic phlebotomy (blood removal)",
"     </span>",
"     &nbsp;&mdash;&nbsp;Therapeutic phlebotomy entails periodic removal of fixed amounts of blood. Over time, phlebotomy returns iron stores back to normal levels. Phlebotomy is appropriate and beneficial for most people with evidence of iron overload, including older adults and people who have no symptoms.",
"    </p>",
"    <p>",
"     The decision to begin phlebotomy in a person with hemochromatosis is usually based on a person's age, sex, and level of ferritin in the blood; when ferritin levels are significantly elevated for a person's age and sex, phlebotomy should be started as soon as possible. Some physicians do not recommend starting phlebotomy until tissue iron overload is documented by one of the three methods listed above.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Phlebotomy procedure &mdash; Phlebotomy is generally safe and can be performed in a clinician's office, blood bank, hospital, or even a person's home. People undergoing phlebotomy should drink an adequate amount of fluids and avoid exercise within 24 hours of the procedure.",
"       <br/>",
"       <br/>",
"       Typically, 1 unit of blood (about 473 mL or 1 pint) is removed per week; however, 1.5 to 2 units of blood can often be removed from men, whereas it may be necessary to remove only 0.5 units of blood from women or frail or elderly patients with other medical problems.",
"       <br/>",
"       <br/>",
"       Iron levels are usually monitored every four to eight weeks during treatment. These values help to determine when the excess iron stores have been depleted; they also help determine if phlebotomy has caused anemia by depleting iron too rapidly. If anemia occurs, phlebotomy may be temporarily stopped.",
"       <br/>",
"       <br/>",
"       In people with hemochromatosis who do not have symptoms at the time of diagnosis, the excess iron stores are depleted to normal after about 30 or fewer phlebotomy sessions. In people who have symptoms at the time of diagnosis, 50 or more phlebotomy sessions may be needed to deplete excess iron stores. Each unit of blood drops the ferritin by about 30",
"       <span class=\"nowrap\">",
"        ng/mL.",
"       </span>",
"      </li>",
"      <li>",
"       Maintenance phlebotomy &mdash; After iron stores have been reduced to normal levels, maintenance phlebotomy is essential to prevent iron from accumulating again. Maintenance phlebotomy entails removing 1 unit of blood every two to four months.",
"      </li>",
"      <li>",
"       Effectiveness of phlebotomy &mdash; Phlebotomy can effectively prevent or resolve some, but not all, complications of hemochromatosis.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"hyphen-block\">",
"      <li>",
"       Phlebotomy can prevent complications of iron overload in people who do not have complications. It can also help to ensure a normal life expectancy. For example, phlebotomy can help prevent the potentially life-threatening complications of cirrhosis and liver cancer.",
"      </li>",
"      <li>",
"       Phlebotomy can resolve or markedly improve weakness, fatigue, and lethargy; darkening of the skin; and high blood ferritin levels. It can also resolve or greatly improve poor liver function, liver enlargement, and liver pain. Phlebotomy is most likely to reverse liver disease when it is in an early stage, but phlebotomy can still improve liver function in people who have developed cirrhosis.",
"      </li>",
"      <li>",
"       Phlebotomy may resolve joint pain and heart disease. Studies suggest that phlebotomy improves joint symptoms in about 20 percent of people with hemochromatosis. Phlebotomy is most likely to reverse heart disease when it is in an early stage.",
"      </li>",
"      <li>",
"       Phlebotomy only rarely improves joint deformity, pituitary disease, elevated blood iron levels, susceptibility to certain infections, diabetes, and thyroid disease. Phlebotomy is most likely to restore normal levels of sex hormones in men who are less than 40 years.",
"      </li>",
"      <li>",
"       Phlebotomy may not reverse cirrhosis or lessen the risk of liver cancer that is associated with cirrhosis.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Dietary considerations",
"     </span>",
"     &nbsp;&mdash;&nbsp;People who are receiving treatment for hemochromatosis do not have to follow a special diet. There is no evidence that the condition is worsened by consuming moderate amounts of iron-rich foods such as red meat and organ meats (eg, liver).",
"    </p>",
"    <p>",
"     However, people with hemochromatosis should avoid iron supplements, and they may also be advised to avoid vitamin C supplements, which promote iron absorption. Alcoholic beverages may be consumed in moderation. However, drinking more than two alcoholic beverages per day increases the risk of cirrhosis. People with hemochromatosis and liver disease should avoid alcohol completely.",
"    </p>",
"    <p>",
"     People with hemochromatosis should avoid eating uncooked seafood because it may contain bacteria that grow well in an iron-rich environment.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Chelation therapy (deferoxamine or deferasirox treatment)",
"     </span>",
"     &nbsp;&mdash;&nbsp;Chelation therapy refers to treatment with the drug deferoxamine or deferasirox. This drug tightly binds iron and removes it from the body, lowering iron stores. However, chelation therapy is seldom used because phlebotomy is a simpler and equally effective treatment.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Treatment of complications",
"     </span>",
"     &nbsp;&mdash;&nbsp;Although phlebotomy can alleviate or even completely resolve some complications of hemochromatosis, other measures may be necessary to treat complications that persist.",
"    </p>",
"    <p>",
"     For example, liver disease may eventually require liver transplantation; diabetes may require insulin therapy. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/3/44084?source=see_link\">",
"      \"Patient information: Cirrhosis (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?18/28/18886?source=see_link\">",
"      \"Patient information: Diabetes mellitus type 2: Insulin treatment (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H20\">",
"     <span class=\"h1\">",
"      IMPLICATIONS FOR THE FAMILY",
"     </span>",
"    </p>",
"    <p>",
"     Hereditary hemochromatosis is almost always caused by a genetic mutation that is passed from both parents to a child. Therefore, clinicians usually recommend that first-degree relatives (parents, siblings, and children) of people with hemochromatosis undergo screening. There is a 25 percent chance that a full brother or sister of a person with hereditary hemochromatosis (with two copies of the C282Y mutation) will have hemochromatosis.",
"    </p>",
"    <p>",
"     The primary goal of screening is to detect hemochromatosis before there are symptoms or complications. The optimal age for screening is between 18 and 30 years; during this time, the condition can be detected, but serious tissue damage has not yet occurred. The optimal strategy for screening is still being determined, so it is important to discuss the advantages and disadvantages of screening with a healthcare provider.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h2\">",
"      Iron levels",
"     </span>",
"     &nbsp;&mdash;&nbsp;The first phase of screening for hemochromatosis may entail blood tests to determine a person's transferrin saturation and ferritin levels.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H22\">",
"     <span class=\"h2\">",
"      Genetic tests",
"     </span>",
"     &nbsp;&mdash;&nbsp;The second phase of screening for hemochromatosis usually involves genetic testing. This testing may not be necessary for all first-degree relatives; the genetic profile of the affected family member may indicate which relatives should be tested.",
"    </p>",
"    <p>",
"     For couples who have or plan to have children, testing of the spouse may be recommended to determine if he or she carries mutations associated with hemochromatosis.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H23\">",
"     <span class=\"h1\">",
"      HOW WILL HEMOCHROMATOSIS AFFECT MY LIFE?",
"     </span>",
"    </p>",
"    <p>",
"     Most people with hemochromatosis have a normal life expectancy. Survival may be shortened in people who develop cirrhosis or diabetes mellitus.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H24\">",
"     <span class=\"h1\">",
"      SUMMARY",
"     </span>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Hemochromatosis causes the body to absorb and store too much iron. The extra iron builds up in organs and can damage them. Without treatment, the iron overload causes these organs to stop working, which can lead to death.",
"      </li>",
"      <li>",
"       The condition is carried in the genes, and can be passed to a child when both parents carry one or two abnormal genes (the genetic material in the sperm and egg).",
"      </li>",
"      <li>",
"       Symptoms of hemochromatosis usually appear after age 40, and may include liver enlargement (",
"       <a class=\"graphic graphic_figure graphicRef64960 \" href=\"UTD.htm?39/54/40804\">",
"        figure 1",
"       </a>",
"       ), weakness, infections, darkened skin and joint pain. People with hemochromatosis are more likely to develop heart disease, type 2 diabetes, thyroid problems, and hormonal changes (eg, bone thinning, irregular or missed menstrual periods, sexual problems in men).",
"      </li>",
"      <li>",
"       Tests are available to diagnose hemochromatosis. Family members (siblings, children) of people with hemochromatosis should also be tested. Early testing and treatment can help to prevent complications.",
"      </li>",
"      <li>",
"       The most common treatment of hemochromatosis is removal of a small amount of blood, which lowers the iron level. Blood removal is similar to the process of donating blood. It is usually done once per week until the iron levels are normal. This may require 9 to 12 months of weekly blood removal.",
"      </li>",
"      <li>",
"       Iron levels are measured with a blood test every month or two. Blood removal is done every two to four months to manage the iron level. Treatment is usually needed for a lifetime.",
"      </li>",
"      <li>",
"       People with hemochromatosis do not need to follow a special diet. Iron supplements and vitamin C supplements should be avoided. Drinking alcohol occasionally (one or two drinks per week) is probably safe unless the person has liver disease (cirrhosis or hepatitis).",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H25\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1804511991\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H112840902\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/15/40179?source=see_link\">",
"      Patient information: Hemochromatosis (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H112840917\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/45/31447?source=see_link\">",
"      Patient information: Hepatitis B (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/4/17478?source=see_link\">",
"      Patient information: Hepatitis C (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/3/44084?source=see_link\">",
"      Patient information: Cirrhosis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/22/9572?source=see_link\">",
"      Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/33/29205?source=see_link\">",
"      Patient information: Sexual problems in men (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/12/29891?source=see_link\">",
"      Patient information: Absent or irregular periods (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/54/15203?source=see_link\">",
"      Patient information: Hypothyroidism (underactive thyroid) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?4/39/4721?source=see_link\">",
"      Patient information: Liver biopsy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?18/28/18886?source=see_link\">",
"      Patient information: Diabetes mellitus type 2: Insulin treatment (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H26\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/49/25370?source=see_link\">",
"      Chelation therapy for iron overload states",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28617?source=see_link\">",
"      Clinical manifestations of hereditary hemochromatosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/13/2266?source=see_link\">",
"      Genetics of hereditary hemochromatosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/61/33748?source=see_link\">",
"      Hepatic iron concentration and hepatic iron index in the diagnosis of iron overload and hereditary hemochromatosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/19/35129?source=see_link\">",
"      Pathophysiology and diagnosis of iron overload syndromes",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/15/12535?source=see_link\">",
"      Screening for hereditary hemochromatosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18952?source=see_link\">",
"      Treatment of hereditary hemochromatosis",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Diabetes and Digestive and Kidney Diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.niddk.nih.gov/\">",
"      www.niddk.nih.gov/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Centers for Disease Control and Prevention",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cdc.gov/\">",
"      www.cdc.gov",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Liver Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.liverfoundation.org/\">",
"      www.liverfoundation.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Hemochromatosis Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.hemochromatosis.org/\">",
"      www.hemochromatosis.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Hemochromatosis Society",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.americanhs.org/\">",
"      www.americanhs.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?2/41/2709/abstract/1-4\">",
"      1-4",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 13, 2011.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?2/41/2709?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2709/abstract/1\">",
"      Bacon BR. Hemochromatosis: diagnosis and management. Gastroenterology 2001; 120:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2709/abstract/2\">",
"      Bacon BR, Powell LW, Adams PC, et al. Molecular medicine and hemochromatosis: at the crossroads. Gastroenterology 1999; 116:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2709/abstract/3\">",
"      Barton JC, McDonnell SM, Adams PC, et al. Management of hemochromatosis. Hemochromatosis Management Working Group. Ann Intern Med 1998; 129:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2709/abstract/4\">",
"      Edwards CQ, Kushner JP. Screening for hemochromatosis. N Engl J Med 1993; 328:1616.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f2_41_2709=[""].join("\n");
var outline_f2_41_2709=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           HEMOCHROMATOSIS OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           HEMOCHROMATOSIS CAUSES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           HEMOCHROMATOSIS SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           HEMOCHROMATOSIS DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H873345\">",
"           TESTS TO DIAGNOSE TISSUE IRON OVERLOAD",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H15\">",
"           HEMOCHROMATOSIS TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H20\">",
"           IMPLICATIONS FOR THE FAMILY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H23\">",
"           HOW WILL HEMOCHROMATOSIS AFFECT MY LIFE?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H24\">",
"           SUMMARY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H25\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/54/40804\" title=\"figure 1\">",
"           Abdomen anatomy adult PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f2_41_2710="Prevention and treatment of acute constipation in infants and children";
var content_f2_41_2710=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prevention and treatment of acute constipation in infants and children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/41/2710/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/41/2710/contributors\">",
"     George D Ferry, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/41/2710/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/41/2710/contributors\">",
"     William J Klish, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/41/2710/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/41/2710/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/41/2710/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Constipation is a common problem throughout childhood and often accepted as a normal variation that will resolve as children get older. The opportunity for early intervention is often missed, and complications, such as anal fissure, stool withholding, and encopresis, may result. The prevention of constipation focuses on timely anticipatory guidance regarding diet, toilet training, and toileting behaviors. The treatment of constipation depends upon the age of the child and the duration of symptoms. It may involve education, dietary changes, behavior changes, and pharmacotherapy, alone or in combination [",
"    <a class=\"abstract\" href=\"UTD.htm?2/41/2710/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prevention and treatment of acute constipation will be discussed here. The definition, etiology, and diagnosis of constipation are presented separately, as is the treatment of chronic constipation and encopresis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/63/15354?source=see_link\">",
"     \"Constipation in children: Etiology and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/28/36298?source=see_link\">",
"     \"Treatment of chronic functional constipation and fecal incontinence in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANTICIPATORY GUIDANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Discussion of dietary and bowel habits should be part of routine health supervision visits for children of all ages. There are certain times during a young child's life when constipation is likely to occur [",
"    <a class=\"abstract\" href=\"UTD.htm?2/41/2710/abstract/3\">",
"     3",
"    </a>",
"    ]. If parents are given appropriate and timely education, these episodes may be anticipated and prevented, or if not prevented, quickly treated with temporary interventions. Complaints of simple constipation should not be ignored. Painful bowel movements can lead to withholding of stool [",
"    <a class=\"abstract\" href=\"UTD.htm?2/41/2710/abstract/4\">",
"     4",
"    </a>",
"    ], worsening constipation, and eventual fecal impaction and encopresis, often without parental awareness of a problem. The pathogenesis of constipation is discussed in detail separately, but mentioned briefly here since it is relevant to the provision of anticipatory guidance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/63/15354?source=see_link\">",
"     \"Constipation in children: Etiology and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Times when constipation is likely to occur include [",
"    <a class=\"abstract\" href=\"UTD.htm?2/41/2710/abstract/3,5\">",
"     3,5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The introduction of solid foods or cow's milk",
"     </li>",
"     <li>",
"      Toilet training",
"     </li>",
"     <li>",
"      School entry",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Transition to solid diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;An inadequate amount of fiber in the diet is common and is often a major contributor to constipation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/41/2710/abstract/6\">",
"     6",
"    </a>",
"    ], particularly when infants are transitioning to solid foods. Ensuring adequate fiber and liquid intake may be helpful in preventing constipation or in treating mild episodic constipation. The recommended daily fiber intake is 14",
"    <span class=\"nowrap\">",
"     grams/1000",
"    </span>",
"    kcals in the diet [",
"    <a class=\"abstract\" href=\"UTD.htm?2/41/2710/abstract/7\">",
"     7",
"    </a>",
"    ]. In young children, this translates to an intake of about 20",
"    <span class=\"nowrap\">",
"     grams/day",
"    </span>",
"    for toddlers and young children. The minimum daily fluid intake depends upon the child's weight and ranges from 32 ounces (960 mL) for a 10 kg child, to 42 ounces (1260 mL) for a 15 kg child, to 50 ounces (1500 mL) for a 20 kg child. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/20/6470?source=see_link\">",
"     \"Maintenance fluid therapy in children\"",
"    </a>",
"    .) Although dietary changes are useful in prevention and treatment of mild constipation, there is little evidence that adding liquid or fiber to the diet is effective in treating severe chronic constipation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/28/36298?source=see_link\">",
"     \"Treatment of chronic functional constipation and fecal incontinence in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Toilet training",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children of toilet training age are susceptible to constipation for a variety of reasons. Their normal dietary intake is low in fiber and high in milk. The excessive consumption of whole cow's milk (&gt;32 oz [960 mL] per day) can slow intestinal motility and satiate the child, thereby diminishing the intake of other fluids and foods that promote soft stools, such as water, fruits, and vegetables [",
"    <a class=\"abstract\" href=\"UTD.htm?2/41/2710/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Milk intake of 24 ounces per day is sufficient to meet the daily calcium requirement of children between one and five years of age. In addition, children using adult-sized toilets without foot-support may not have sufficient leverage to successfully evacuate their stools. If stool passage is painful, these children may begin to withhold stool. Once withholding behavior has started, it can only be reversed by making the stools soft and passage of stools pain-free. Although decreasing milk intake and increasing fiber intake might help, it is often necessary to use laxatives in this situation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/0/18441?source=see_link&amp;anchor=H20#H20\">",
"     \"Dietary recommendations for toddlers, preschool, and school-age children\", section on 'Cow's milk/calcium'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/45/37592?source=see_link\">",
"     \"Toilet training\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     School entry",
"    </span>",
"    &nbsp;&mdash;&nbsp;As children reach school age they often use the bathroom by themselves; parents may not be aware of the frequency or type of stools. Clinicians should encourage parents to regularly ask about their child's bowel movements. Parents also should be encouraged to monitor whether their child is holding back from or embarrassed about using the toilet at school. In addition, parents should promote routine, unhurried time on the toilet after meals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ACUTE CONSTIPATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a history of constipation is obtained, even if it is of short duration (ie, less than two weeks), it is important to determine what intervention is needed and what follow-up is appropriate. All recommendations should include a follow-up plan to be sure that the constipation has resolved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     In older children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dietary changes may be sufficient for children with hard stools and some straining if pain is minimal and there is no withholding behavior, bleeding, or anal fissure. Adequate fluid intake (32 to 64 ounces [960 to 1920 mL] per day) and foods naturally high in fiber (ie, &ge;3 grams of fiber per serving), (",
"    <a class=\"graphic graphic_table graphicRef77796 \" href=\"UTD.htm?0/17/285\">",
"     table 1",
"    </a>",
"    ) should be recommended. Information regarding a high fiber diet, and a sample-menu for a 7- to 10-year-old child that can be printed out and given to parents is provided in the tables (",
"    <a class=\"graphic graphic_table graphicRef76461 graphicRef50180 graphicRef62957 \" href=\"UTD.htm?0/2/38\">",
"     table 2A-C",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     In infants less than one year of age",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute constipation in infants who have not yet begun solid foods can be treated by the addition of undigestible, osmotically active carbohydrates to the formula, titrating the dose to induce a daily bowel movement [",
"    <a class=\"abstract\" href=\"UTD.htm?2/41/2710/abstract/2\">",
"     2",
"    </a>",
"    ]. One such option is addition of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/33/32275?source=see_link\">",
"     sorbitol",
"    </a>",
"    -containing juices (eg, apple, prune, or pear). For infants four to eight months old, two to four ounces of 100-percent fruit juice per day is a reasonable starting dose. In infants who have begun solid foods, sorbitol-containing fruit purees can be used. Dark corn syrup has been used in the past. However, current preparations of dark corn syrup may not contain the glycoproteins that are fermented into osmotically active particles in the colon, so the syrup may be ineffective for treating constipation. Barley cereal may be substituted for rice cereal [",
"    <a class=\"abstract\" href=\"UTD.htm?2/41/2710/abstract/2\">",
"     2",
"    </a>",
"    ].",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/10/26787?source=see_link\">",
"     Glycerin",
"    </a>",
"    suppositories or rectal stimulation with a lubricated rectal thermometer can be used occasionally if there is very hard stool in the rectum, but should not be used frequently.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     RECURRENT CONSTIPATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to identify and appropriately address continuing dietary problems",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    any precipitating events in infants and children who have recurrent acute episodes of constipation. Precipitating events may include recurrent episodes of painful defecation (eg, due to anal fissure, hard stool), fear of using the bathroom at school, and inadequate time to use the bathroom after meals or at school. Anal fissures can be treated topically with petroleum jelly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Older children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Older children with recurrent episodes of constipation may need one or more interventions during the time that precipitating factors are being addressed.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Those who are unable or unwilling to consume adequate dietary fiber may need fiber supplements. The recommended intake of fiber is 14",
"      <span class=\"nowrap\">",
"       grams/1000",
"      </span>",
"      kcals in the diet, which translates to approximately 20",
"      <span class=\"nowrap\">",
"       grams/day",
"      </span>",
"      in early childhood, rising to 29",
"      <span class=\"nowrap\">",
"       grams/day",
"      </span>",
"      for adolescent girls and young women, and 38",
"      <span class=\"nowrap\">",
"       grams/day",
"      </span>",
"      for adolescent boys and young men [",
"      <a class=\"abstract\" href=\"UTD.htm?2/41/2710/abstract/7\">",
"       7",
"      </a>",
"      ]. Fiber supplements that are safe for children are available over-the-counter (",
"      <a class=\"graphic graphic_table graphicRef64009 \" href=\"UTD.htm?26/8/26763\">",
"       table 3",
"      </a>",
"      ). However, to be effective, children who use these supplements should also consume 32 to 64 ounces (960 to 1920 mL) water or other non-milk liquids per day.",
"     </li>",
"     <li>",
"      Children with recurrent constipation also may need one or two doses of a laxative (",
"      <a class=\"graphic graphic_table graphicRef63381 \" href=\"UTD.htm?5/56/6029\">",
"       table 4",
"      </a>",
"      ) to encourage regular bowel movements.",
"     </li>",
"     <li>",
"      Regular use of laxatives, as described for chronic constipation (",
"      <a class=\"graphic graphic_table graphicRef61175 \" href=\"UTD.htm?33/43/34491\">",
"       table 5",
"      </a>",
"      ), should be considered if the stools remain hard, large in diameter, or continue to cause pain. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/28/36298?source=see_link\">",
"       \"Treatment of chronic functional constipation and fecal incontinence in infants and children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Children who have not had a bowel movement for several days and cannot pass a stool may have fecal impaction. Such children may be treated with a",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/47/36599?source=see_link\">",
"       sodium phosphate",
"      </a>",
"      enema followed by one or two doses of a laxative (",
"      <a class=\"graphic graphic_table graphicRef63381 \" href=\"UTD.htm?5/56/6029\">",
"       table 4",
"      </a>",
"      ). The dosing of sodium phosphate enemas is discussed separately. (See",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/47/36599?source=see_link\">",
"       \"Sodium phosphate: Pediatric drug information\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Infants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants with recurrent constipation should be treated with the same dietary interventions as described above for acute constipation. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Acute constipation'",
"    </a>",
"    above.) They may need additional measures to address fecal impaction.",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/10/26787?source=see_link\">",
"     Glycerin",
"    </a>",
"    suppositories or rectal stimulation with a lubricated rectal thermometer can be used, if necessary, to remove desiccated stool in the rectum [",
"    <a class=\"abstract\" href=\"UTD.htm?2/41/2710/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. However, these interventions should not be used as the mainstay of therapy since infants can become behaviorally conditioned to depend upon rectal stimulation to initiate stooling [",
"    <a class=\"abstract\" href=\"UTD.htm?2/41/2710/abstract/1,10\">",
"     1,10",
"    </a>",
"    ]. The use of enemas is not recommended for infants.",
"   </p>",
"   <p>",
"    In infants older than six months whose stools remain hard despite dietary interventions, osmotic laxatives (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/24/39299?source=see_link\">",
"     lactulose",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/33/32275?source=see_link\">",
"     sorbitol",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/38/25189?source=see_link\">",
"     polyethylene glycol",
"    </a>",
"    without electrolytes) may be tried [",
"    <a class=\"abstract\" href=\"UTD.htm?2/41/2710/abstract/1,11\">",
"     1,11",
"    </a>",
"    ]. Stimulant laxatives (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/1/42003?source=see_link\">",
"     senna",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/56/42883?source=see_link\">",
"     bisacodyl",
"    </a>",
"    ),",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/28/20931?source=see_link\">",
"     mineral oil",
"    </a>",
"    , and enemas should be avoided in infants because of their potential adverse effects [",
"    <a class=\"abstract\" href=\"UTD.htm?2/41/2710/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parents should be encouraged to call if constipation does not resolve quickly. Although it is not necessary for every child to have a daily bowel movement, intervention to soften and increase the stool frequency is essential if hard or painful stools persist. Early intervention may help to prevent fecal retention, which may progress to chronic constipation and encopresis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/63/15354?source=see_link\">",
"     \"Constipation in children: Etiology and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/9/44182?source=see_link\">",
"     \"Definition, clinical manifestations, and evaluation of functional fecal incontinence in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/2/43041?source=see_link\">",
"       \"Patient information: Constipation in children (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/21/36179?source=see_link\">",
"       \"Patient information: Giving your child over-the-counter medicines (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?15/7/15477?source=see_link\">",
"       \"Patient information: Constipation in infants and children (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Constipation is a common problem throughout childhood. Early intervention during acute or recurrent episodes of acute constipation can prevent complications such as anal fissure, stool withholding, chronic constipation, and encopresis.",
"   </p>",
"   <p>",
"    Discussion of dietary and bowel habits should be part of routine health supervision visits for children of all ages. Children are susceptible to constipation at certain times of life [",
"    <a class=\"abstract\" href=\"UTD.htm?2/41/2710/abstract/3\">",
"     3",
"    </a>",
"    ]. These episodes may be anticipated and prevented, or if not prevented, quickly treated, if parents are given appropriate and timely anticipatory guidance. This includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      During the transition to solid foods and toilet training, the recommended daily fiber intake should be approximately 20",
"      <span class=\"nowrap\">",
"       grams/day",
"      </span>",
"      (",
"      <a class=\"graphic graphic_table graphicRef77796 \" href=\"UTD.htm?0/17/285\">",
"       table 1",
"      </a>",
"      ). The minimum daily fluid intake depends upon the child's age and ranges from 32 to 64 ounces (960 to 1920 mL) per day.",
"     </li>",
"     <li>",
"      Consumption of whole cow's milk should be limited to 24 ounces (720 mL) per day.",
"     </li>",
"     <li>",
"      During toilet training, a potty seat that provides appropriate foot support and leverage for elimination should be used. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/45/37592?source=see_link\">",
"       \"Toilet training\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Acute episodes of constipation can usually be treated with dietary changes (eg, increasing fiber in older children, the addition of osmotically active carbohydrates in infants).",
"     </li>",
"     <li>",
"      Continuing dietary problems",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      precipitating events must be identified and appropriately addressed to prevent recurrent episodes of acute constipation.",
"     </li>",
"     <li>",
"      Additional interventions may be necessary while dietary problems or precipitating events are being addressed. These include fiber supplementation (",
"      <a class=\"graphic graphic_table graphicRef64009 \" href=\"UTD.htm?26/8/26763\">",
"       table 3",
"      </a>",
"      ) and laxative therapy (",
"      <a class=\"graphic graphic_table graphicRef63381 \" href=\"UTD.htm?5/56/6029\">",
"       table 4",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Fecal impaction in infants may be treated with a",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/10/26787?source=see_link\">",
"       glycerin",
"      </a>",
"      suppository.",
"     </li>",
"     <li>",
"      Children who have not had a bowel movement for several days and cannot pass a stool may be treated with a",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/47/36599?source=see_link\">",
"       sodium phosphate",
"      </a>",
"      enema followed by one or two doses of a laxative (",
"      <a class=\"graphic graphic_table graphicRef63381 \" href=\"UTD.htm?5/56/6029\">",
"       table 4",
"      </a>",
"      ). The dosing of sodium phosphate enemas is discussed separately. (See",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/47/36599?source=see_link\">",
"       \"Sodium phosphate: Pediatric drug information\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2710/abstract/1\">",
"      Abi-Hanna A, Lake AM. Constipation and encopresis in childhood. Pediatr Rev 1998; 19:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2710/abstract/2\">",
"      Constipation Guideline Committee of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. Evaluation and treatment of constipation in infants and children: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2006; 43:e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2710/abstract/3\">",
"      Di Lorenzo C. Pediatric anorectal disorders. Gastroenterol Clin North Am 2001; 30:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2710/abstract/4\">",
"      Borowitz SM, Cox DJ, Tam A, et al. Precipitants of constipation during early childhood. J Am Board Fam Pract 2003; 16:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2710/abstract/5\">",
"      Abrahamian FP, Lloyd-Still JD. Chronic constipation in childhood: a longitudinal study of 186 patients. J Pediatr Gastroenterol Nutr 1984; 3:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2710/abstract/6\">",
"      Loening-Baucke V. Clinical approach to fecal soiling in children. Clin Pediatr (Phila) 2000; 39:603.",
"     </a>",
"    </li>",
"    <li>",
"     United States Department of Agriculture, Center for Nutrition Policy and Promotion: Dietary guidelines for Americans, 2010. Available at: file://www.cnpp.usda.gov/dietaryguidelines.htm (Accessed on June 07, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2710/abstract/8\">",
"      Michel RS. Toilet training. Pediatr Rev 1999; 20:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2710/abstract/9\">",
"      DAVIDSON M, KUGLER MM, BAUER CH. Diagnosis and management in children with severe and protracted constipation and obstipation. J Pediatr 1963; 62:261.",
"     </a>",
"    </li>",
"    <li>",
"     Belamarich, PF. Constipation. In: Primary Pediatric Care, 4th ed, Hoekelman, RA (Ed), Mosby, St. Louis 2001. p.1066.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2710/abstract/11\">",
"      Loening-Baucke V. Prevalence, symptoms and outcome of constipation in infants and toddlers. J Pediatr 2005; 146:359.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5872 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-1.234.2.38-C3DAD56939-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_41_2710=[""].join("\n");
var outline_f2_41_2710=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANTICIPATORY GUIDANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Transition to solid diet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Toilet training",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      School entry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ACUTE CONSTIPATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      In older children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      In infants less than one year of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      RECURRENT CONSTIPATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Older children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5872\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5872|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/17/285\" title=\"table 1\">",
"      High fiber foods",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/2/33836\" title=\"table 2A\">",
"      High fiber diet guidelines A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/2/36909\" title=\"table 2B\">",
"      High fiber diet guidelines B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/30/12780\" title=\"table 2C\">",
"      High fiber diet guidelines C",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/8/26763\" title=\"table 3\">",
"      OTC fiber supplements",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/56/6029\" title=\"table 4\">",
"      Laxatives for children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/43/34491\" title=\"table 5\">",
"      Medical treatment of chronic constipation in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/63/15354?source=related_link\">",
"      Constipation in children: Etiology and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/9/44182?source=related_link\">",
"      Definition, clinical manifestations, and evaluation of functional fecal incontinence in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/0/18441?source=related_link\">",
"      Dietary recommendations for toddlers, preschool, and school-age children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/20/6470?source=related_link\">",
"      Maintenance fluid therapy in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/2/43041?source=related_link\">",
"      Patient information: Constipation in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/7/15477?source=related_link\">",
"      Patient information: Constipation in infants and children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/21/36179?source=related_link\">",
"      Patient information: Giving your child over-the-counter medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/47/36599?source=related_link\">",
"      Sodium phosphate: Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/45/37592?source=related_link\">",
"      Toilet training",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/28/36298?source=related_link\">",
"      Treatment of chronic functional constipation and fecal incontinence in infants and children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_41_2711="Postmenopausal uterine bleeding";
var content_f2_41_2711=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Postmenopausal uterine bleeding",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/41/2711/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/41/2711/contributors\">",
"     Anne Kathryn Goodman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/41/2711/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/41/2711/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/41/2711/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/41/2711/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/41/2711/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postmenopausal bleeding (PMB) refers to any uterine bleeding in a menopausal woman (other than the expected cyclic bleeding that occurs in women taking sequential postmenopausal hormone therapy). It accounts for about 5 percent of office gynecology visits [",
"    <a class=\"abstract\" href=\"UTD.htm?2/41/2711/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    All postmenopausal women with unexpected uterine bleeding patients should be evaluated for endometrial carcinoma since this potentially lethal disease will be the cause of bleeding in approximately 10 percent (range 1 to 25 percent, depending upon risk factors) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/41/2711/abstract/2\">",
"     2",
"    </a>",
"    ]. However, the most common cause of bleeding in these women is atrophy of the vaginal mucosa or endometrium [",
"    <a class=\"abstract\" href=\"UTD.htm?2/41/2711/abstract/3\">",
"     3",
"    </a>",
"    ]. In the early menopausal years, endometrial hyperplasia, polyps, and submucosal fibroids are also common etiologies [",
"    <a class=\"abstract\" href=\"UTD.htm?2/41/2711/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The evaluation of postmenopausal women with vaginal bleeding will be reviewed here. Evaluation and management of premenopausal women with vaginal bleeding is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/24/23944?source=see_link\">",
"     \"Terminology and evaluation of abnormal uterine bleeding in premenopausal women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/18/35113?source=see_link\">",
"     \"Overview of causes of genital tract bleeding in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaginal bleeding occurs in approximately four to 11 percent of postmenopausal women [",
"    <a class=\"abstract\" href=\"UTD.htm?2/41/2711/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. The incidence of bleeding appears to correlate with time since menopause, with the likelihood of bleeding decreasing over time. As an example in a study that asked 271 postmenopausal women to complete a daily record, the estimated incidence of bleeding fell from",
"    <span class=\"nowrap\">",
"     409/1000",
"    </span>",
"    person-years immediately after the first 12 months of amenorrhea following menopause to",
"    <span class=\"nowrap\">",
"     42/1000",
"    </span>",
"    person-years more than three years after menopause [",
"    <a class=\"abstract\" href=\"UTD.htm?2/41/2711/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormal bleeding noted in the genital area is usually attributed to an intrauterine source, but may actually arise from the cervix, vagina, vulva, or fallopian tubes, or be related to ovarian pathology. The origin of bleeding can also involve nongynecologic sites, such as the urethra, bladder, and",
"    <span class=\"nowrap\">",
"     rectum/bowel.",
"    </span>",
"    Cervical stenosis may inhibit egress of blood from the uterine cavity; hematometra may result.",
"   </p>",
"   <p>",
"    The differential diagnosis of bleeding in postmenopausal women is less broad than that for abnormal bleeding in premenopausal women since the various causes of anovulation are not relevant. A series of 1138 women age 41 to 91 years with postmenopausal bleeding (n = 351 on postmenopausal hormone therapy) reported the following types and frequency of histopathology [",
"    <a class=\"abstract\" href=\"UTD.htm?2/41/2711/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Atrophy (59 percent)",
"     </li>",
"     <li>",
"      Polyps (12 percent)",
"     </li>",
"     <li>",
"      Endometrial cancer (10 percent)",
"     </li>",
"     <li>",
"      Endometrial hyperplasia (9.8 percent)",
"     </li>",
"     <li>",
"      Hormonal effect (7 percent)",
"     </li>",
"     <li>",
"      Cervical cancer (less than 1 percent)",
"     </li>",
"     <li>",
"      Other (eg, hydrometra, pyometra, hematometra: 2 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    By comparison, two studies determined the background prevalence of endometrial pathology in asymptomatic postmenopausal women by evaluating gynecologically asymptomatic breast cancer patients prior to administration of adjuvant therapy. Both studies reported the baseline risk of an endometrial abnormality in this group was 17 to 18 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/41/2711/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. As with symptomatic women, the most common abnormalities were atrophy and polyps.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Atrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoestrogenism causes atrophy of the endometrium and vagina. In the uterus, the collapsed, atrophic endometrial surfaces contain little or no fluid to prevent intracavitary friction [",
"    <a class=\"abstract\" href=\"UTD.htm?2/41/2711/abstract/11\">",
"     11",
"    </a>",
"    ]. This results in microerosions of the surface epithelium and a subsequent chronic inflammatory reaction (chronic endometritis), which is prone to light bleeding or spotting.",
"   </p>",
"   <p>",
"    Classic vaginal findings of atrophy include a pale, dry vaginal epithelium that is smooth and shiny with loss of most rugation. If inflammation is present, additional findings may include patchy erythema, petechiae, blood vessels visible through the thinned out epithelium, friability, bleeding, and discharge. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/54/8039?source=see_link\">",
"     \"Clinical manifestations and diagnosis of vaginal atrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 5 to 10 percent of women with postmenopausal vaginal bleeding have endometrial cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?2/41/2711/abstract/2,12-16\">",
"     2,12-16",
"    </a>",
"    ]. The incidence of cancer as a cause of uterine bleeding increases with increasing age and adenocarcinoma of the endometrium is the most common genital cancer in women over 45 years of age.",
"   </p>",
"   <p>",
"    A model that used clinical history alone to predict the risk of endometrial cancer in post- or peri-menopausal women with abnormal uterine bleeding found that nulliparous women over the age of 70 with diabetes mellitus had an 87 percent risk of complex hyperplasia or endometrial cancer compared to 3 percent in women without these characteristics [",
"    <a class=\"abstract\" href=\"UTD.htm?2/41/2711/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/27/18874?source=see_link\">",
"     \"Endometrial carcinoma: Epidemiology and risk factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Sarcomas of the uterus constitute only 3 to 5 percent of all uterine tumors and may present with postmenopausal bleeding. These cancers arise from the stroma of the endometrium (endometrial stromal sarcomas) or the myometrium. They may look and feel like benign leiomyomas. Endometrial histology may be normal; diagnosis requires a hysterectomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/22/2408?source=see_link\">",
"     \"Uterine sarcoma: Classification, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fallopian tube or ovarian cancer can cause postmenopausal uterine bleeding. Cervical and vaginal cancers typically present with vaginal bleeding. Vulvar cancers are not associated with bleeding until they are advanced. (See individual topic reviews for each cancer).",
"   </p>",
"   <p>",
"    Choriocarcinoma is a rare cause of uterine bleeding in menopausal women [",
"    <a class=\"abstract\" href=\"UTD.htm?2/41/2711/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Polyps",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polyps are benign endometrial growths of unknown etiology that are a common cause of perimenopausal and early postmenopausal uterine bleeding. Growth of polyps can be stimulated by estrogen therapy or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/10/7336?source=see_link\">",
"     \"Endometrial polyps\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Postmenopausal hormone therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many postmenopausal women who take estrogen therapy develop vaginal bleeding; the frequency depends upon the regimen used. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/53/16218?source=see_link&amp;anchor=H28#H28\">",
"     \"Preparations for postmenopausal hormone therapy\", section on 'Endometrial monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Endometrial hyperplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endometrial hyperplasia may manifest clinically as uterine bleeding. Since postmenopausal women should be estrogen deficient, endometrial hyperplasia at this time is abnormal and requires an explanation. Endogenous estrogen production from ovarian or adrenal tumors or exogenous estrogen therapy are possible causes. Obese women also have high levels of endogenous estrogen due to the conversion of androstenedione to estrone and the aromatization of androgens to estradiol, both of which occur in peripheral adipose tissue. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/58/26535?source=see_link\">",
"     \"Classification and diagnosis of endometrial hyperplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Leiomyomata uteri",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leiomyomata uteri (fibroids) are the most common pelvic tumors in women. The prevalence in postmenopausal women is one-tenth that of premenopausal women, thus they are a potential, but uncommon, cause of uterine bleeding in menopausal women [",
"    <a class=\"abstract\" href=\"UTD.htm?2/41/2711/abstract/20\">",
"     20",
"    </a>",
"    ]. The diagnosis of a uterine sarcoma should be considered in postmenopausal women with presumed uterine leiomyomas producing symptoms; the incidence of sarcoma is higher in this group, but is still small. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/17/6426?source=see_link\">",
"     \"Epidemiology, clinical manifestations, diagnosis, and natural history of uterine leiomyomas (fibroids)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/22/2408?source=see_link\">",
"     \"Uterine sarcoma: Classification, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Adenomyosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adenomyosis is a benign histologic finding of the uterus in which endometrial glands are infiltrating into the myometrial wall. It can cause pain and menorrhagia during the reproductive years. The diagnosis may be suspected by ultrasound or magnetic resonance imaging, but can only be confirmed by pathologic examination following hysterectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/41/2711/abstract/21\">",
"     21",
"    </a>",
"    ]. Symptomatic adenomyosis does not occur after menopause in the absence of postmenopausal hormone therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27191?source=see_link\">",
"     \"Uterine adenomyosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Disease in adjacent organs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inflammation of neighboring organs, such as diverticulitis, can occasionally cause a corresponding inflammation of the female upper genital tract. A ruptured sigmoid diverticulum may fistulize into the uterus and present as uterine bleeding, discharge, and endometritis.",
"   </p>",
"   <p>",
"    Diseases of the urethra (eg, urethritis), bladder (eg, cancer or urinary tract infection), and bowel (eg, inflammatory bowel disease or hemorrhoids) may cause bleeding that is mistaken for genital tract bleeding. These disorders should be considered and evaluated for in patients with bleeding in whom there is no obvious genital tract etiology. A radiograph of the pelvis to rule out fracture should be considered when there is genital bleeding after trauma, especially in a postmenopausal woman with osteoporosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Post radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaginal bleeding can be a late effect of radiation therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/41/2711/abstract/22\">",
"     22",
"    </a>",
"    ]. Obliterative endarteritis and the vascular narrowing of aging and arteriosclerosis lead to devascularization of the radiated tissues. Tissue necrosis causes viscus perforation, tissue sloughing, and bleeding. Hemorrhagic cystitis and proctitis can lead to significant blood loss. Vaginal vault necrosis may cause uncontrolled bleeding and pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Anticoagulant therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of anticoagulants may cause uterine bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10674615\">",
"    <span class=\"h2\">",
"     Herbal and dietary supplements",
"    </span>",
"    &nbsp;&mdash;&nbsp;Soy and other phytoestrogens in large doses may be associated with stimulation of the endometrial lining [",
"    <a class=\"abstract\" href=\"UTD.htm?2/41/2711/abstract/23\">",
"     23",
"    </a>",
"    ]. One series reports the association of soy with polyp and leiomyoma growth [",
"    <a class=\"abstract\" href=\"UTD.htm?2/41/2711/abstract/24\">",
"     24",
"    </a>",
"    ]. A randomized trial of 376 postmenopausal women who received soy versus placebo showed a significant increase in endometrial hyperplasia over a five-year period [",
"    <a class=\"abstract\" href=\"UTD.htm?2/41/2711/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endometritis is an uncommon cause of postmenopausal bleeding. In the developing world, however, endometrial tuberculosis may present as postmenopausal bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?2/41/2711/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/1/17431?source=see_link&amp;anchor=H14#H14\">",
"     \"Endometritis unrelated to pregnancy\", section on 'Tuberculous endometritis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary goal in the diagnostic evaluation of postmenopausal women with uterine bleeding is to exclude malignancy since age is a significant risk factor for this disorder.",
"   </p>",
"   <p>",
"    The following discussion applies only to women who are",
"    <strong>",
"     NOT",
"    </strong>",
"    taking postmenopausal hormone therapy. The evaluation and management of abnormal bleeding in women who are taking hormone replacement is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/53/16218?source=see_link&amp;anchor=H28#H28\">",
"     \"Preparations for postmenopausal hormone therapy\", section on 'Endometrial monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     History and physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Information that is important in the history includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      When did the bleeding start?",
"     </li>",
"     <li>",
"      Were there precipitating factors, such as trauma?",
"     </li>",
"     <li>",
"      What is the nature of the bleeding (temporal pattern, duration, postcoital, quantity)?",
"     </li>",
"     <li>",
"      Are there any associated symptoms such as pain, fever, or changes in bladder or bowel function?",
"     </li>",
"     <li>",
"      What is the medical history and are any medications being taken (eg, hormones, anticoagulants)?",
"     </li>",
"     <li>",
"      Are any soy-containing herbal or dietary supplements being taken?",
"     </li>",
"     <li>",
"      Is there a family history of breast, colon, and endometrial cancer?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The answers to these questions may help to direct the clinician toward one of the major categories of abnormal bleeding: neoplasm; atrophy; medication; foreign body. As an example, obesity, diabetes mellitus, and use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    are risk factors for endometrial cancer; vaginal dryness and soreness with dyspareunia and bleeding after intercourse suggest atrophy; and a foreign body may be the source of bleeding in a woman who uses a pessary.",
"   </p>",
"   <p>",
"    The patient&rsquo;s body mass index (BMI) should be calculated, since obesity is a risk factor for endometrial cancer (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?39/41/40593?source=see_link\">",
"     calculator 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Thorough physical examination of the external and internal anatomy of the female genital tract is important. The focus of the evaluation is to determine the bleeding site; to note any suspicious lesions, lacerations, or foreign bodies; and to assess the size, contour, and tenderness of the uterus. Lower genital tract (vulva, vagina, exocervix) causes of bleeding can usually be excluded by a normal physical examination.",
"   </p>",
"   <p>",
"    In addition, a general examination should be performed to look for signs of systemic illness (eg, hepatitis, renal disease, splenomegaly).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Endometrial evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Either endometrial biopsy or transvaginal ultrasound can be used as an initial test for evaluating the endometrium. A detailed discussion of these tests for evaluation of the endometrium can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38744?source=see_link\">",
"     \"Evaluation of the endometrium for malignant or premalignant disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We suggest endometrial biopsy as the initial diagnostic test for women with abnormal uterine bleeding due to its high sensitivity, low complication rate, and low cost. If a cause for the bleeding is determined, then further management depends upon the clinical diagnosis. However, endometrial biopsy is not a sensitive technique for diagnosing structural abnormalities, such as polyps.",
"   </p>",
"   <p>",
"    Transvaginal ultrasound examination is an acceptable alternative initial test in postmenopausal women who cannot tolerate office biopsy and in women in whom evaluation of the adnexa or myometrium is indicated. Endometrial cancer can reasonably be excluded in postmenopausal women with a thin, homogeneous endometrium. Endometrial biopsy is required if:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The endometrial lining is thicker than 4 mm",
"     </li>",
"     <li>",
"      The endometrium shows diffuse or focal increased echogenicity (heterogeneity)",
"     </li>",
"     <li>",
"      The endometrium is not adequately visualized",
"     </li>",
"     <li>",
"      The woman has persistent bleeding.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Persistent bleeding can be a sign of endometrial cancer even when the endometrial thickness is less than 4 to 5 mm since a thin or indistinct endometrial stripe does not reliably exclude type 2 endometrial cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?2/41/2711/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. Therefore, women with persistent bleeding should be evaluated further.",
"   </p>",
"   <p>",
"    The evaluation of women with (1) insufficient or nondiagnostic tissue from a biopsy procedure, or (2) persistent bleeding (despite a normal endometrial biopsy or thin endometrium on ultrasound examination) is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38744?source=see_link\">",
"     \"Evaluation of the endometrium for malignant or premalignant disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Cervical cytology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mean age of cervical cancer diagnosis is 52.2 years; the distribution of cases is bimodal, with peaks at 35 to 39 years and 60 to 64 years [",
"    <a class=\"abstract\" href=\"UTD.htm?2/41/2711/abstract/31\">",
"     31",
"    </a>",
"    ]. All women need cervical cancer screening as part of the evaluation of abnormal bleeding, as it can be difficult to distinguish between endocervical and upper uterine bleeding. Any visible lesion needs to be biopsied, even if the cytology is normal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35337?source=see_link\">",
"     \"Cervical cancer screening tests: Techniques and test characteristics of cervical cytology and human papillomavirus testing\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28537?source=see_link\">",
"     \"Invasive cervical cancer: Epidemiology, risk factors, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In postmenopausal women, uterine bleeding is usually light and self-limited. Exclusion of cancer is the main objective; therefore, treatment is usually unnecessary once cancer (or premalignant histology) has been excluded.",
"   </p>",
"   <p>",
"    Further diagnostic evaluation is indicated for recurrent or persistent bleeding. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38744?source=see_link\">",
"     \"Evaluation of the endometrium for malignant or premalignant disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If a benign lesion is discovered, it can be treated, as appropriate, if symptoms are bothersome. Malignant lesions are evaluated and treated according to standard guidelines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?22/18/22820?source=see_link\">",
"       \"Patient information: Abnormal uterine bleeding (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Postmenopausal bleeding refers to any uterine bleeding in a menopausal woman (other than the expected cyclic bleeding that occurs in women taking sequential postmenopausal hormone therapy). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Endometrial atrophy and endometrial polyps are the most common causes of postmenopausal bleeding. Endometrial carcinoma is the cause in about 10 percent of patients. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The primary goal in the diagnostic evaluation of postmenopausal women with uterine bleeding is to exclude malignancy. Either endometrial biopsy or transvaginal ultrasound can be used as an initial test for evaluating the endometrium. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Diagnostic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Uterine bleeding in postmenopausal women is usually light and self-limited. Exclusion of cancer is the main objective; therefore, treatment is usually unnecessary once cancer has been excluded. Further diagnostic evaluation is indicated for recurrent or persistent bleeding. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2711/abstract/1\">",
"      Moodley M, Roberts C. Clinical pathway for the evaluation of postmenopausal bleeding with an emphasis on endometrial cancer detection. J Obstet Gynaecol 2004; 24:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2711/abstract/2\">",
"      Karlsson B, Granberg S, Wikland M, et al. Transvaginal ultrasonography of the endometrium in women with postmenopausal bleeding--a Nordic multicenter study. Am J Obstet Gynecol 1995; 172:1488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2711/abstract/3\">",
"      Iatrakis G, Diakakis I, Kourounis G, et al. Postmenopausal uterine bleeding. Clin Exp Obstet Gynecol 1997; 24:157.",
"     </a>",
"    </li>",
"    <li>",
"     APGO educational series on women's health issues. Clinical management of abnormal uterine bleeding. Association of Professors of Gynecology and Obstetrics, 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2711/abstract/5\">",
"      Astrup K, Olivarius Nde F. Frequency of spontaneously occurring postmenopausal bleeding in the general population. Acta Obstet Gynecol Scand 2004; 83:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2711/abstract/6\">",
"      Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2711/abstract/7\">",
"      Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 1996; 275:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2711/abstract/8\">",
"      Smith-Bindman R, Weiss E, Feldstein V. How thick is too thick? When endometrial thickness should prompt biopsy in postmenopausal women without vaginal bleeding. Ultrasound Obstet Gynecol 2004; 24:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2711/abstract/9\">",
"      Duffy S, Jackson TL, Lansdown M, et al. The ATAC adjuvant breast cancer trial in postmenopausal women: baseline endometrial subprotocol data. BJOG 2003; 110:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2711/abstract/10\">",
"      Berli&egrave;re M, Radikov G, Galant C, et al. Identification of women at high risk of developing endometrial cancer on tamoxifen. Eur J Cancer 2000; 36 Suppl 4:S35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2711/abstract/11\">",
"      Ferenczy A. Pathophysiology of endometrial bleeding. Maturitas 2003; 45:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2711/abstract/12\">",
"      MacMahon B. Overview of studies on endometrial cancer and other types of cancer in humans: perspectives of an epidemiologist. Semin Oncol 1997; 24:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2711/abstract/13\">",
"      Burbos N, Musonda P, Giarenis I, et al. Age-related differential diagnosis of vaginal bleeding in postmenopausal women: a series of 3047 symptomatic postmenopausal women. Menopause Int 2010; 16:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2711/abstract/14\">",
"      Bani-Irshaid I, Al-Sumadi A. Histological findings in women with postmenopausal bleeding: Jordanian figures. East Mediterr Health J 2011; 17:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2711/abstract/15\">",
"      Ronghe R, Gaudoin M. Women with recurrent postmenopausal bleeding should be re-investigated but are not more likely to have endometrial cancer. Menopause Int 2010; 16:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2711/abstract/16\">",
"      van Hanegem N, Breijer MC, Khan KS, et al. Diagnostic evaluation of the endometrium in postmenopausal bleeding: an evidence-based approach. Maturitas 2011; 68:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2711/abstract/17\">",
"      Feldman S, Cook EF, Harlow BL, Berkowitz RS. Predicting endometrial cancer among older women who present with abnormal vaginal bleeding. Gynecol Oncol 1995; 56:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2711/abstract/18\">",
"      Tsukamoto N, Iwasaka T, Kashimura Y, et al. Gestational trophoblastic disease in women aged 50 or more. Gynecol Oncol 1985; 20:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2711/abstract/19\">",
"      Marcu M, Chefani A, Sajin M. Postmenopausal choriocarcinoma: a case report. Rom J Morphol Embryol 2005; 46:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2711/abstract/20\">",
"      Parazzini F, La Vecchia C, Negri E, et al. Epidemiologic characteristics of women with uterine fibroids: a case-control study. Obstet Gynecol 1988; 72:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2711/abstract/21\">",
"      Reinhold C, McCarthy S, Bret PM, et al. Diffuse adenomyosis: comparison of endovaginal US and MR imaging with histopathologic correlation. Radiology 1996; 199:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2711/abstract/22\">",
"      Shoff SM, Newcomb PA. Diabetes, body size, and risk of endometrial cancer. Am J Epidemiol 1998; 148:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2711/abstract/23\">",
"      van Hunsel FP, Kampsch&ouml;er P. [Postmenopausal bleeding and dietary supplements: a possible causal relationship with hop- and soy-containing preparations]. Ned Tijdschr Geneeskd 2012; 156:A5095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2711/abstract/24\">",
"      Chandrareddy A, Muneyyirci-Delale O, McFarlane SI, Murad OM. Adverse effects of phytoestrogens on reproductive health: a report of three cases. Complement Ther Clin Pract 2008; 14:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2711/abstract/25\">",
"      Unfer V, Casini ML, Costabile L, et al. Endometrial effects of long-term treatment with phytoestrogens: a randomized, double-blind, placebo-controlled study. Fertil Steril 2004; 82:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2711/abstract/26\">",
"      Sabadell J, Castellv&iacute; J, Bar&oacute; F. Tuberculous endometritis presenting as postmenopausal bleeding. Int J Gynaecol Obstet 2007; 96:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2711/abstract/27\">",
"      Mengistu Z, Engh V, Melby KK, et al. Postmenopausal vaginal bleeding caused by endometrial tuberculosis. Acta Obstet Gynecol Scand 2007; 86:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2711/abstract/28\">",
"      G&uuml;ng&ouml;rd&uuml;k K, Ulker V, Sahbaz A, et al. Postmenopausal tuberculosis endometritis. Infect Dis Obstet Gynecol 2007; 2007:27028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2711/abstract/29\">",
"      Wang J, Wieslander C, Hansen G, et al. Thin endometrial echo complex on ultrasound does not reliably exclude type 2 endometrial cancers. Gynecol Oncol 2006; 101:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2711/abstract/30\">",
"      Chandavarkar U, Kuperman J, Muderspach L, et al. Postmenopausal endometrial cancer: Reevaluating the role of endometrial echo complex. Gynecol Oncol 2011; 120:S11.",
"     </a>",
"    </li>",
"    <li>",
"     file://seer.cancer.gov/csr/1975_2007/browse_csr.php?section=5&amp;page=sect_05_table.07.html (Accessed on March 14, 2011).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5421 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-60.18.131.125-10F4DE3033-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_41_2711=[""].join("\n");
var outline_f2_41_2711=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Atrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Polyps",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Postmenopausal hormone therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Endometrial hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Leiomyomata uteri",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Adenomyosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Disease in adjacent organs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Post radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Anticoagulant therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10674615\">",
"      Herbal and dietary supplements",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      History and physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Endometrial evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Cervical cytology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?39/41/40593?source=related_link\" title=\"calculator 1\">",
"      Calculator: Body mass index (BMI; Quetelet's index)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35337?source=related_link\">",
"      Cervical cancer screening tests: Techniques and test characteristics of cervical cytology and human papillomavirus testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/58/26535?source=related_link\">",
"      Classification and diagnosis of endometrial hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/54/8039?source=related_link\">",
"      Clinical manifestations and diagnosis of vaginal atrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/27/18874?source=related_link\">",
"      Endometrial carcinoma: Epidemiology and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/10/7336?source=related_link\">",
"      Endometrial polyps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/1/17431?source=related_link\">",
"      Endometritis unrelated to pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/17/6426?source=related_link\">",
"      Epidemiology, clinical manifestations, diagnosis, and natural history of uterine leiomyomas (fibroids)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38744?source=related_link\">",
"      Evaluation of the endometrium for malignant or premalignant disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28537?source=related_link\">",
"      Invasive cervical cancer: Epidemiology, risk factors, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/18/35113?source=related_link\">",
"      Overview of causes of genital tract bleeding in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/18/22820?source=related_link\">",
"      Patient information: Abnormal uterine bleeding (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/53/16218?source=related_link\">",
"      Preparations for postmenopausal hormone therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/24/23944?source=related_link\">",
"      Terminology and evaluation of abnormal uterine bleeding in premenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27191?source=related_link\">",
"      Uterine adenomyosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/22/2408?source=related_link\">",
"      Uterine sarcoma: Classification, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_41_2712="Renal cystic diseases in children";
var content_f2_41_2712=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Renal cystic diseases in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/41/2712/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/41/2712/contributors\">",
"     Patrick Niaudet, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/41/2712/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/41/2712/contributors\">",
"     Tej K Mattoo, MD, DCH, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/41/2712/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/41/2712/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/41/2712/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 31, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal cysts occur in a variety of diseases in children (",
"    <a class=\"graphic graphic_table graphicRef68570 \" href=\"UTD.htm?32/14/33003\">",
"     table 1",
"    </a>",
"    ). Cysts may be due to nonhereditary fetal malformations, genetic disorders, or they may be rarely acquired. Cysts may also occur as an isolated finding or as part of a syndrome.",
"   </p>",
"   <p>",
"    An overview of the different forms of pediatric renal cystic disease will be reviewed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NONHEREDITARY RENAL MALFORMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cystic renal dysplasia, defined by microscopic features, is due to renal parenchymal malformation of the fetal kidney. As a result, the kidney contains primitive ducts and cysts, and nonrenal tissues such as cartilage, fat, and hematopoietic tissue. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22472?source=see_link&amp;anchor=H5#H5\">",
"     \"Overview of congenital anomalies of the kidney and urinary tract (CAKUT)\", section on 'Renal parenchymal malformations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the nonheritable mechanisms responsible for this disorder remain unclear, an alteration in renal mitogen expression may in part underlie the abnormalities in renal parenchymal differentiation. One study of multicystic renal dysplasia, for example, found significant temporal and spatial alterations in insulin-like growth factor and insulin-like growth factor binding protein expression during early fetal life and the postnatal period [",
"    <a class=\"abstract\" href=\"UTD.htm?2/41/2712/abstract/1\">",
"     1",
"    </a>",
"    ]. The pathogenetic significance of these changes is uncertain.",
"   </p>",
"   <p>",
"    Cystic dysplasia is also often associated with antenatal obstruction of the urinary tract, which may be associated with posterior urethral valves or ureteropelvic junction obstruction. Cystic dysplasia is frequently observed in the atrophic pole of a kidney with duplicated ureters or an ectopic ureterocele.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Multicystic dysplastic kidney",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most severe form of cystic renal dysplasia is the multicystic dysplastic kidney (MCDK), which is commonly detected by antenatal ultrasonography (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef79332 \" href=\"UTD.htm?36/10/37024\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef80361 \" href=\"UTD.htm?20/3/20528\">",
"     image 2",
"    </a>",
"    ). The MCDK consists of numerous noncommunicating cysts separated by dysplastic tissue (",
"    <a class=\"graphic graphic_picture graphicRef66837 \" href=\"UTD.htm?19/37/20052\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef68485 \" href=\"UTD.htm?43/34/44576\">",
"     image 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef73581 \" href=\"UTD.htm?22/54/23393\">",
"     image 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef59147 \" href=\"UTD.htm?20/63/21491\">",
"     picture 2",
"    </a>",
"    ). There is no identifiable renal tissue, although in some cases some minimal functional renal tissue may exist in the dysplastic area. The ureter is absent or atretic [",
"    <a class=\"abstract\" href=\"UTD.htm?2/41/2712/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The overall reported incidence is between 0.3 and 1 in 1000 live births with more than half of the cases detected antenatally [",
"    <a class=\"abstract\" href=\"UTD.htm?2/41/2712/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. MCKD may involve both kidneys, but most cases are unilateral, with the left kidney being more often affected. The incidence is greater in boys than in girls. In the majority of cases, involution of the MCDK occurs as demonstrated by repeat ultrasound exam. The rate of involution is generally greatest during the first two to three years of life [",
"    <a class=\"abstract\" href=\"UTD.htm?2/41/2712/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the contralateral kidney is normal, it usually undergoes compensatory hypertrophy, which begins in utero resulting in a kidney size that is greater than two standard deviations beyond the mean length. The absence of compensatory hypertrophy suggests abnormalities of the contralateral kidney. The contralateral urinary tract may be associated with a variety of other defects, including rotational or positional anomalies, hypoplasia, areas of dysplasia, vesicoureteral reflux (VUR), ureterocele, ureteropelvic junction obstruction (UPJ obstruction), or genital abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?2/41/2712/abstract/2,7-9\">",
"     2,7-9",
"    </a>",
"    ]. VUR is the most common renal abnormality occurring in up to 25 percent of contralateral kidneys of affected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/41/2712/abstract/2,7,8\">",
"     2,7,8",
"    </a>",
"    ]. Extrarenal malformations also may be seen (eg, heart defects, esophageal or intestinal atresia, or myelomeningocele).",
"   </p>",
"   <p>",
"    In the neonate, the MCDK can be detected as a palpable flank mass. It is usually easily distinguished from hydronephrosis by ultrasonography, which reveals large, peripheral cysts without recognizable renal parenchyma. Complications are very uncommon; thus, the diagnosis is not made in many cases unless there is a palpable mass or a radiologic procedure of the kidney is performed for some other reason.",
"   </p>",
"   <p>",
"    Hypertension and neoplasia have been reported in selected cases [",
"    <a class=\"abstract\" href=\"UTD.htm?2/41/2712/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. However, a systemic review of 29 studies found six cases of hypertension in the entire pool of 1115 patients, an incidence that is lower than that found in the general pediatric population [",
"    <a class=\"abstract\" href=\"UTD.htm?2/41/2712/abstract/13\">",
"     13",
"    </a>",
"    ]. In case reports of patients with MCDK and hypertension, nephrectomy resulted in resolution of hypertension in only 25 to 50 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/41/2712/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. These data suggest that MCDK is not a significant etiology for pediatric hypertension.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Course",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most cases of MCDK, the natural history without intervention is involution of the affected kidney as illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a 2008 review of the literature, analysis of 105 reports of MCDK demonstrated involution or regression of 60 percent of MCDK kidneys within the first three years of life [",
"      <a class=\"abstract\" href=\"UTD.htm?2/41/2712/abstract/16\">",
"       16",
"      </a>",
"      ]. About 25 percent of patients will have VUR in the contralateral kidney, of which 90 percent is grade III or below. There appears to be no clinically significant increased risk of hypertension and Wilms tumor compared with the general population. All cases of Wilms tumor were detected before four years of age and 70 percent presented as a palpable mass.",
"     </li>",
"     <li>",
"      In a prospective study from a regional registry of 323 patients with MCDK from 1985 to 2009, 10 percent of antenatally detected MCDK had involuted by the time of the first postnatal ultrasound [",
"      <a class=\"abstract\" href=\"UTD.htm?2/41/2712/abstract/17\">",
"       17",
"      </a>",
"      ]. Long-term follow-up (mean 10.1 years) demonstrated complete involution of 35, 47, and 62 percent of MCDK kidneys at 2-, 5-, and 10-year follow-up, respectively. Involution was more likely to occur in patients with a MCDK that was initially less than 5 cm in length. Contralateral abnormalities were observed in 14 percent of patients including VUR (11 percent) and UPJ obstruction (3 percent). At 10-year follow-up, 6 of 94 patients had blood pressure that exceed the 95",
"      <sup>",
"       th",
"      </sup>",
"      percentile, of which four were noted to have &ldquo;white coat&rdquo; hypertension with normal 24-hour ambulatory blood pressure measurements. There was no reported malignancy during the follow-up period. The median estimated glomerular filtration rate in 76 patients (7 and 69 patients at 5- and 10-year follow-up, respectively) was 93",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      (range 47 to 181). Thirty-three patients (43 percent) had mild renal impairment with an estimated GFR between 60 and 90",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      . Thirty-one of these 33 patients (94 percent) had compensatory hypertrophy. As a result, ongoing follow-up of renal function is needed even in patients with compensatory hypertrophy. In a retrospective study of 80 patients from a single center, involution or disappearance of the affected kidney occurred in 72 patients (90 percent) and renal hypertrophy of the contralateral kidney in 60 percent of the patients [",
"      <a class=\"abstract\" href=\"UTD.htm?2/41/2712/abstract/18\">",
"       18",
"      </a>",
"      ]. At a mean follow-up of five years, no patient had developed hypertension, chronic renal insufficiency, or malignancy.",
"     </li>",
"     <li>",
"      In another retrospective review of 105 patients from a single center, complete involution of the affected kidney occurred in 60 percent of the group within five years, and compensatory hypertrophy was noted in 74 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?2/41/2712/abstract/19\">",
"       19",
"      </a>",
"      ]. Contralateral abnormalities included VUR (17 percent), ureteropelvic junction obstruction (4 percent), and megaureter (2 percent). At a mean follow-up, eight of 82 patients had a reduced estimated GFR of less than 90",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95167046\">",
"    <span class=\"h3\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because most cases of MCDK naturally involute without any long-term complications, conservative management (ie, observation) is recommended. However, long-term follow-up is required because individual patients may develop renal impairment as noted above [",
"    <a class=\"abstract\" href=\"UTD.htm?2/41/2712/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Our current management approach for patients with unilateral MCDK includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serial ultrasonographic evaluation to monitor contralateral kidney growth and MCDK involution at birth, and at four weeks, two years, five years, and 10 years of age [",
"      <a class=\"abstract\" href=\"UTD.htm?2/41/2712/abstract/20\">",
"       20",
"      </a>",
"      ]. Serial ultrasounds also may detect any significant renal scarring to the normal contralateral kidney due to recurrent urinary tract infection.",
"     </li>",
"     <li>",
"      Routine follow-up that includes blood pressure measurement, urinalysis to detect proteinuria, and renal function studies (eg, serum creatinine) especially in children with contralateral abnormalities who are at risk for developing chronic kidney disease [",
"      <a class=\"abstract\" href=\"UTD.htm?2/41/2712/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The necessity of performing a voiding cystourethrogram (VCUG, which is an invasive study) in patients with MCDK, has been increasingly questioned [",
"    <a class=\"abstract\" href=\"UTD.htm?2/41/2712/abstract/2,21\">",
"     2,21",
"    </a>",
"    ]. Although VUR has been reported to occur in 4 to 14 percent of contralateral kidneys [",
"    <a class=\"abstract\" href=\"UTD.htm?2/41/2712/abstract/9,22\">",
"     9,22",
"    </a>",
"    ], it is usually low grade and generally resolves in early life [",
"    <a class=\"abstract\" href=\"UTD.htm?2/41/2712/abstract/20,22\">",
"     20,22",
"    </a>",
"    ]. Patients with MCDK and VUR are also more likely to have ultrasonographic abnormalities of the contralateral kidney. In one study of 61 children with MCDK and VUR (documented by VCUG), only four had normal ultrasounds at birth and at one month [",
"    <a class=\"abstract\" href=\"UTD.htm?2/41/2712/abstract/2\">",
"     2",
"    </a>",
"    ]. As a result, the authors concluded that performing a VCUG is unnecessary in patients with two successive normal renal ultrasound scans because it is highly unlikely that VUR is present. However, if there is significant contralateral hydronephrosis or a history of urinary tract infection, then a VCUG should be performed.",
"   </p>",
"   <p>",
"    Although other centers have used renal scintography as a diagnostic tool [",
"    <a class=\"abstract\" href=\"UTD.htm?2/41/2712/abstract/23\">",
"     23",
"    </a>",
"    ], we do not routinely perform renal scintography as it does not change our management approach, and in some cases, there is detectable function of MCDK on renal scintography making this an unreliable diagnostic study [",
"    <a class=\"abstract\" href=\"UTD.htm?2/41/2712/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some clinicians have recommended resection to eliminate the risk of malignancy, particularly Wilms tumor; however, there appears to be no increased risk for Wilms tumor in MCDK. This was illustrated in a systemic literature review of 26 studies, in which there were",
"    <strong>",
"     no",
"    </strong>",
"    cases of Wilms tumor in the 1041 children with a unilateral MCDK [",
"    <a class=\"abstract\" href=\"UTD.htm?2/41/2712/abstract/25\">",
"     25",
"    </a>",
"    ]. In addition, a review article reported that data from the National Wilms Tumor Study Pathology Center demonstrated only one case of MCDK among more than 6000 cases of nephroblastoma [",
"    <a class=\"abstract\" href=\"UTD.htm?2/41/2712/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, an unequivocal diagnosis of MCDK is important because patients in whom the diagnosis is equivocal may actually have another potentially life-threatening disease. As an example, one noncompliant patient initially suspected of having MCDK presented with an extensive Wilms tumor after being lost to follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?2/41/2712/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95167550\">",
"    <span class=\"h1\">",
"     GENETIC DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic disorders that may present with renal cystic disease in children include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Polycystic kidney disease in children due to two hereditary conditions, which are discussed separately:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Autosomal recessive polycystic kidney disease (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29913?source=see_link\">",
"       \"Autosomal recessive polycystic kidney disease in children\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Autosomal dominant polycystic kidney disease (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/58/28584?source=see_link\">",
"       \"Autosomal dominant polycystic kidney disease in children\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Glomerular cortical cysts either as an isolated abnormality or associated with genetic syndromes",
"     </li>",
"     <li>",
"      Cysts due to tubular dilation or injury, which are associated with genetic syndromes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most of these hereditary disorders are due to defects in ciliary function [",
"    <a class=\"abstract\" href=\"UTD.htm?2/41/2712/abstract/27\">",
"     27",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_table graphicRef62947 \" href=\"UTD.htm?0/20/334\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Renal ultrasound may be able to differentiate among some renal cystic disorders including nonhereditary causes, such as multicystic dysplastic kidney [",
"    <a class=\"abstract\" href=\"UTD.htm?2/41/2712/abstract/28\">",
"     28",
"    </a>",
"    ]; however, in others, the cause may only be determined by renal biopsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Glomerular cortical cysts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glomerular cysts due to genetic disorders can present as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Isolated abnormality referred to as glomerulocystic kidney disease.",
"     </li>",
"     <li>",
"      In association with maturity-onset diabetes of the young due to mutations of the hepatocyte nuclear factor-1-beta gene.",
"     </li>",
"     <li>",
"      In association with genetic syndromes such as oro-facial-digital syndrome, Jeune syndrome, Zellweger syndrome, brachymesomelia-renal syndrome, and trisomy 13 (",
"      <a class=\"graphic graphic_table graphicRef82584 \" href=\"UTD.htm?24/48/25356\">",
"       table 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/41/2712/abstract/29,30\">",
"       29,30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H170183491\">",
"    <span class=\"h3\">",
"     Glomerulocystic kidney disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glomerulocystic kidney disease is characterized by glomerular cysts that typically involve five percent of nephrons without tubular dilation. It appears to be an autosomal dominant disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?2/41/2712/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. Kidneys are typically normal in size or slightly larger than normal as the cysts are small [",
"    <a class=\"abstract\" href=\"UTD.htm?2/41/2712/abstract/33\">",
"     33",
"    </a>",
"    ]. There is a loss of corticomedullary differentiation on ultrasonography.",
"   </p>",
"   <p>",
"    Some patients have hypertension and progress to end-stage renal disease (ESRD). ESRD appears to be most common when glomerulocystic disease is associated with renal hypoplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?2/41/2712/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. In these patients, the kidney may be small in size.",
"   </p>",
"   <p>",
"    An infant with autosomal dominant polycystic kidney disease (ADPKD) may also present with glomerulocystic disease. A positive family history of ADPKD can help distinguish the two disorders. Glomerulocystic kidney disease can also be seen in association with tuberous sclerosis complex, where about two thirds of",
"    <em>",
"     TSC2",
"    </em>",
"    -associated disease is new mutations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/58/28584?source=see_link&amp;anchor=H91671504#H91671504\">",
"     \"Autosomal dominant polycystic kidney disease in children\", section on 'Differential diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/18/43303?source=see_link&amp;anchor=H3#H3\">",
"     \"Renal manifestations of tuberous sclerosis and renal angiomyolipoma\", section on 'Renal lesions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/38/34410?source=see_link&amp;anchor=H140867425#H140867425\">",
"     \"Tuberous sclerosis complex: Genetics, clinical features, and diagnosis\", section on 'Renal manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H170183551\">",
"    <span class=\"h3\">",
"     Renal cyst and diabetes (RCAD) syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations of the gene that encodes hepatocyte nuclear factor-1-beta (HNF-1-beta) are responsible for the syndrome referred to as maturity-onset diabetes of the young (MODY) type 5 and are associated with renal cysts. The combination of these two findings is referred to as renal cysts and diabetes (RCAD) syndrome. HNF-1-beta is a regulator of gene expression in several organs, including the liver, the kidney, the intestine and the pancreas, and mutations of this gene are associated with a wide spectrum of renal abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?2/41/2712/abstract/34\">",
"     34",
"    </a>",
"    ]. Renal cortical cysts are the most common renal finding.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, 25 of 80 children with ultrasonographic findings including renal cysts, hyperechogenicity, hypoplasia, or singe kidney were carriers of a HNF-1-beta gene defect including complete deletion of the gene in 14 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?2/41/2712/abstract/35\">",
"       35",
"      </a>",
"      ]. Renal anomalies were bilateral in all patients and included 13 cases of bilateral isolated renal cysts, 8 with multicystic dysplastic kidneys with a contralateral anomaly, and 4 with",
"      <span class=\"nowrap\">",
"       hypo/dysplastic",
"      </span>",
"      kidneys.",
"     </li>",
"     <li>",
"      In a second study, 23 of 160 patients with unexplained renal disease had mutations of the HNF-1-beta gene [",
"      <a class=\"abstract\" href=\"UTD.htm?2/41/2712/abstract/36\">",
"       36",
"      </a>",
"      ]. Of the 15 patients with whole HNF-1-beta gene deletions, 13 had renal cysts, including three with glomerulocystic kidney disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    RCAD syndrome is an autosomal dominant disorder. Extrarenal symptoms include hyperuricemia, hypomagnesemia, increased transaminase, and genital anomalies [",
"    <a class=\"abstract\" href=\"UTD.htm?2/41/2712/abstract/34\">",
"     34",
"    </a>",
"    ]. There is no correlation between the genotype and the phenotype, with a high intrafamilial variability of the phenotype. De novo mutations occur in 50 percent of cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H170184575\">",
"    <span class=\"h3\">",
"     Nephronophthisis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cortical microcysts also may occur in combination with chronic tubulointerstitial nephritis in patients with NPHP2 (inversin) gene mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?2/41/2712/abstract/37\">",
"     37",
"    </a>",
"    ]. This autosomal recessive disorder is typically associated with severe hypertension and progresses to ESRD before two years of age. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/56/10120?source=see_link&amp;anchor=H5#H5\">",
"     \"Genetics and pathogenesis of nephronophthisis\", section on 'NPHP2 gene'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H170183611\">",
"    <span class=\"h2\">",
"     Tubular cysts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cysts due to tubular dilation and injury are associated with the following genetic disorders (",
"    <a class=\"graphic graphic_table graphicRef82584 \" href=\"UTD.htm?24/48/25356\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Meckel-Gruber (or Meckel) syndrome is an autosomal recessive disorder characterized by bilateral renal cystic dysplasia, posterior encephalocele, cleft palate, and polydactyly. Meckel-Gruber syndrome is associated with defects in the",
"      <em>",
"       MKS1",
"      </em>",
"      gene (located at 17q23) and",
"      <em>",
"       MKS2",
"      </em>",
"      gene (located at 11q13) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/41/2712/abstract/38,39\">",
"       38,39",
"      </a>",
"      ]. In addition, mutations in the",
"      <em>",
"       NPHP6",
"      </em>",
"      ,",
"      <em>",
"       RPGRIP1L",
"      </em>",
"      , and",
"      <em>",
"       TMEM67",
"      </em>",
"      (also known as the",
"      <em>",
"       MKS3",
"      </em>",
"      gene) genes can cause either Meckel-Gruber or Jobert syndrome. Products of these affected genes are all involved with ciliary function. These syndromes are discussed in separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/22/16744?source=see_link&amp;anchor=H6#H6\">",
"       \"Clinical manifestations, diagnosis, and treatment of nephronophthisis\", section on 'Joubert syndrome'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/22/16744?source=see_link&amp;anchor=H7#H7\">",
"       \"Clinical manifestations, diagnosis, and treatment of nephronophthisis\", section on 'Meckel-Gruber syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bardet-Biedel syndrome is an autosomal recessive disorder characterized by obesity, microorchidism in males, cognitive disability, retinal dystrophy, polydactyly, and renal malformations including medullary cysts. Polyuria and polydipsia are common and early symptoms due to a urinary concentrating defect. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/2/21545?source=see_link&amp;anchor=H14#H14\">",
"       \"Clinical manifestations and causes of nephrogenic diabetes insipidus\", section on 'Bardet-Biedl syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Beckwith-Wiedemann syndrome is a genetic disorder due to deregulation of imprinting genes within the 11p15.5 region that results in a pediatric overgrowth disorder with a predisposition for tumor development. Renal anomalies include medullary dysplasia, duplicated collecting system, nephrocalcinosis, medullary sponge kidney, cystic changes, diverticula, and nephromegaly. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/57/24473?source=see_link\">",
"       \"Beckwith-Wiedemann syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Nephronophthisis is an autosomal recessive genetically heterogenic disorder with identified mutations in a number of genes that encode proteins involved in the function of primary cilia, basal bodies, and centrosomes. These mutations result in severe tubular damage with thickened basement membranes alternating with groups of dilated or collapsed tubules, moderate interstitial fibrosis, and corticomedullary cysts. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/56/10120?source=see_link&amp;anchor=H15#H15\">",
"       \"Genetics and pathogenesis of nephronophthisis\", section on 'Pathology'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ISOLATED RENAL CYSTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isolated renal cysts are commonly observed within the general population, and the prevalence rises with increasing age. For both affected adults and children, the principle clinical concern is accurately distinguishing simple renal cysts from complex renal cysts that are associated with malignancy. In adults, the Bosniak renal cyst classification categorizes cysts based on computerized tomographic (CT) findings into four categories, which separates benign cysts from those that are more likely to be associated with malignancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/3/27704?source=see_link&amp;anchor=H2#H2\">",
"     \"Simple and complex renal cysts in adults\", section on 'Bosniak classification of renal cysts'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Simple renal cysts (Bosniak category I) with a thin wall without septa, calcifications, or solid components are most commonly seen in children. Children with isolated simple cysts, normal renal function, and no renal dysplasia have been followed for several years without evidence of deterioration in renal function or malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/41/2712/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Complex renal cysts are uncommon in children; however, further evaluation is required because of the risk of malignancy. In one case series, surgical resection performed in 5 of 39 children with complex cysts revealed benign cysts in three and renal cell carcinoma in the other two patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/41/2712/abstract/41\">",
"     41",
"    </a>",
"    ]. The decision for surgical resection was based on risk assessment using the Bosniak classification based on CT or magnetic resonance findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H170183979\">",
"    <span class=\"h1\">",
"     ACQUIRED RENAL CYSTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acquired renal cysts are rare in the general pediatric population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95166757\">",
"    <span class=\"h2\">",
"     End-stage renal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;As seen in adults with end-stage renal disease (ESRD), acquired renal cysts may be observed in children with ESRD who are undergoing chronic dialysis. The incidence of acquired cystic disease rises with increased duration of dialysis as illustrated in one study of 54 children receiving continuous ambulatory peritoneal dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/41/2712/abstract/42\">",
"     42",
"    </a>",
"    ]. The prevalence of acquired cystic disease was 9, 50, and 80 percent among those who had undergone dialysis for zero to 4 years, 5 to 9 years, and longer than 10 years, respectively. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/5/23638?source=see_link\">",
"     \"Acquired cystic disease of the kidney in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H170183987\">",
"    <span class=\"h2\">",
"     Liver transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acquired renal cysts are common in children who have undergone liver transplantation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one case series from a single center, 33 of 108 children (30 percent) after liver transplantation developed renal cysts [",
"      <a class=\"abstract\" href=\"UTD.htm?2/41/2712/abstract/43\">",
"       43",
"      </a>",
"      ]. Risk factors for cyst formation included moderate renal dysfunction, biopsy-proven chronic liver graft rejection, and thrombosis of the retrohepatic vena cava.",
"     </li>",
"     <li>",
"      In a second case series of 235 children undergoing liver transplantation at a single center, 11 percent of patients developed one or more renal cysts [",
"      <a class=\"abstract\" href=\"UTD.htm?2/41/2712/abstract/44\">",
"       44",
"      </a>",
"      ]. Multivariate analysis identified treatment with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/24/34176?source=see_link\">",
"       cyclosporine",
"      </a>",
"      as the only independent risk factor.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H170184027\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal cysts occur in a variety of diseases in children (",
"    <a class=\"graphic graphic_table graphicRef68570 \" href=\"UTD.htm?32/14/33003\">",
"     table 1",
"    </a>",
"    ). Cysts may be due to a nonhereditary fetal malformations (ie, cystic renal dysplasia), genetic disorder, or they may be rarely acquired. Cysts may also occur as an isolated finding or as part of a syndrome.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Multicystic dysplastic kidney (MCDK) is the most severe form of cystic renal dysplasia. It consists of numerous noncommunicating cysts separated by dysplastic tissue with no identifiable renal tissue (",
"      <a class=\"graphic graphic_picture graphicRef66837 \" href=\"UTD.htm?19/37/20052\">",
"       picture 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef68485 \" href=\"UTD.htm?43/34/44576\">",
"       image 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef73581 \" href=\"UTD.htm?22/54/23393\">",
"       image 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef59147 \" href=\"UTD.htm?20/63/21491\">",
"       picture 2",
"      </a>",
"      ). The diagnosis is most frequently made by antenatal ultrasound with an overall incidence of 0.3 to 1 per 1000 live births. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Multicystic dysplastic kidney'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Because the natural history of MCKD is involution of the affected kidney and there are usually no associated complications, we recommend conservative management of MCKD (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Management consists of serial renal ultrasounds to monitor contralateral kidney growth and any evidence of renal scarring, and involution of the affected kidney. In addition, routine follow-up includes blood pressure measurements to detect hypertension, urinalysis to detect proteinuria, and renal function studies. (See",
"      <a class=\"local\" href=\"#H95167046\">",
"       'Management'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Course'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Genetic disorders that present with renal cystic disease in children include the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Autosomal recessive and dominant polycystic kidney disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29913?source=see_link\">",
"       \"Autosomal recessive polycystic kidney disease in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/58/28584?source=see_link\">",
"       \"Autosomal dominant polycystic kidney disease in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Glomerular cortical cysts that present as isolated abnormality (eg, glomerulocystic kidney disease) or associated with genetic syndromes including oro-facial-digital syndrome, Jeune syndrome, Zellweger syndrome, brachymesomelia-renal syndrome, and trisomy 13 (",
"      <a class=\"graphic graphic_table graphicRef82584 \" href=\"UTD.htm?24/48/25356\">",
"       table 3",
"      </a>",
"      ). Renal cysts and diabetes (RCAD) syndrome is due to mutations of the hepatocyte nuclear factor-1-beta gene. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Glomerular cortical cysts'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Genetic syndromes that may present with tubular-derived cysts include Meckel-Gruber syndrome, Bardet-Biedel syndrome, Beckwith-Wiedemann syndrome, tuberous sclerosis, and nephronophthisis. (See",
"      <a class=\"local\" href=\"#H170183611\">",
"       'Tubular cysts'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Isolated renal cysts are commonly observed. The main clinical concern is differentiating a simple benign cyst with a thin wall without septa, calcifications, or solid components from a complex cyst that is associated with an increased risk of malignancy. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Isolated renal cysts'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although acquired renal cysts are rare in the general pediatric population, they are more frequently observed in children with end-stage renal disease who undergo chronic dialysis and in children after liver transplantation. (See",
"      <a class=\"local\" href=\"#H170183979\">",
"       'Acquired renal cysts'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2712/abstract/1\">",
"      Matsell DG, Bennett T, Armstrong RA, et al. Insulin-like growth factor (IGF) and IGF binding protein gene expression in multicystic renal dysplasia. J Am Soc Nephrol 1997; 8:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2712/abstract/2\">",
"      Ismaili K, Avni FE, Alexander M, et al. Routine voiding cystourethrography is of no value in neonates with unilateral multicystic dysplastic kidney. J Pediatr 2005; 146:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2712/abstract/3\">",
"      Eckoldt F, Woderich R, Smith RD, Heling KS. Antenatal diagnostic aspects of unilateral multicystic kidney dysplasia--sensitivity, specificity, predictive values, differential diagnoses, associated malformations and consequences. Fetal Diagn Ther 2004; 19:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2712/abstract/4\">",
"      James CA, Watson AR, Twining P, Rance CH. Antenatally detected urinary tract abnormalities: changing incidence and management. Eur J Pediatr 1998; 157:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2712/abstract/5\">",
"      Siqueira Rabelo EA, Oliveira EA, Silva JM, et al. Ultrasound progression of prenatally detected multicystic dysplastic kidney. Urology 2006; 68:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2712/abstract/6\">",
"      Ylinen E, Ahonen S, Ala-Houhala M, Wikstr&ouml;m S. Nephrectomy for multicystic dysplastic kidney: if and when? Urology 2004; 63:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2712/abstract/7\">",
"      Onal B, Kogan BA. Natural history of patients with multicystic dysplastic kidney-what followup is needed? J Urol 2006; 176:1607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2712/abstract/8\">",
"      Guarino N, Casamassima MG, Tadini B, et al. Natural history of vesicoureteral reflux associated with kidney anomalies. Urology 2005; 65:1208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2712/abstract/9\">",
"      Merrot T, Lumenta DB, Tercier S, et al. Multicystic dysplastic kidney with ipsilateral abnormalities of genitourinary tract: experience in children. Urology 2006; 67:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2712/abstract/10\">",
"      Dimmick JE, Johnson HW, Coleman GU, Carter M. Wilms tumorlet, nodular renal blastema and multicystic renal dysplasia. J Urol 1989; 142:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2712/abstract/11\">",
"      Noe HN, Marshall JH, Edwards OP. Nodular renal blastema in the multicystic kidney. J Urol 1989; 142:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2712/abstract/12\">",
"      Beckwith JB. Should asymptomatic unilateral multicystic dysplastic kidneys be removed because of the future risk of neoplasia? Pediatr Nephrol 1992; 6:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2712/abstract/13\">",
"      Narchi H. Risk of hypertension with multicystic kidney disease: a systematic review. Arch Dis Child 2005; 90:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2712/abstract/14\">",
"      Husmann DA. Renal dysplasia: the risks and consequences of leaving dysplastic tissue in situ. Urology 1998; 52:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2712/abstract/15\">",
"      Snodgrass WT. Hypertension associated with multicystic dysplastic kidney in children. J Urol 2000; 164:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2712/abstract/16\">",
"      Cambio AJ, Evans CP, Kurzrock EA. Non-surgical management of multicystic dysplastic kidney. BJU Int 2008; 101:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2712/abstract/17\">",
"      Hayes WN, Watson AR, Trent &amp; Anglia MCDK Study Group. Unilateral multicystic dysplastic kidney: does initial size matter? Pediatr Nephrol 2012; 27:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2712/abstract/18\">",
"      Weinstein A, Goodman TR, Iragorri S. Simple multicystic dysplastic kidney disease: end points for subspecialty follow-up. Pediatr Nephrol 2008; 23:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2712/abstract/19\">",
"      Mansoor O, Chandar J, Rodriguez MM, et al. Long-term risk of chronic kidney disease in unilateral multicystic dysplastic kidney. Pediatr Nephrol 2011; 26:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2712/abstract/20\">",
"      Aslam M, Watson AR, Trent &amp; Anglia MCDK Study Group. Unilateral multicystic dysplastic kidney: long term outcomes. Arch Dis Child 2006; 91:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2712/abstract/21\">",
"      Welch TR, Wacksman J. The changing approach to multicystic dysplastic kidney in children. J Pediatr 2005; 146:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2712/abstract/22\">",
"      Kuwertz-Broeking E, Brinkmann OA, Von Lengerke HJ, et al. Unilateral multicystic dysplastic kidney: experience in children. BJU Int 2004; 93:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2712/abstract/23\">",
"      Kessler OJ, Ziv N, Livne PM, Merlob P. Involution rate of multicystic renal dysplasia. Pediatrics 1998; 102:E73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2712/abstract/24\">",
"      Metcalfe PD, Wright JR Jr, Anderson PA. MCDK not excluded by virtue of function on renal scan. Can J Urol 2002; 9:1690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2712/abstract/25\">",
"      Narchi H. Risk of Wilms' tumour with multicystic kidney disease: a systematic review. Arch Dis Child 2005; 90:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2712/abstract/26\">",
"      Minevich E, Wacksman J, Phipps L, et al. The importance of accurate diagnosis and early close followup in patients with suspected multicystic dysplastic kidney. J Urol 1997; 158:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2712/abstract/27\">",
"      Gascue C, Katsanis N, Badano JL. Cystic diseases of the kidney: ciliary dysfunction and cystogenic mechanisms. Pediatr Nephrol 2011; 26:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2712/abstract/28\">",
"      Avni FE, Hall M. Renal cystic diseases in children: new concepts. Pediatr Radiol 2010; 40:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2712/abstract/29\">",
"      Joshi VV, Kasznica J. Clinicopathologic spectrum of glomerulocystic kidneys: report of two cases and a brief review of literature. Pediatr Pathol 1984; 2:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2712/abstract/30\">",
"      Melnick SC, Brewer DB, Oldham JS. Cortical microcystic disease of the kidney with dominant inheritance: a previously undescribed syndrome. J Clin Pathol 1984; 37:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2712/abstract/31\">",
"      Kaplan BS, Gordon I, Pincott J, Barratt TM. Familial hypoplastic glomerulocystic kidney disease: a definite entity with dominant inheritance. Am J Med Genet 1989; 34:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2712/abstract/32\">",
"      Rizzoni G, Loirat C, Levy M, et al. Familial hypoplastic glomerulocystic kidney. A new entity? Clin Nephrol 1982; 18:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2712/abstract/33\">",
"      Fitch SJ, Stapleton FB. Ultrasonographic features of glomerulocystic disease in infancy: similarity to infantile polycystic kidney disease. Pediatr Radiol 1986; 16:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2712/abstract/34\">",
"      Heidet L, Decramer S, Pawtowski A, et al. Spectrum of HNF1B mutations in a large cohort of patients who harbor renal diseases. Clin J Am Soc Nephrol 2010; 5:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2712/abstract/35\">",
"      Ulinski T, Lescure S, Beaufils S, et al. Renal phenotypes related to hepatocyte nuclear factor-1beta (TCF2) mutations in a pediatric cohort. J Am Soc Nephrol 2006; 17:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2712/abstract/36\">",
"      Edghill EL, Oram RA, Owens M, et al. Hepatocyte nuclear factor-1beta gene deletions--a common cause of renal disease. Nephrol Dial Transplant 2008; 23:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2712/abstract/37\">",
"      Gagnadoux MF, Bacri JL, Broyer M, Habib R. Infantile chronic tubulo-interstitial nephritis with cortical microcysts: variant of nephronophthisis or new disease entity? Pediatr Nephrol 1989; 3:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2712/abstract/38\">",
"      Kytt&auml;l&auml; M, Tallila J, Salonen R, et al. MKS1, encoding a component of the flagellar apparatus basal body proteome, is mutated in Meckel syndrome. Nat Genet 2006; 38:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2712/abstract/39\">",
"      Roume J, Genin E, Cormier-Daire V, et al. A gene for Meckel syndrome maps to chromosome 11q13. Am J Hum Genet 1998; 63:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2712/abstract/40\">",
"      McHugh K, Stringer DA, Hebert D, Babiak CA. Simple renal cysts in children: diagnosis and follow-up with US. Radiology 1991; 178:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2712/abstract/41\">",
"      Wallis MC, Lorenzo AJ, Farhat WA, et al. Risk assessment of incidentally detected complex renal cysts in children: potential role for a modification of the Bosniak classification. J Urol 2008; 180:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2712/abstract/42\">",
"      Acquired cystic kidney disease in children undergoing continuous ambulatory peritoneal dialysis. Kyushu Pediatric Nephrology Study Group. Am J Kidney Dis 1999; 34:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2712/abstract/43\">",
"      Franchi-Abella S, Mourier O, Pariente D, et al. Acquired renal cystic disease after liver transplantation in children. Transplant Proc 2007; 39:2601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/41/2712/abstract/44\">",
"      Calvo-Garcia MA, Campbell KM, O'Hara SM, et al. Acquired renal cysts after pediatric liver transplantation: association with cyclosporine and renal dysfunction. Pediatr Transplant 2008; 12:666.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6144 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-122.72.76.133-1D88657B2A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_41_2712=[""].join("\n");
var outline_f2_41_2712=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H170184027\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NONHEREDITARY RENAL MALFORMATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Multicystic dysplastic kidney",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Course",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H95167046\">",
"      - Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H95167550\">",
"      GENETIC DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Glomerular cortical cysts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H170183491\">",
"      - Glomerulocystic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H170183551\">",
"      - Renal cyst and diabetes (RCAD) syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H170184575\">",
"      - Nephronophthisis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H170183611\">",
"      Tubular cysts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ISOLATED RENAL CYSTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H170183979\">",
"      ACQUIRED RENAL CYSTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H95166757\">",
"      End-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H170183987\">",
"      Liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H170184027\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6144\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6144|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?36/10/37024\" title=\"diagnostic image 1\">",
"      Prenatal ultrasound bilateral MCDK",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?20/3/20528\" title=\"diagnostic image 2\">",
"      Prenatal ultrasound of unilateral MCDK",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?43/34/44576\" title=\"diagnostic image 3\">",
"      US and intraop MCDK",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?22/54/23393\" title=\"diagnostic image 4\">",
"      CT scan horseshoe kidney",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6144|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/37/20052\" title=\"picture 1\">",
"      Multicyst dysplastic kidney",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/63/21491\" title=\"picture 2\">",
"      Multicystic dysplastic kidney",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6144|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/14/33003\" title=\"table 1\">",
"      Cysts in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/20/334\" title=\"table 2\">",
"      Hereditary renal cystic disease and genes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/48/25356\" title=\"table 3\">",
"      Cyst malformations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/5/23638?source=related_link\">",
"      Acquired cystic disease of the kidney in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/58/28584?source=related_link\">",
"      Autosomal dominant polycystic kidney disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29913?source=related_link\">",
"      Autosomal recessive polycystic kidney disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/57/24473?source=related_link\">",
"      Beckwith-Wiedemann syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/2/21545?source=related_link\">",
"      Clinical manifestations and causes of nephrogenic diabetes insipidus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/22/16744?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of nephronophthisis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/56/10120?source=related_link\">",
"      Genetics and pathogenesis of nephronophthisis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22472?source=related_link\">",
"      Overview of congenital anomalies of the kidney and urinary tract (CAKUT)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/18/43303?source=related_link\">",
"      Renal manifestations of tuberous sclerosis and renal angiomyolipoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/3/27704?source=related_link\">",
"      Simple and complex renal cysts in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/38/34410?source=related_link\">",
"      Tuberous sclerosis complex: Genetics, clinical features, and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_41_2713="Erythrodermic sarcoidosis - chest";
var content_f2_41_2713=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F51460%7EDERM%2F63230&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F51460%7EDERM%2F63230&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Erythrodermic sarcoidosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythrodermic sarcoidosis. This patient has large, geometric, erythematous plaques covering most of the body.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc. Original photo provided by NYU (Tisch) Department of Dermatology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Erythrodermic sarcoidosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythrodermic sarcoidosis. This patient has large, confluent, geometric erythematous plaques covering most of the body.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_41_2713=[""].join("\n");
var outline_f2_41_2713=null;
var title_f2_41_2714="Doxycycline: Drug information";
var content_f2_41_2714=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Doxycycline: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?35/10/36005?source=see_link\">",
"    see \"Doxycycline: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/54/12136?source=see_link\">",
"    see \"Doxycycline: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F163331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Adoxa&reg;;",
"     </li>",
"     <li>",
"      Alodox&trade;;",
"     </li>",
"     <li>",
"      Doryx&reg;;",
"     </li>",
"     <li>",
"      Doxy 100&trade;;",
"     </li>",
"     <li>",
"      Monodox&reg;;",
"     </li>",
"     <li>",
"      Ocudox&trade;;",
"     </li>",
"     <li>",
"      Oracea&reg;;",
"     </li>",
"     <li>",
"      Oraxyl&trade;;",
"     </li>",
"     <li>",
"      Vibramycin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F163332\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Doxy Tabs&reg;;",
"     </li>",
"     <li>",
"      Apo-Doxy&reg;;",
"     </li>",
"     <li>",
"      Dom-Doxycycline;",
"     </li>",
"     <li>",
"      Doxycin;",
"     </li>",
"     <li>",
"      Doxytab;",
"     </li>",
"     <li>",
"      Novo-Doxylin;",
"     </li>",
"     <li>",
"      Nu-Doxycycline;",
"     </li>",
"     <li>",
"      Periostat&reg;;",
"     </li>",
"     <li>",
"      PHL-Doxycycline;",
"     </li>",
"     <li>",
"      PMS-Doxycycline;",
"     </li>",
"     <li>",
"      Vibra-Tabs&reg;;",
"     </li>",
"     <li>",
"      Vibramycin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F163364\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Tetracycline Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F163336\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Usual dosage range:",
"     </b>",
"     Oral, I.V.: 100-200 mg/day in 1-2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acute bacterial rhinosinusitis (unlabeled use):",
"     </b>",
"     Oral: 200 mg/day in 1-2 divided doses for 5-7 days (Chow, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Anthrax:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Inhalational (postexposure prophylaxis):",
"     </i>",
"     Oral, I.V. (use oral route when possible): 100 mg every 12 hours for 60 days (ACIP, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Cutaneous (treatment):",
"     </i>",
"     Oral: 100 mg every 12 hours for 60 days.",
"     <b>",
"      Note:",
"     </b>",
"     In the presence of systemic involvement, extensive edema, lesions on head/neck, refer to I.V. dosing for treatment of inhalational/gastrointestinal/oropharyngeal anthrax",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Inhalational/gastrointestinal/oropharyngeal (treatment):",
"     </i>",
"     I.V.: Initial: 100 mg every 12 hours; switch to oral therapy when clinically appropriate; some recommend initial loading dose of 200 mg, followed by 100 mg every 8-12 hours (Franz, 1997).",
"     <b>",
"      Note:",
"     </b>",
"     Initial treatment should include two or more agents predicted to be effective (CDC, 2001). Agents suggested for use in conjunction with doxycycline or ciprofloxacin include rifampin, vancomycin, imipenem, penicillin, ampicillin, chloramphenicol, clindamycin, and clarithromycin. May switch to oral antimicrobial therapy when clinically appropriate. Continue combined therapy for 60 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Brucellosis:",
"     </b>",
"     Oral: 100 mg twice daily for 6 weeks with rifampin or streptomycin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cellulitis (purulent) due to community-acquired MRSA (unlabeled use):",
"     </b>",
"     Oral: 100 mg twice daily for 5-10 days (Liu, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chlamydial infections, uncomplicated:",
"     </b>",
"     Oral: 100 mg twice daily for &ge;7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Community-acquired pneumonia, bronchitis:",
"     </b>",
"     Oral, I.V.: 100 mg twice daily (Ailani, 1999; Mandell, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Epididymitis:",
"     </b>",
"     Oral: 100 mg twice daily for 10 days (in combination with ceftriaxone) (CDC, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gonococcal infection, uncomplicated:",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Azithromycin is preferred over doxycycline as the second antimicrobial in combination with ceftriaxone in uncomplicated infections due to a high prevalence of tetracycline resistance in isolates (CDC, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Cervix, rectum, urethra:",
"     </i>",
"     100 mg twice daily for 7 days in combination with ceftriaxone (preferred) or cefixime (only if ceftriaxone is not available and test-of-cure follow up in 7 days) (CDC, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Pharynx:",
"     </i>",
"     100 mg twice daily for 7 days in combination with ceftriaxone (CDC, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alternatively, the manufacturer recommends a single-visit dose in nonanorectal infections in men: 300 mg initially, repeat dose in 1 hour (total dose: 600 mg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Granuloma inguinale (donovanosis):",
"     </b>",
"     Oral: 100 mg twice daily for at least 3 weeks (and until lesions have healed) (CDC, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lyme disease:",
"     </b>",
"     Oral (Halperin, 2007; Wormser, 2006):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Prevention:",
"     </i>",
"     Initiate within 72 hours of tick removal: 200 mg administered as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Treatment (early lyme disease without neurologic manifestations):",
"     </i>",
"     100 mg twice daily for 10-21 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Treatment (meningitis or other early neurologic manifestations):",
"     </i>",
"     100-200 mg twice daily for 14 days (range: 10-28 days)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lymphogranuloma venereum:",
"     </b>",
"     Oral: 100 mg twice daily for 21 days (CDC, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Malaria chemoprophylaxis:",
"     </b>",
"     Oral: 100 mg/day. Start 1-2 days prior to travel to endemic area; continue daily during travel and for 4 weeks after leaving endemic area",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Malaria, severe, treatment (unlabeled use):",
"     </b>",
"     Oral, I.V.: 100 mg every 12 hours for 7 days with quinidine gluconate.",
"     <b>",
"      Note:",
"     </b>",
"     Quinidine gluconate duration is region specific; consult CDC for current recommendations (CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Malaria, uncomplicated, treatment (unlabeled use):",
"     </b>",
"     Oral: 100 mg twice daily for 7 days with quinine sulfate.",
"     <b>",
"      Note:",
"     </b>",
"     Quinine sulfate duration is region specific; consult CDC for current recommendations (CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Nongonococcal urethritis:",
"     </b>",
"     Oral: 100 mg twice daily for 7 days (CDC, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pelvic inflammatory disease:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Treatment, inpatient:",
"     </i>",
"     Oral, I.V.: 100 mg twice daily (in combination with cefoxitin or cefotetan); may transition to oral doxycycline (add clindamycin or metronidazole if tubo-ovarian abscess present) to complete 14 days of treatment (CDC, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Treatment, outpatient:",
"     </i>",
"     Oral: 100 mg twice daily for 14 days (with or without  metronidazole); preceded by a single I.M. dose of cefoxitin (plus oral probenecid) or ceftriaxone (CDC, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Periodontitis:",
"     </b>",
"     Oral (Periostat&reg;): 20 mg twice daily as an adjunct following scaling and root planing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Periodontitis, refractory (unlabeled use):",
"     </b>",
"     Oral: 100-200 mg daily (Jolkovsky, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Proctitis:",
"     </b>",
"     Oral: 100 mg twice daily for 7 days (in combination with ceftriaxone) (CDC, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Q fever:",
"     </b>",
"     Oral: 100 mg every 12 hours for 15-21days (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Rosacea",
"     </b>",
"     (Oracea&reg;): Oral: 40 mg once daily in the morning",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Sclerosing agent for pleural effusion (unlabeled use):",
"     </b>",
"     Intrapleural:  500 mg as a single dose in 100 mL NS (Porcel, 2006); may require a repeat dose (Kvale, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Syphilis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Primary/secondary syphilis:",
"     </i>",
"     Oral: 100 mg twice daily for 14 days (CDC, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Latent syphilis:",
"     </i>",
"     Oral: 100 mg twice daily for 28 days (CDC, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tickborne rickettsial disease:",
"     </b>",
"     Oral, I.V.: 100 mg twice daily for 5-7 days; severe or complicated disease may require longer treatment; human granulocytotropic anaplasmosis (HGA) should be treated for 10-14 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tularemia:",
"     </b>",
"     I.V. (may transition to oral if clinically appropriate): Initial: 100 mg every 12 hours for 14-21 days (Dennis, 2001)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Vibrio cholerae:",
"      </i>",
"     </b>",
"     Oral: 300 mg as a single dose (WHO, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Yersinia pestis",
"      </i>",
"     </b>",
"     <b>",
"      (plague):",
"     </b>",
"     Oral, I.V.: 200 mg initially then 100 mg twice daily",
"     <b>",
"      or",
"     </b>",
"     200 mg once daily for 10 days (Daya, 2005; Inglesby, 2000)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F163349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/54/12136?source=see_link\">",
"      see \"Doxycycline: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Usual dosage range:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &gt;8 years (&le;45 kg): Oral, I.V.: 2-5 mg/kg/day in 1-2 divided doses, not to exceed 200 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &gt;8 years (&gt;45 kg): Oral, I.V.: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Anthrax:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Inhalational (postexposure prophylaxis)",
"     </i>",
"     (ACIP, 2010): Oral, I.V. (use oral route when possible):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &le;8 years: 2.2 mg/kg every 12 hours for 60 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &gt;8 years and &le;45 kg: 2.2 mg/kg every 12 hours for 60 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &gt;8 years and &gt;45 kg: 100 mg every 12 hours for 60 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Cutaneous (treatment):",
"     </i>",
"     Oral: See dosing for &ldquo;Inhalational (postexposure prophylaxis)&rdquo;",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     In the presence of systemic involvement, extensive edema, and/or lesions on head/neck, doxycycline should initially be administered I.V.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Inhalational/gastrointestinal/oropharyngeal (treatment):",
"     </i>",
"     I.V.: Refer to dosing for inhalational anthrax (postexposure prophylaxis); switch to oral therapy when clinically appropriate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Initial treatment should include two or more agents predicted to be effective (CDC, 2001). Agents suggested for use in conjunction with doxycycline or ciprofloxacin include rifampin, vancomycin, imipenem, penicillin, ampicillin, chloramphenicol, clindamycin, and clarithromycin. May switch to oral antimicrobial therapy when clinically appropriate. Continue combined therapy for 60 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Community-acquired pneumonia (CAP) (IDSA/PIDS, 2011):",
"     </b>",
"     Children &gt;7 years: Oral:",
"     <b>",
"      Note:",
"     </b>",
"     A beta-lactam antibiotic should be added if typical bacterial pneumonia cannot be ruled out.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Presumed atypical, mild atypical (",
"     <i>",
"      M. pneumoniae, C. pneumoniae, C. trachomatis",
"     </i>",
"     ) infection or step-down therapy (alternative to azithromycin): 2-4 mg/kg/day in 2 divided doses (maximum: 200 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cellulitis (purulent) due to community-acquired MRSA (unlabeled use):",
"     </b>",
"     Oral: Children &gt;8 years and &le;45 kg: 2 mg/kg/dose every 12 hours for 5-10 days; &gt;45 kg: Refer to adult dosing (Liu, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chlamydial infections, uncomplicated:",
"     </b>",
"     Children &gt;8 years and &gt;45 kg: Oral: 100 mg twice daily for 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Localized juvenile periodontitis (LJP) (unlabeled use):",
"     </b>",
"     Oral: 50-100 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lyme disease:",
"     </b>",
"     Children &ge;8 years: Oral (Halperin, 2007; Wormser, 2006):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Prevention:",
"     </i>",
"     4 mg/kg (maximum: 200 mg) administered as a single dose;",
"     <b>",
"      Note:",
"     </b>",
"     Initiate within 72 hours of tick removal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Treatment (early lyme disease without neurologic manifestations):",
"     </i>",
"     1-2 mg/kg twice daily for 10-21 days (maximum: 100 mg/dose)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Treatment (meningitis and other early neurologic manifestations):",
"     </i>",
"     4-8 mg/kg/day in 2 divided doses for 10-28 days (maximum: 200 mg/dose)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Malaria chemoprophylaxis:",
"     </b>",
"     Children &ge;8 years: Oral: 2.2 mg/kg/day (maximum: 100 mg/day). Start 1-2 days prior to travel to endemic area; continue daily during travel and for 4 weeks after leaving endemic area (CDC, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Malaria, severe, treatment (unlabeled use):",
"     </b>",
"     Children &ge;8 years: Oral, I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &lt;45 kg: 2.2 mg/kg (maximum dose: 100 mg) every 12 hours for 7 days with quinidine gluconate.",
"     <b>",
"      Note:",
"     </b>",
"     Quinidine gluconate duration is region specific; consult CDC for current recommendations (CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &ge;45 kg: 100 mg every 12 hours for 7 days with quinidine gluconate.",
"     <b>",
"      Note:",
"     </b>",
"     Quinidine gluconate duration is region specific; consult CDC for current recommendations (CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Malaria, uncomplicated, treatment (unlabeled use):",
"     </b>",
"     Children &ge;8 years: Oral: 2.2 mg/kg (maximum dose: 100 mg) every 12 hours for 7 days with quinine sulfate.",
"     <b>",
"      Note:",
"     </b>",
"     Quinine sulfate duration is region specific, consult CDC for current recommendations (CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prosthetic joint infection (unlabeled use):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Chronic oral antimicrobial suppression:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Propionibacterium",
"     </i>",
"     spp (alternative to penicillin or amoxicillin): 100 mg twice daily (Osmon, 2013)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Staphylococci (oxacillin-resistant): 100 mg twice daily (Osmon, 2013)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Staphylococci (oxacillin-sensitive or &ndash;resistant) oral phase treatment (after completion of pathogen-specific I.V) following 1-stage exchange:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Total ankle, elbow, hip, or shoulder arthroplasty: 100 mg twice daily for 3 months;",
"     <b>",
"      Note:",
"     </b>",
"     Must be used in combination with rifampin (Osmon, 2013).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Total knee arthroplasty: 100 mg twice daily for 6 months;",
"     <b>",
"      Note:",
"     </b>",
"     Must be used in combination with rifampin (Osmon, 2013)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Q fever:",
"     </b>",
"     Oral: 2.2 mg/kg twice/day for 15-21 days. Some clinicians may recommend trimethoprim/sulfamethoxazole for children &lt;8 years of age (Hartzell, 2008).",
"     <b>",
"      Note:",
"     </b>",
"     Use of tetracyclines should be avoided during tooth development (children &le;8 years of age) unless other drugs are unlikely to be effective or are contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tickborne rickettsial disease:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     The American Academy of Pediatrics Committee on Infectious Diseases identifies doxycycline as the drug of choice in children of any age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &le;8 years: Oral, I.V.: 2.2 mg/kg (maximum dose: 100 mg) every 12 hours for 5-7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &gt;8 years and &gt;45 kg: Oral, I.V.: 100 mg twice daily for 5-7days; severe or complicated disease may require longer treatment; human granulocytotropic anaplasmosis (HGA) should be treated for 10-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tularemia:",
"     </b>",
"     I.V. (may transition to oral if clinically indicated) (Dennis, 2001):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &lt;45 kg: 2.2 mg/kg every 12 hours for 14-21 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;45 kg: 100 mg every 12 hours for 14-21 days",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F163337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F163338\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment necessary in renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Poorly dialyzed; no supplemental dose or dosage adjustment necessary, including patients on intermittent hemodialysis, peritoneal dialysis, or continuous renal replacement therapy (eg, CVVHD).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15804929\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F163303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral [strength expressed as base]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oracea&reg;: 40 mg [30 mg (immediate release) and 10 mg (delayed release)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral, as hyclate [strength expressed as base]: 50 mg, 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocudox&trade;: 50 mg [kit includes Ocudox&trade; capsules (60s), Ocusoft&reg; Lid Scrub&trade; Plus eyelid cleanser pads, and Tears Again&reg; advanced spray]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oraxyl&trade;: 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vibramycin&reg;: 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral, as monohydrate [strength expressed as base]: 50 mg, 75 mg, 100 mg, 150 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adoxa&reg;: 150 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Monodox&reg;: 50 mg [DSC], 75 mg, 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as hyclate [strength expressed as base]: 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Doxy 100&trade;: 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for suspension, oral, as monohydrate [strength expressed as base]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vibramycin&reg;: 25 mg/5 mL (60 mL) [raspberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Syrup, oral, as calcium [strength expressed as base]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vibramycin&reg;: 50 mg/5 mL (473 mL) [contains propylene glycol, sodium metabisulfite; raspberry-apple flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hyclate [strength expressed as base]: 20 mg, 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alodox&trade;: 20 mg [kit includes Alodox&trade; tablets (60s), Ocusoft&reg; Lid Scrub&trade; pads, eyelid cleanser, and goggles]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Periostat&reg;: 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as monohydrate [strength expressed as base]: 50 mg, 75 mg, 100 mg, 150 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, delayed release coated beads, oral, as hyclate [strength expressed as base]: 75 mg, 100 mg, 150 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, delayed release coated pellets, oral, as hyclate [strength expressed as base]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Doryx&reg;: 150 mg [scored; contains sodium 9 mg (0.392 mEq)/tablet]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F163288\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes capsule (variable release), powder for suspension, syrup",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F163306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral administration is preferable unless patient has significant nausea and vomiting;  I.V. and oral routes are bioequivalent.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: May give with meals to decrease GI upset. Capsule and tablet: Administer with at least 8 ounces of water and have patient sit up for at least 30 minutes after taking to reduce the risk of esophageal irritation and ulceration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oracea&reg;: Take on an empty stomach 1 hour before or 2 hours after meals.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Doryx&reg;: May be administered by carefully breaking up the tablet and sprinkling tablet contents on a spoonful of cold applesauce. The delayed release pellets must not be crushed or damaged when breaking up tablet. Should be administered immediately after preparation and without chewing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: Infuse I.V. doxycycline over 1-4 hours; avoid extravasation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Intrapleural (unlabeled route): Add to 100 mL NS and instill into chest tube (Porcel, 2006)",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F163370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Solutions for I.V. infusion are stable in NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, Ringer's injection, LR, D",
"     <sub>",
"      5",
"     </sub>",
"     LR.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acyclovir, amifostine, amiodarone, aztreonam, bivalirudin, cisatracurium, cyclophosphamide, cyclosporine, dexmedetomidine, diltiazem, docetaxel, etoposide phosphate, fenoldopam, filgrastim, fludarabine, gemcitabine, granisetron, hetastarch in lactate electrolyte injection (Hextend&reg;), hydromorphone, linezolid, magnesium sulfate, melphalan, meperidine, morphine, ondansetron, oxytocin, propofol, remifentanil, sargramostim, tacrolimus, telavancin, teniposide, theophylline, thiotepa, vinorelbine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Allopurinol, heparin, pemetrexed, piperacillin/tazobactam.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Meropenem.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Doxapram.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F163304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Principally in the treatment of infections caused by susceptible",
"     <i>",
"      Rickettsia",
"     </i>",
"     ,",
"     <i>",
"      Chlamydia",
"     </i>",
"     , and",
"     <i>",
"      Mycoplasma",
"     </i>",
"     ; alternative to mefloquine for malaria prophylaxis; treatment for syphilis, uncomplicated",
"     <i>",
"      Neisseria gonorrhoeae",
"     </i>",
"     (alternative agent),",
"     <i>",
"      Listeria",
"     </i>",
"     ,",
"     <i>",
"      Actinomyces israelii",
"     </i>",
"     , and",
"     <i>",
"      Clostridium",
"     </i>",
"     infections in penicillin-allergic patients; used for community-acquired pneumonia and other common infections due to susceptible organisms; anthrax due to",
"     <i>",
"      Bacillus anthracis,",
"     </i>",
"     including inhalational anthrax (postexposure); treatment of infections caused by uncommon susceptible gram-negative and gram-positive organisms including",
"     <i>",
"      Borrelia recurrentis",
"     </i>",
"     ,",
"     <i>",
"      Ureaplasma urealyticum",
"     </i>",
"     ,",
"     <i>",
"      Haemophilus ducreyi",
"     </i>",
"     ,",
"     <i>",
"      Yersinia pestis",
"     </i>",
"     ,",
"     <i>",
"      Francisella tularensis",
"     </i>",
"     ,",
"     <i>",
"      Vibrio cholerae",
"     </i>",
"     ,",
"     <i>",
"      Campylobacter fetus",
"     </i>",
"     ,",
"     <i>",
"      Brucella",
"     </i>",
"     spp,",
"     <i>",
"      Bartonella bacilliformis",
"     </i>",
"     , and",
"     <i>",
"      Klebsiella granulomatis,",
"     </i>",
"     Q fever, Lyme disease; treatment of inflammatory lesions associated with rosacea; intestinal amebiasis; severe acne",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F163361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sclerosing agent for pleural effusion (injection); vancomycin-resistant enterococci (VRE); alternate treatment for MRSA infections; treatment of periodontitis (refractory); localized juvenile periodontitis (LJP); treatment of acute bacterial rhinosinusitis (ABRS) (adults); oral phase treatment of prosthetic joint infection; chronic oral antimicrobial suppression of prosthetic joint infection",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F163372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Doxycycline may be confused with dicyclomine, doxepin, doxylamine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Doxy100&trade; may be confused with Doxil&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Monodox&reg; may be confused with Maalox&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Oracea&reg; may be confused with Orencia&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Vibramycin&reg; may be confused with vancomycin, Vibativ&trade;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F163362\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Intracranial hypertension, pericarditis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Angioneurotic edema, erythema multiforme, exfoliative dermatitis (rare), photosensitivity, rash, skin hyperpigmentation, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Brown/black discoloration of thyroid gland (no dysfunction reported), hypoglycemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, diarrhea, dysphagia, enterocolitis, esophagitis (rare), esophageal ulcerations (rare), glossitis, inflammatory lesions in anogenital region, nausea, oral (mucosal) pigmentation, pseudomembranous colitis, tooth discoloration (children), vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Eosinophilia, hemolytic anemia, neutropenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Hepatotoxicity (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: BUN increased (dose related)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylactoid purpura, anaphylaxis, bulging fontanels (infants), serum sickness, SLE exacerbation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Adverse effects in clinical trials occurring at a frequency more than 1% greater than placebo:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Periostat&reg;: Diarrhea, dyspepsia, joint pain, menstrual cramp, nausea, dyspepsia, pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Oracea&reg;: Abdominal distention, abdominal pain, anxiety, AST increased, back pain, fungal infection, hyperglycemia, influenza, LDH increased, nasal congestion, nasopharyngitis, pain, sinus headache, sinusitis, xerostomia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F163310\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to doxycycline, tetracycline or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F163292\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Autoimmune syndromes: Have been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity: Rarely occurs; if symptomatic, conduct LFT and discontinue drug.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Increased BUN: May be associated with increases in BUN secondary to antianabolic effects; use caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Photosensitivity: May cause photosensitivity; discontinue if skin erythema occurs. Use skin protection and avoid prolonged exposure to sunlight; do not use tanning equipment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pseudotumor cerebri: Has been (rarely) reported with tetracycline use; usually resolves with discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tissue hyperpigmentation: May induce hyperpigmentation in many organs, including nails, bone, skin (diffuse pigmentation as well as over sites of scars and injury), eyes, thyroid, visceral tissue, oral cavity (teeth, mucosa, alveolar bone), sclerae, and heart valves independently of time or amount of drug administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: May cause tissue hyperpigmentation, enamel hypoplasia, or permanent tooth discoloration; more common with long-term use, but observed with repeated, short courses; use of tetracyclines should be avoided during tooth development (children &lt;8 years of age [product labeling]; use between age 6-7 years has minimal effect [Chapman, 2006]) unless other drugs are not likely to be effective or are contraindicated. Recommended in treatment of anthrax exposure (CDC, 2001) and tickborne rickettsial diseases (CDC, 2006).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy: Do not use during pregnancy. In addition to affecting tooth development, tetracycline use has been associated with retardation of skeletal development and reduced bone growth.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Oracea&reg;: Should not be used for the treatment or prophylaxis of bacterial infections, since the lower dose of drug per capsule may be subefficacious and promote resistance.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Syrup: Contains sodium metabisulfite.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Periodontitis: Effectiveness has not been established in patients with coexistent oral candidiasis; use with caution in patients with a history or predisposition to oral candidiasis.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F163358\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F163297\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the absorption of Tetracycline Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May decrease the serum concentration of Doxycycline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Tetracycline Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bismuth: May decrease the serum concentration of Tetracycline Derivatives. Management: Consider dosing tetracyclines 2 hours before, or 6 hours after, bismuth. The need to separate doses during Helicobacter pylori eradication regimens is questionable.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bismuth Subsalicylate: May decrease the serum concentration of Tetracycline Derivatives. Management: Consider dosing tetracyclines 2 hours before, or 6 hours after, bismuth subsalicylate. The need to separate doses during Helicobacter pylori eradication regimens is questionable.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: May decrease the serum concentration of Tetracycline Derivatives. Management: If coadministration of oral calcium with oral tetracyclines can not be avoided, consider separating administration of each agent by several hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May decrease the serum concentration of Doxycycline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of Doxycycline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: May decrease the absorption of Tetracycline Derivatives. Only a concern with orally administered products.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ferric Gluconate; Ferumoxytol; Iron Dextran Complex; Iron Sucrose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lanthanum: May decrease the serum concentration of Tetracycline Derivatives. Management: Administer oral tetracycline antibiotics at least two hours before or after lanthanum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Salts: May decrease the absorption of Tetracycline Derivatives. Only applicable to oral preparations of each agent.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mipomersen: Tetracycline Derivatives may enhance the hepatotoxic effect of Mipomersen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Tetracycline Derivatives. Management: If coadministration of a polyvalent cation-containing multivitamin with oral tetracyclines can not be avoided, separate administration of each agent by several hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents: Tetracycline Derivatives may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Penicillins: Tetracycline Derivatives may diminish the therapeutic effect of Penicillins.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of Doxycycline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinapril: May decrease the serum concentration of Tetracycline Derivatives. Management: Separate doses of quinapril and oral tetracycline derivatives by at least 2 hours in order to reduce the risk of interaction. Monitor for reduced efficacy of the tetracycline if these products are used concomitantly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Retinoic Acid Derivatives: Tetracycline Derivatives may enhance the adverse/toxic effect of Retinoic Acid Derivatives. The development of pseudotumor cerebri is of particular concern.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Adapalene; Alitretinoin; Tretinoin (Topical).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Strontium Ranelate: May decrease the serum concentration of Tetracycline Derivatives. Management: In order to minimize any potential impact of strontium ranelate on tetracycline antibiotic concentrations, it is recommended that strontium ranelate treatment be interrupted during tetracycline therapy.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sucralfate: May decrease the absorption of Tetracycline Derivatives. Management: Administer the tetracycline derivative at least 2 hours prior to sucralfate in order to minimize the impact of this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Tetracycline Derivatives may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F163326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Chronic ethanol ingestion may reduce the serum concentration of doxycycline.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Doxycycline serum levels may be slightly decreased if taken with food or milk. Administration with iron or calcium may decrease doxycycline absorption. May decrease absorption of calcium, iron, magnesium, zinc, and amino acids.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease doxycycline levels. Avoid dong quai, St John's wort (may also cause photosensitization).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F163300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F163313\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tetracyclines cross the placenta and accumulate in developing teeth and long tubular bones. Therapeutic doses of doxycycline during pregnancy are unlikely to produce substantial teratogenic risk, but data are insufficient to say that there is no risk. In general, reports of exposure have been limited to short durations of therapy in the first trimester. Tetracyclines may discolor fetal teeth following maternal use during pregnancy; the specific teeth involved and the portion of the tooth affected depends on the timing and duration of exposure relative to tooth calcification. As a class, tetracyclines are generally considered second-line antibiotics in pregnant women and their use should be avoided. Tetracycline medications should be used during pregnancy only when other medications are contraindicated or ineffective (Mylonas, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F163343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F3415107\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Doxycycline is excreted in breast milk (Chung, 2002). According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother. Although nursing is not specifically contraindicated, the effects of long-term exposure via breast milk are not known. Oral absorption of doxycycline is not markedly influenced by simultaneous ingestion of milk; therefore, oral absorption of doxycycline by the breast-feeding infant would not be expected to be diminished by the calcium in the maternal milk. Nondose-related effects could include modification of bowel flora.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F163314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracyclines (in general): Take with food if gastric irritation occurs. While administration with food may decrease GI absorption of doxycycline by up to 20%, administration on an empty stomach is not recommended due to GI intolerance. Of currently available tetracyclines, doxycycline has the least affinity for calcium.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oracea&reg;: Take on an empty stomach 1 hour before or 2 hours after meals.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Some products may contain sodium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F163312\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsule, delayed release",
"     </b>",
"     (Oracea Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (30): $501.12",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsule, enteric pellets",
"     </b>",
"     (Doxycycline Hyclate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (50): $261.86",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Adoxa Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (60): $2564.38",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Doxycycline Hyclate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (50): $108.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (50): $164.10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Doxycycline Monohydrate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $118.74",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     75 mg (100): $1294.56",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (50): $96.92",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (60): $1479.01",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Monodox Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     75 mg (100): $1824.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (50): $960.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Morgidox Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (30): $266.66",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Oraxyl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (100): $93.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Vibramycin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (50): $328.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Alodox Convenience Combination)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (1): $113.76",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Ocudox Combination)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (1): $30.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Doxy 100 Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (1): $16.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Doxycycline Hyclate Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (1): $14.52",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension (reconstituted)",
"     </b>",
"     (Vibramycin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg/5 mL (60 mL): $25.30",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Syrup",
"     </b>",
"     (Vibramycin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg/5 mL (473 mL): $308.89",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, EC",
"     </b>",
"     (Doryx Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (60): $1260.34",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, EC",
"     </b>",
"     (Doxycycline Hyclate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     75 mg (60): $613.45",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $1314.83",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (100): $1759.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Adoxa Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $929.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     75 mg (100): $1277.12",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (50): $798.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Adoxa Pak 1/100 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (31): $306.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Adoxa Pak 1/150 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (30): $597.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Adoxa Pak 2/100 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (60): $592.63",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Doxycycline Hyclate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (100): $118.98",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (50): $164.10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Doxycycline Monohydrate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $335.71",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     75 mg (100): $498.35",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (50): $246.02",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (30): $274.17",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F6473884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Perform culture and sensitivity testing prior to initiating therapy. CBC, renal and liver function tests periodically with prolonged therapy. When used as part of alternative treatment for gonococcal infection, test of cure 7 days after dose (CDC, 2012).",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F163315\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Amermycin (HK, TH);",
"     </li>",
"     <li>",
"      Azudoxat (DE);",
"     </li>",
"     <li>",
"      Bactidox (PH);",
"     </li>",
"     <li>",
"      Bassado (IT);",
"     </li>",
"     <li>",
"      Biodoxi (IN);",
"     </li>",
"     <li>",
"      Biomixin (MX);",
"     </li>",
"     <li>",
"      Ciclonal (MX);",
"     </li>",
"     <li>",
"      Cyclidox (ZA);",
"     </li>",
"     <li>",
"      Cytragen (PH);",
"     </li>",
"     <li>",
"      Dagramycine (LU);",
"     </li>",
"     <li>",
"      Dentacline (KP);",
"     </li>",
"     <li>",
"      Dentistar (KP);",
"     </li>",
"     <li>",
"      Deoxymykoin (CZ);",
"     </li>",
"     <li>",
"      Docyl (TH);",
"     </li>",
"     <li>",
"      Doinmycin (TW);",
"     </li>",
"     <li>",
"      Doksiciklin (HR);",
"     </li>",
"     <li>",
"      Doksin (TR);",
"     </li>",
"     <li>",
"      Domiken (MX);",
"     </li>",
"     <li>",
"      Doryx (AU, NZ);",
"     </li>",
"     <li>",
"      Doxat (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Doxiclat (ES);",
"     </li>",
"     <li>",
"      Doximed (FI);",
"     </li>",
"     <li>",
"      Doximycin (FI);",
"     </li>",
"     <li>",
"      Doxin (PH, TH);",
"     </li>",
"     <li>",
"      Doxine (NZ);",
"     </li>",
"     <li>",
"      Doxiplus (PE);",
"     </li>",
"     <li>",
"      Doxsig (AU);",
"     </li>",
"     <li>",
"      Doxy 200 (LU);",
"     </li>",
"     <li>",
"      Doxy Komb (LU);",
"     </li>",
"     <li>",
"      Doxy M (EE);",
"     </li>",
"     <li>",
"      Doxy SMB (LU);",
"     </li>",
"     <li>",
"      Doxy-1 (IN);",
"     </li>",
"     <li>",
"      Doxy-100 (DE, NZ);",
"     </li>",
"     <li>",
"      Doxybene (CZ);",
"     </li>",
"     <li>",
"      Doxycap (SG);",
"     </li>",
"     <li>",
"      Doxycline (LU, TH);",
"     </li>",
"     <li>",
"      Doxycyclin AL (HU);",
"     </li>",
"     <li>",
"      Doxycycline (BE);",
"     </li>",
"     <li>",
"      Doxycycline-Ethypharm (LU);",
"     </li>",
"     <li>",
"      Doxycycline-Eurogenerics (LU);",
"     </li>",
"     <li>",
"      Doxyhexal (CZ, HU, LU);",
"     </li>",
"     <li>",
"      Doxylag (AE, BB, BF, BH, BJ, BM, BS, BZ, CI, CY, EG, ET, GH, GM, GN, GY, IQ, IR, JM, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SR, SY, TN, TT, TZ, UG, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Doxylcap (TH);",
"     </li>",
"     <li>",
"      Doxylets (LU);",
"     </li>",
"     <li>",
"      Doxylin (AU, IL, NO, NZ);",
"     </li>",
"     <li>",
"      Doxyline (SG);",
"     </li>",
"     <li>",
"      Doxylis (FR);",
"     </li>",
"     <li>",
"      Doxymycin (TW, ZA);",
"     </li>",
"     <li>",
"      Doxymycine (LU);",
"     </li>",
"     <li>",
"      Doxypharm (HU);",
"     </li>",
"     <li>",
"      Dumoxin (AE, BH, CY, EG, ID, IQ, IR, JO, KW, LB, LY, NO, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Duo Di (CL);",
"     </li>",
"     <li>",
"      Efracea (GB, IE);",
"     </li>",
"     <li>",
"      Etidoxina (CO);",
"     </li>",
"     <li>",
"      Genobiotic-Doxi (MX);",
"     </li>",
"     <li>",
"      Granudoxy (FR, LU);",
"     </li>",
"     <li>",
"      Hiramicin (HR);",
"     </li>",
"     <li>",
"      Interdoxin (ID);",
"     </li>",
"     <li>",
"      Madoxy (TH);",
"     </li>",
"     <li>",
"      Medomycin (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, MY, NE, NG, SC, SD, SG, SL, SN, TH, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Miraclin (IT);",
"     </li>",
"     <li>",
"      Monocin (KP);",
"     </li>",
"     <li>",
"      Monodox (CO);",
"     </li>",
"     <li>",
"      Periostat (GB, IE);",
"     </li>",
"     <li>",
"      Quedox (PH);",
"     </li>",
"     <li>",
"      Radox (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Remycin (TW);",
"     </li>",
"     <li>",
"      Servidoxine (EC);",
"     </li>",
"     <li>",
"      Siadocin (TH);",
"     </li>",
"     <li>",
"      Sigadoxin (PT);",
"     </li>",
"     <li>",
"      Supracyclin (AT, CH, PE);",
"     </li>",
"     <li>",
"      Supramycina (CR, DO, EC, GT, HN, NI, PA, PY, SV);",
"     </li>",
"     <li>",
"      Tenutan (BB, BM, BS, BZ, GY, JM, SR, TT);",
"     </li>",
"     <li>",
"      Tolexine (FR);",
"     </li>",
"     <li>",
"      Tolexine Ge (FR);",
"     </li>",
"     <li>",
"      Torymycin (TH);",
"     </li>",
"     <li>",
"      Unidox (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, PL, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Unidoxy (KP);",
"     </li>",
"     <li>",
"      Veemycin (TH);",
"     </li>",
"     <li>",
"      Vibradox (DK, PT);",
"     </li>",
"     <li>",
"      Vibramicina (AR, CO, MX, PE, PT, UY);",
"     </li>",
"     <li>",
"      Vibramicina C (VE);",
"     </li>",
"     <li>",
"      Vibramycin (AE, AT, AU, BB, BF, BG, BH, BJ, BM, BS, BZ, CH, CI, CY, DE, EG, ET, GB, GH, GM, GN, GR, GY, HK, HU, ID, IE, IQ, IR, JM, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, MY, NE, NG, NL, NO, OM, PH, PK, QA, RU, SA, SC, SD, SE, SL, SN, SR, SY, TH, TN, TT, TZ, UG, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Vibramycine (FR);",
"     </li>",
"     <li>",
"      Vibratab (BE);",
"     </li>",
"     <li>",
"      Vibraveineuse (FR);",
"     </li>",
"     <li>",
"      Vibravenos (DE);",
"     </li>",
"     <li>",
"      Viclorax (PE);",
"     </li>",
"     <li>",
"      Vivradoxil (MX);",
"     </li>",
"     <li>",
"      Weibamycin (TW);",
"     </li>",
"     <li>",
"      Yong Xi (CL);",
"     </li>",
"     <li>",
"      Zadorin (AE, BB, BF, BH, BJ, BM, BS, BZ, CI, CY, EG, ET, GH, GM, GN, GY, IQ, IR, JM, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SR, SY, TN, TT, TZ, UG, YE, ZM, ZW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F163291\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits protein synthesis by binding with the 30S and possibly the 50S ribosomal subunit(s) of susceptible bacteria; may also cause alterations in the cytoplasmic membrane",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Periostat&reg; capsules (proposed mechanism): Has been shown to inhibit collagenase activity",
"     <i>",
"      in vitro",
"     </i>",
"     . Also has been noted to reduce elevated collagenase activity in the gingival crevicular fluid of patients with periodontal disease. Systemic levels do not reach inhibitory concentrations against bacteria.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F163309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Almost complete",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Widely into body tissues and fluids including synovial, pleural, prostatic, seminal fluids, and bronchial secretions; saliva, aqueous humor, and CSF penetration is poor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Not hepatic; partially inactivated in GI tract by chelate formation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Reduced at high pH; may be clinically significant in patients with gastrectomy, gastric bypass surgery or who are otherwise deemed achlorhydric",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 12-15 hours (usually increases to 22-24 hours with multiple doses); End-stage renal disease: 18-25 hours; Oracea&reg;: 21 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 1.5-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (30%); urine (23%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Abramowicz M, &ldquo;Antimicrobial Prophylaxis in Surgery,&rdquo;",
"      <i>",
"       Medical Letter on Drugs and Therapeutics, Handbook of Antimicrobial Therapy",
"      </i>",
"      , 16th ed, New York, NY: Medical Letter, 2002.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ailani RK, Agastya G, Ailani RK, et al, &ldquo;Doxycycline is a Cost-Effective Therapy for Hospitalized Patients With Community-Acquired Pneumonia,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1999, 159(3):266-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/41/2714/abstract-text/9989538/pubmed\" id=\"9989538\" target=\"_blank\">",
"        9989538",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      B&ouml;cker R, M&uuml;hlberg W, Platt D, et al, &ldquo;Serum Level, Half-Life and Apparent Volume of Distribution of Doxycycline in Geriatric Patients,&rdquo;",
"      <i>",
"       Eur J Clin Pharmacol",
"      </i>",
"      , 1986, 30(1):105-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/41/2714/abstract-text/3709622/pubmed\" id=\"3709622\" target=\"_blank\">",
"        3709622",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bradley JS, Byington CL, Shah SS, et al.  &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;,",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2011, 53(7):e25-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/41/2714/abstract-text/21880587/pubmed\" id=\"21880587\" target=\"_blank\">",
"        21880587",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bryant SG, Fisher S, and Kluge RM, &ldquo;Increased Frequency of Doxycycline Side Effects,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1987, 7(4):125-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/41/2714/abstract-text/3684731/pubmed\" id=\"3684731\" target=\"_blank\">",
"        3684731",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Center for Disease Control and Prevention (CDC), &ldquo;Diagnosis and Management of Tickborne Rickettsial Diseases: Rocky Mountain Spotted Fever, Ehrlichioses, and Anaplasmosis - United States,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2006 55(RR-4):1-27.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/41/2714/abstract-text/16572105/pubmed\" id=\"16572105\" target=\"_blank\">",
"        16572105",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Guidelines for Treatment of Malaria in the United States,&rdquo; Treatment Table Update, September 23, 2011. Available at",
"      <a href=\"file://www.cdc.gov/malaria/pdf/treatmenttable.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/malaria/pdf/treatmenttable.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Q Fever,\" 2009. Available at:",
"      <a href=\"file://www.cdc.gov/ncidod/dvrd/qfever/#treatment\" target=\"_blank\">",
"       file://www.cdc.gov/ncidod/dvrd/qfever/#treatment",
"      </a>",
"      . Accessed November 29, 2010.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Sexually Transmitted Diseases Treatment Guidelines, 2010,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2010, 59(RR-12):1-110.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/41/2714/abstract-text/21160459/pubmed\" id=\"21160459\" target=\"_blank\">",
"        21160459",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Update to CDC's Sexually Transmitted Diseases Treatment Guidelines, 2010:  Oral Cephalosporins No Longer a Recommended Treatment for Gonococcal Infections&rdquo;,",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2012, 61(31):590-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/41/2714/abstract-text/22874837/pubmed\" id=\"22874837\" target=\"_blank\">",
"        22874837",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Use of Anthrax Vaccine in the United States. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009,\"",
"      <i>",
"       MMWR",
"      </i>",
"      , 2010, 59(6):1-30. Available at",
"      <a href=\"file://www.cdc.gov/mmwr/preview/mmwrhtml/rr5906a1.htm?s_cid=rr5906a1_e\" target=\"_blank\">",
"       file://www.cdc.gov/mmwr/preview/mmwrhtml/rr5906a1.htm?s_cid=rr5906a1_e",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/41/2714/abstract-text/20651644/pubmed\" id=\"20651644\" target=\"_blank\">",
"        20651644",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Update: Investigation of Bioterrorism-Related Anthrax and Interim Guidelines for Exposure Management and Antimicrobial Therapy, October 2001,&rdquo;",
"      <i>",
"       MMWR",
"      </i>",
"      , October 26, 2001, 50(42):909-19.  Available at",
"      <a href=\"file://www.cdc.gov/mmwr/preview/mmwrhtml/mm5042a1.htm\" target=\"_blank\">",
"       file://www.cdc.gov/mmwr/preview/mmwrhtml/mm5042a1.htm",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/41/2714/abstract-text/11699843/pubmed\" id=\"11699843\" target=\"_blank\">",
"        11699843",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chow AW, Benninger MS, Brook I, et al, &ldquo;IDSA Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2012, 54(8):e72-112.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/41/2714/abstract-text/22438350/pubmed\" id=\"22438350\" target=\"_blank\">",
"        22438350",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chung AM, Reed MD, and Blumer JL, \"Antibiotics and Breast-Feeding: A Critical Review of the Literature,\"",
"      <i>",
"       Paediatr Drugs",
"      </i>",
"      , 2002, 4(12):817-37.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/41/2714/abstract-text/12431134/pubmed\" id=\"12431134\" target=\"_blank\">",
"        12431134",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Daunt N, Brodribb TR, and Dickey JD, &ldquo;Oesophageal Ulceration Due to Doxycycline,&rdquo;",
"      <i>",
"       Br J Radiol",
"      </i>",
"      , 1985, 58(696):1209-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/41/2714/abstract-text/3842633/pubmed\" id=\"3842633\" target=\"_blank\">",
"        3842633",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Daya M and Nakamura Y, \"Pulmonary Disease From Biological Agents: Anthrax, Plague, Q Fever, and Tularemia,\"",
"      <i>",
"       Crit Care Clin",
"      </i>",
"      , 2005, 21(4):747-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/41/2714/abstract-text/16168313/pubmed\" id=\"16168313\" target=\"_blank\">",
"        16168313",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dennis DT, Inglesby TV, Henderson DA, et al, \"Tularemia as a Biological Weapon: Medical and Public Health Management,\"",
"      <i>",
"       JAMA",
"      </i>",
"      , 2001, 285(21):2763-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/41/2714/abstract-text/11386933/pubmed\" id=\"11386933\" target=\"_blank\">",
"        11386933",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Francke EL and Neu HC, &ldquo;Chloramphenicol and Tetracyclines,&rdquo;",
"      <i>",
"       Med Clin North Am",
"      </i>",
"      , 1987, 71(6):155-68.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/41/2714/abstract-text/3320617/pubmed\" id=\"3320617\" target=\"_blank\">",
"        3320617",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gould FK, Denning DW, Elliott TS, et al, &ldquo;Guidelines for the Diagnosis and Antibiotic Treatment of Endocarditis in Adults:  A Report of the Working Party of the British Society for Antimicrobial Chemotherapy,&rdquo;",
"      <i>",
"       J Antimicrob Chemother",
"      </i>",
"      , 2012, 67(2):269-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/41/2714/abstract-text/22086858/pubmed\" id=\"22086858\" target=\"_blank\">",
"        22086858",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Halperin JJ, Shapiro ED, Logigian E, et al, &ldquo;Practice Parameter: Treatment of Nervous System Lyme Disease (an Evidence-Based Review): Report of the Quality Standards Subcommittee of the American Academy of Neurology,\"",
"      <i>",
"       Neurology",
"      </i>",
"      , 2007, 69(1):91-102.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/41/2714/abstract-text/17522387/pubmed\" id=\"17522387\" target=\"_blank\">",
"        17522387",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hartzell JD, Wood-Morris RN, Martinez LJ, et al, \"Q Fever: Epidemiology, Diagnosis, and Treatment,\"",
"      <i>",
"       Mayo Clin Proc",
"      </i>",
"      , 2008, 83(5):574-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/41/2714/abstract-text/18452690/pubmed\" id=\"18452690\" target=\"_blank\">",
"        18452690",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Inglesby TV, Dennis DT, Henderson DA, et al, \"Plague as a Biological Weapon: Medical and Public Health Management. Working Group on Civilian Biodefense,\"",
"      <i>",
"       JAMA",
"      </i>",
"      , 2000, 283(17):2281-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/41/2714/abstract-text/10807389/pubmed\" id=\"10807389\" target=\"_blank\">",
"        10807389",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jolkovsky DL and Ciancio S, \"Chemotherapeutic Agents,\" Newman MG, Takei HH, Klokkevold PR, et al, eds,",
"      <i>",
"       Clinical Periodontology",
"      </i>",
"      , 10th ed, St Louis, MO: Saunders/Elsevier, 2006, 802-3.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Joshi N and Miller DQ, &ldquo;Doxycycline Revisited,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1997, 157(13):1421-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/41/2714/abstract-text/9224219/pubmed\" id=\"9224219\" target=\"_blank\">",
"        9224219",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kvale PA, Selecky, Prakash BS, et al, &ldquo;Palliative Care In Lung Cancer: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition),&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2007, 132(Suppl 3):268-403.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/41/2714/abstract-text/17873181/pubmed\" id=\"17873181\" target=\"_blank\">",
"        17873181",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lipsky BA, Berendt AR, Cornia PB, et al, \"2012 Infectious Diseases Society of America Clinical Practice Guideline for the Diagnosis and Treatment of Diabetic Foot Infections,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2012, 54(12):e132-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/41/2714/abstract-text/22619242/pubmed\" id=\"22619242\" target=\"_blank\">",
"        22619242",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Liu C, Bayer A, Cosgrove SE, et al, &ldquo;Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant",
"      <i>",
"       Staphylococcus Aureus",
"      </i>",
"      Infections in Adults and Children: Executive Summary,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2011, 52(3):285-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/41/2714/abstract-text/21217178/pubmed\" id=\"21217178\" target=\"_blank\">",
"        21217178",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ljungberg B and Nilsson-Ehle I, &ldquo;Pharmacokinetics of Antimicrobial Agents in the Elderly,&rdquo;",
"      <i>",
"       Rev Infect Dis",
"      </i>",
"      , 1987, 9(2):250-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/41/2714/abstract-text/3296097/pubmed\" id=\"3296097\" target=\"_blank\">",
"        3296097",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mandell LA, Wunderink RG, Anzueto A, et al, &ldquo;Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines On The Management Of Community-Acquired Pneumonia In Adults,&rdquo; 2007,",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 44(Suppl 2):27-72",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/41/2714/abstract-text/17278083/pubmed\" id=\"17278083\" target=\"_blank\">",
"        17278083",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mylonas I, \"Antibiotic Chemotherapy During Pregnancy and Lactation Period: Aspects for Consideration,\"",
"      <i>",
"       Arch Gynecol Obstet",
"      </i>",
"      , 2011, 283(1):7-18.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/41/2714/abstract-text/20814687/pubmed\" id=\"20814687\" target=\"_blank\">",
"        20814687",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Osmon DR, Berbari EF, Berendt AR, et al, &ldquo;Diagnosis and Management of Prosthetic Joint Infection: Clinical Practice Guideline by the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2013, 56(1):e1-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/41/2714/abstract-text/23223583/pubmed\" id=\"23223583\" target=\"_blank\">",
"        23223583",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Porcel JM, Salud A, Nabal M, et al, &ldquo;Rapid Pleurodesis With Doxycycline Through a Small-Bore Catheter for the Treatment of Metastatic Malignant Effusions,&rdquo;",
"      <i>",
"       Support Care Cancer",
"      </i>",
"      , 2006, 14(5):475-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/41/2714/abstract-text/16404570/pubmed\" id=\"16404570\" target=\"_blank\">",
"        16404570",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rams TE and Slots J, &ldquo;Antibiotics in Periodontal Therapy: An Update,&rdquo;",
"      <i>",
"       Compendium",
"      </i>",
"      , 1992, 13(12):1130, 1132, 1134.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/41/2714/abstract-text/1298559/pubmed\" id=\"1298559\" target=\"_blank\">",
"        1298559",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ross J, Judlin P, and Nilas L, &ldquo;European Guideline for the Management of Pelvic Inflammatory Disease, 2008. Available at file://www.iusti.org/regions/europe/PID_v5.pdf. Accessed December 1, 2010.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Saivin S and Hovin G, &ldquo;Clinical Pharmacokinetics of Doxycycline and Minocycline,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1985, 15:355-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/41/2714/abstract-text/3072140/pubmed\" id=\"3072140\" target=\"_blank\">",
"        3072140",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smilack JD, Wilson WR, and Cockerill FR 3d, &ldquo;Tetracyclines, Chloramphenicol, Erythromycin, Clindamycin, and Metronidazole,&rdquo;",
"      <i>",
"       Mayo Clin Proc",
"      </i>",
"      , 1991, 66(12):1270-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/41/2714/abstract-text/1749296/pubmed\" id=\"1749296\" target=\"_blank\">",
"        1749296",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wilson WR and Cockerill FR 3d, &ldquo;Tetracyclines, Chloramphenicol, Erythromycin, and Clindamycin,&rdquo;",
"      <i>",
"       Mayo Clin Proc",
"      </i>",
"      , 1987, 62(10):906-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/41/2714/abstract-text/3657308/pubmed\" id=\"3657308\" target=\"_blank\">",
"        3657308",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wormser GP, Dattwyler RJ, Shapiro ED, et al, &ldquo;The Clinical Assessment, Treatment, and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis: Clinical Practice Guidelines by the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2006, 43(9):1089-134.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/41/2714/abstract-text/17029130/pubmed\" id=\"17029130\" target=\"_blank\">",
"        17029130",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wyler DJ, &ldquo;Malaria: Overview and Update,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 1993, 16(4):449-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/41/2714/abstract-text/8513046/pubmed\" id=\"8513046\" target=\"_blank\">",
"        8513046",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9393 Version 52.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-655E7897C0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_41_2714=[""].join("\n");
var outline_f2_41_2714=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163331\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163332\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163364\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163336\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163349\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163337\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163338\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15804929\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163303\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163288\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163306\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163370\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163304\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163361\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163372\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163362\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163310\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163292\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163358\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163297\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163326\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163300\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163313\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163343\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3415107\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163314\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163312\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6473884\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163315\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163291\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163309\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9393\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9393|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?35/10/36005?source=related_link\">",
"      Doxycycline: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/54/12136?source=related_link\">",
"      Doxycycline: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_41_2715="Potassium distribution";
var content_f2_41_2715=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F79106&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F79106&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Potassium distribution between cells and ECF",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Physiologic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sodium-potassium-ATPase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Catecholamines",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Insulin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Plasma potassium concentration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aldosterone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Exercise",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Pathologic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Extracellular pH",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperosmolality",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rate of cell breakdown and production",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_41_2715=[""].join("\n");
var outline_f2_41_2715=null;
var title_f2_41_2716="Etiology of septic arthritis by age";
var content_f2_41_2716=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F53150&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F53150&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Most common causes of bacterial arthritis in children according to age",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Age group",
"       </td>",
"       <td class=\"subtitle1\">",
"        Most common bacteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        &lt;3 months",
"       </td>",
"       <td>",
"        <em>",
"         Staphylococcus aureus",
"        </em>",
"        (MSSA and MRSA)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Group B streptococcus (",
"        <em>",
"         Streptococcus agalactiae",
"        </em>",
"        )",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gram negative bacilli",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Neisseria gonorrhea",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        3 months to&nbsp;3 years",
"       </td>",
"       <td>",
"        <em>",
"         S. aureus",
"        </em>",
"        (MSSA and MRSA)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Kingella kingae",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Group A streptococcus (",
"        <em>",
"         S. pyogenes",
"        </em>",
"        )",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Streptococcus pneumoniae",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Haemophilus influenzae",
"        </em>",
"        type b (Hib) (in incompletely immunized children in regions with low Hib immunization rates)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        &gt;3 years",
"       </td>",
"       <td>",
"        <em>",
"         S. aureus",
"        </em>",
"        (MSSA and MRSA)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Group A streptococcus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         S. pneumoniae",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         N. gonorrhea",
"        </em>",
"        (in sexually active adolescents)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     MSSA: methicillin-susceptible",
"     <em>",
"      S. aureus",
"     </em>",
"     ; MRSA: methicillin-resistant",
"     <em>",
"      S. aureus",
"     </em>",
"     .",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_41_2716=[""].join("\n");
var outline_f2_41_2716=null;
var title_f2_41_2717="Approaches for ERCP in patients with Roux-en-Y anatomy";
var content_f2_41_2717=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F54031&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F54031&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Approaches for ERCP in patients with Roux-en-Y anatomy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Technique",
"       </td>",
"       <td class=\"subtitle1\">",
"        Advantages",
"       </td>",
"       <td class=\"subtitle1\">",
"        Disadvantages",
"       </td>",
"       <td class=\"subtitle1\">",
"        Best application",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Duodenoscope advanced transorally through anatomic route",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Ideal instrument for cannulation and therapy of native papilla",
"         </li>",
"         <li>",
"          Minimally invasive",
"         </li>",
"        </ul>",
"       </td>",
"       <td class=\"indent1\">",
"        Frequently unsuccessful due to inability to reach target",
"       </td>",
"       <td>",
"        Patients with short Roux limb and native papilla",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Colonoscope/enteroscope advanced transorally through anatomic route",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Greater depth of insertion compared to duodenoscope",
"         </li>",
"         <li>",
"          Minimally invasive",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Frequently unsuccessful in patients with long Roux limb",
"         </li>",
"         <li>",
"          Forward view",
"         </li>",
"         <li>",
"          Lack of elevator",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        Patients with short Roux limb and bilioenteric/ pancreatoenteric anastomosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Deep enteroscopy assisted ERCP",
"       </td>",
"       <td class=\"indent1\">",
"        Greater reliability in reaching target, even in patients with long Roux limb",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Forward view",
"         </li>",
"         <li>",
"          Lack of elevator",
"         </li>",
"         <li>",
"          Limited availability of accessories and instruments",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        Patients with long Roux limb and bilioenteric/ pancreatoenteric anastomosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Transgastrostomy tract ERCP",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Allows use of side viewing duodenoscope and all standard accessories",
"         </li>",
"         <li>",
"          Provides reliable access for repeat procedures",
"         </li>",
"        </ul>",
"       </td>",
"       <td class=\"indent1\">",
"        More invasive than purely endoscopic techniques",
"       </td>",
"       <td>",
"        RYGB patients with native papilla, or when repeated procedures are anticipated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Laparoscopy-assisted ERCP",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Allows use of side viewing duodenoscope and all standard accessories",
"         </li>",
"         <li>",
"          Ability to diagnosis and treat internal hernias",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          More invasive than purely endoscopic techniques",
"         </li>",
"         <li>",
"          Requires significant coordination between surgery and endoscopy teams",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        RYGB patients with native papilla, particularly when internal hernia is suspected",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Percutaneous approaches via interventional radiology",
"       </td>",
"       <td class=\"indent1\">",
"        Less invasive than surgical approaches",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Morbidity (pain, external drains)",
"         </li>",
"         <li>",
"          No access to pancreas",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        Patients with biliary tract pathology who are poor surgical candidates",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ERCP: endoscopic retrograde cholangiopancreatography; RYGB: Roux-en-Y gastric bypass.",
"    </div>",
"    <div class=\"reference\">",
"     Original figure modified for this publication. Lopes TL, Wilcox CM. Endoscopic retrograde cholangiopancreatography in patients with Roux-en-Y anatomy. Gastroenterol Clin North Am 2010; 39:99. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_41_2717=[""].join("\n");
var outline_f2_41_2717=null;
var title_f2_41_2718="Macrocephaly syndromes";
var content_f2_41_2718=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F75193&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F75193&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical features of selected syndromes associated with macrocephaly",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Syndrome",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical features (in addition to macrocephaly)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Predominantly cutaneous syndromes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Tuberous sclerosis*",
"        </p>",
"        <p>",
"         OMIM 191100",
"        </p>",
"       </td>",
"       <td>",
"        Facial angiofibromas, shagreen patch, hypopigmented macules, periungual fibromas, gingival fibromas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Neurofibromatosis type 1*",
"        </p>",
"        <p>",
"         OMIM 162200",
"        </p>",
"       </td>",
"       <td>",
"        Caf&eacute;-au-lait spots, axillary freckling, dermal neurofibroma, short stature, Lisch nodules",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Linear epidermal nevus syndrome",
"        </p>",
"        <p>",
"         OMIM 163200",
"        </p>",
"       </td>",
"       <td>",
"        Asymmetric overgrowth, coloboma (eyelids, iris, choroid), linear nevus sebaceous; associated with basal cell carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Klippel-Trenaunay-Weber",
"        </p>",
"        <p>",
"         OMIM 149000",
"        </p>",
"       </td>",
"       <td>",
"        Large cutaneous hemangioma with hypertrophy of related bones and soft tissues; syndactyly; polydactyly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Proteus",
"        </p>",
"        <p>",
"         OMIM 176920",
"        </p>",
"       </td>",
"       <td>",
"        Asymmetric, disproportionate overgrowth of body parts, epidermal nevi, hypertrophy of skin of soles, hemangioma (thorax, upper abdomen)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Macrocephaly cutis marmorata telangiectatica congenita",
"        </p>",
"        <p>",
"         OMIM 602501",
"        </p>",
"       </td>",
"       <td>",
"        Vascular mottling of the skin; congenital telangiectasias, syndactyly of second and third toes; polydactyly; asymmetry of the head, face, or body; nevus flameus of the lip and/or philtrum; overgrowth with prenatal onset",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Nevoid basal cell carcinoma syndrome* (Gorlin syndrome)",
"        </p>",
"        <p>",
"         OMIM 109400",
"        </p>",
"       </td>",
"       <td>",
"        Frontoparietal bossing, broad nasal bridge, coarse facial features, highly arched eyebrows, pouting lower lip; odontogenic keratocysts of the mandible and maxilla; increased risk of basal cell carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"2\">",
"        PTEN hamartoma tumor syndromes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        <p>",
"         Bannayan-Riley Ruvalcaba*",
"        </p>",
"        <p>",
"         OMIM 153480",
"        </p>",
"       </td>",
"       <td class=\"sublist_other\">",
"        Lipomas, hemangiomas, pigmented macules; congenital macrosomia (birth weight usually &gt;4 kg) followed by postnatal growth deceleration and normal adult height; down-slanting palpebral fissures; increased risk of certain malignancies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        <p>",
"         Cowden* and Lhermitte-Duclos*",
"        </p>",
"        <p>",
"         OMIM 158350",
"        </p>",
"       </td>",
"       <td class=\"sublist_other\">",
"        Birdlike facies; hypoplastic mandible and maxilla; cataract; microstomia; high-arched palate; pectus excavatum; genitourinary anomalies; skin tags; lipomas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Predominantly overgrowth syndromes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Sotos",
"        </p>",
"        <p>",
"         OMIM 117550",
"        </p>",
"       </td>",
"       <td>",
"        High-prominent forehead, down-slanting palpebral fissures, long pointed chin, high-arched palate; tall stature and advanced bone age; normal adult height",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Weaver*",
"        </p>",
"        <p>",
"         OMIM 277590",
"        </p>",
"       </td>",
"       <td>",
"        Accelerated growth with prenatal onset, advanced bone age, broad forehead, flat occiput, long philtrum, camptodactyly, broad thumbs, loose skin, deep-set nails; deep palmar and plantar creases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Simpson-Golabi",
"        </p>",
"        <p>",
"         OMIM 312870",
"        </p>",
"       </td>",
"       <td>",
"        Accelerated growth with prenatal onset (weight more affected than height), coarse facial features, down-slanting palpebral fissures, thickened lips, wide mouth, large tongue, high-arched palate, prominent jaw, short neck, supernumary nipples, hepatomegaly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Beckwith-Wiedemann*",
"        </p>",
"        <p>",
"         OMIM 130650",
"        </p>",
"       </td>",
"       <td>",
"        Omphalocele (or other umbilical abnormalities), hemihypertrophy, coarse facial features, macroglossia, neonatal macrosomia, neonatal hypoglycemia, increased risk of certain tumors (eg, Wilms tumor, hepatoblastoma)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Neuro-cardio-facio-cutaneous syndromes",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Noonan*",
"        </p>",
"        <p>",
"         OMIM 163950",
"        </p>",
"       </td>",
"       <td>",
"        Short stature (postnatal onset), congenital heart defects (atrial septal defect, ventricular septal defect, pulmonic stenosis), webbed neck, abnormal chest, hypertelorism, down-slanting palpebral fissures, epicanthal folds, deafness (sensorineural); deeply grooved philtrum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         LEOPARD*",
"        </p>",
"        <p>",
"         OMIM 151100",
"        </p>",
"       </td>",
"       <td>",
"        Lentigenes, ECG conduction abnormalities, ocular hypertelorism, pulmonic stenosis, abnormal genitalia, retardation of growth, deafness (sensorineural)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Costello*",
"        </p>",
"        <p>",
"         OMIM 218040",
"        </p>",
"       </td>",
"       <td>",
"        Failure to thrive, short stature, developmental delay, coarse facial features, deep palmar and plantar creases, papillomata, cardiac abnormalities, risk for tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Cardiofaciocutaneous",
"        </p>",
"        <p>",
"         OMIM 115150",
"        </p>",
"       </td>",
"       <td>",
"        Cardiac abnormalities (atrial septal defect, pulmonic stenosis, hypertrophic cardiomyopathy), cutaneous abnormalities (ichthyosis, hyperkeratosis, hemangioma), postnatal short stature, prominent forehead, bitemporal narrowing, coarse facial features, prominent philtrum, down-slanting palpebral fissures, short upturned nose",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PTEN: phosphate and tensin homolog deleted on chromosome gene.",
"     <br>",
"      * Autosomal dominant inheritance.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       Associated with mutations in the RAS/MAP kinase signaling pathway genes.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      <ol>",
"       <li>",
"        Williams CA, Dagli A, Battaglia A. Genetic disorders associated with macrocephaly. Am J Med Genet A 2008; 146A:2023.",
"       </li>",
"       <li>",
"        Olney AH. Macrocephaly syndromes. Semin Pediatr Neurol 2007; 14:128.",
"       </li>",
"       <li>",
"        Firth HV, Hurst JA, Hall JG. Macrocephaly. In: Oxford Desk Reference: Clinical Genetics, 1st ed. Oxford University Press, Oxford 2005. p.162.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_41_2718=[""].join("\n");
var outline_f2_41_2718=null;
var title_f2_41_2719="Sequential response H load";
var content_f2_41_2719=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F80104&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F80104&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sequential response to a H+ load, culminating in the restoration of acid-base balance by the renal excretion of the excess H+",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 181px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAC1AbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAryj/hdGnf2h9h+wr9u/4Sv/AIRj7P8Aa18zGcfatuM7M8Y9e9er15x/wqTR/N837Xd+Z/wlH/CU78Jnz/8Anlnb/q/br70AbXh/4h+G9f8AFOp6BpmowS31j5XIlQpcb0L/ALkhjv2gHdgcVH4m8bJ4e8deHdBvbNFtNZhupRftcBFg+zxmSTepHTbt+bd3PpzqaT4T0bSfEOra3YWaxajqnlfaZMkg+UhRNo6L8pOcYz3rO8aeAtM8YaxpF9q0lxt06C9tvIjYKsyXUPlSBj1GF6EEc0AWNK8d+HNW0m71HTNQN1bWhjEwit5WkQSBSh8vbvIYMCCBgjJzwa57x38X/Dfhnwimt2dzFq7z263dra27ndLEZUjLlgp2AF8fNjkFevFU7H4L6RaaDf6euq6m8141j5l0WQEx2aKkMTIF2MgVeQyndnJyQMZdz+z7oEnh2z0mLVtVhSGxfTZZlMZeeA3f2oKwK4BWTkFQCRwc0Aez0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRUV1cwWkDT3c0UEK43SSsFUZOBknjrQBLRWV/wAJHof/AEGdN/8AApP8aP8AhI9D/wCgzpv/AIFJ/jQBq0Vlf8JHof8A0GdN/wDApP8AGj/hI9D/AOgzpv8A4FJ/jQBq0Vlf8JHof/QZ03/wKT/Gj/hI9D/6DOm/+BSf40AatFZX/CR6H/0GdN/8Ck/xo/4SPQ/+gzpv/gUn+NAGrRWV/wAJHof/AEGdN/8AApP8aP8AhI9D/wCgzpv/AIFJ/jQBq0Vlf8JHof8A0GdN/wDApP8AGj/hI9D/AOgzpv8A4FJ/jQBq0Vlf8JHof/QZ03/wKT/Gj/hI9D/6DOm/+BSf40AatFZX/CR6H/0GdN/8Ck/xo/4SPQ/+gzpv/gUn+NAGrRWV/wAJHof/AEGdN/8AApP8aP8AhI9D/wCgzpv/AIFJ/jQBq0Vlf8JHof8A0GdN/wDApP8AGj/hI9D/AOgzpv8A4FJ/jQBq1zfgC7uL3QrqW7meaRdV1OIM5yQiX06Iv0CqoHsBV/8A4SPQ/wDoM6b/AOBSf41y/wAOdf0eLw/drLq2nox1jVWAa5QHB1C4IPXoQQR9aAO9orK/4SPQ/wDoM6b/AOBSf40f8JHof/QZ03/wKT/GgDVorK/4SPQ/+gzpv/gUn+NH/CR6H/0GdN/8Ck/xoA1aKyv+Ej0P/oM6b/4FJ/jR/wAJHof/AEGdN/8AApP8aANWisr/AISPQ/8AoM6b/wCBSf40f8JHof8A0GdN/wDApP8AGgDVorK/4SPQ/wDoM6b/AOBSf40f8JHof/QZ03/wKT/GgDVorK/4SPQ/+gzpv/gUn+NH/CR6H/0GdN/8Ck/xoA1aKyv+Ej0P/oM6b/4FJ/jR/wAJHof/AEGdN/8AApP8aANWisr/AISPQ/8AoM6b/wCBSf40f8JHof8A0GdN/wDApP8AGgDVorK/4SPQ/wDoM6b/AOBSf40f8JHof/QZ03/wKT/GgDVorK/4SPQ/+gzpv/gUn+NWLLVtOv5TFY39pcyhdxSGZXIHrgHpyKALtFFFABRRRQAUUUUAFFFFABRRRQAVyXxQjSbwvbRTIskT6xpSsjDIYHULcEEdxXW1zfj+0uL3QrWK0heaRdV0yUqgyQiX0Du30CqxPsDQBf8A+Ec0P/oDab/4Cp/hR/wjmh/9AbTf/AVP8K1aKAMr/hHND/6A2m/+Aqf4Uf8ACOaH/wBAbTf/AAFT/CtWigDK/wCEc0P/AKA2m/8AgKn+FH/COaH/ANAbTf8AwFT/AArVooAyv+Ec0P8A6A2m/wDgKn+FH/COaH/0BtN/8BU/wrVooAyv+Ec0P/oDab/4Cp/hR/wjmh/9AbTf/AVP8K1aKAMr/hHND/6A2m/+Aqf4Uf8ACOaH/wBAbTf/AAFT/CtWigDK/wCEc0P/AKA2m/8AgKn+FH/COaH/ANAbTf8AwFT/AArVooA4L4WaBo83wx8ISzaTp8kj6PZsztbISxMKZJOOTXUf8I5of/QG03/wFT/CqHw1tLiw+HPhWzvYXgurfSrSKWKQYaN1hUMpHYggiukoAyv+Ec0P/oDab/4Cp/hR/wAI5of/AEBtN/8AAVP8K1aKAMr/AIRzQ/8AoDab/wCAqf4Uf8I5of8A0BtN/wDAVP8ACtWigDK/4RzQ/wDoDab/AOAqf4Uf8I5of/QG03/wFT/CtWigDK/4RzQ/+gNpv/gKn+FH/COaH/0BtN/8BU/wrVooAyv+Ec0P/oDab/4Cp/hR/wAI5of/AEBtN/8AAVP8K1aKAMr/AIRzQ/8AoDab/wCAqf4Vy+n6Bo5+J2vxHSdPMa6PprKhtkwCZr4EgY6nA/IV3tc3YWlwnxG1y8eFxay6Vp8UcpHys6TXhZQfUB0J/wB4etAF/wD4RzQ/+gNpv/gKn+FH/COaH/0BtN/8BU/wrVooAyv+Ec0P/oDab/4Cp/hR/wAI5of/AEBtN/8AAVP8K1aKAMr/AIRzQ/8AoDab/wCAqf4Uf8I5of8A0BtN/wDAVP8ACtWigDK/4RzQ/wDoDab/AOAqf4Uf8I5of/QG03/wFT/CtWigDK/4RzQ/+gNpv/gKn+FH/COaH/0BtN/8BU/wrVooAyv+Ec0P/oDab/4Cp/hR/wAI5of/AEBtN/8AAVP8K1aKAMr/AIRzQ/8AoDab/wCAqf4Vz76bY6f8U9B+wWdta79G1Lf5MSpuxPY4zgc9T+ddrXN39pcP8RtDvEhc2sWlahFJKB8qu81mVUn1IRyP90+lAHSUUUUAFFFFABRRRQAUUVj+LvEem+EvD13reuTNBp1rs82RULkbnVBwOT8zCgDYorL8Pa1Drtk9zbWuo2yJIYyl/ZS2rkgA5CyKCRz1xjII7Go9T8R6bpniHRdEvJmTUdY877HGEJD+Sgd8kDAwCOvWgDYooooAKKK4K0+LHha6+xbJdQT7Xqp0VPNsJk2Xg2fuZMr8jfOOGx0b+6cAHe0Vm+JNatPDmhXmr6l5/wBitE8yYwwtKypnltqgnA6k9gCTwDU2jalbaxpFjqdg5ks72CO5hcqVLI6hlODyOCKALlFFFABRRRQAUUVT1nUrbR9IvtTv3MdnZQSXMzhSxVEUsxwOTwDQBcorlfCHj3QvFl21rpU1ylz9ljvUiu7aS3ea3ckLNGrgF48jG5cjkc8iuqoAKKKpaZqMeo/a/Kgu4fs1w9s32m3eHey4yybgN6HPDjKnnBoAu0UVj+HPEem+Iv7U/sqZpf7NvpdNudyFds8eN6jI5A3DkcUAbFFFFABRRRQAUUUUAFFFFABRWPpniPTdT8Q61olnMz6jo/k/bIyhATzkLpgkYOQD06Uan4j03TPEOi6JeTMmo6x532OMISH8lA75IGBgEdetAGxRRRQAUUVwVp8WPC119i2S6gn2vVToqebYTJsvBs/cyZX5G+ccNjo3904AO9orN8Sa1aeHNCvNX1Lz/sVonmTGGFpWVM8ttUE4HUnsASeAam0bUrbWNIsdTsHMlnewR3MLlSpZHUMpweRwRQBcooooAKKKKACiiigAorH8OeI9N8Rf2p/ZUzS/2bfS6bc7kK7Z48b1GRyBuHI4rYoAKKKKACiiigAorH8OeI9N8Rf2p/ZUzS/2bfS6bc7kK7Z48b1GRyBuHI4rYoAKKKKACuK+M3hS+8b/AA21jw9pUttDe3nk+W9yzLGNkyOclQT0U9jzXa1wHx78Q6p4V+E+u6zoN19k1K28jypvLWTbunjRvlYEH5WI5HegDE8WeAvEPibQNF0+E2Ph++sbqWSPWY9Xu9QvbONk58mV1jdjIWKMHfaEAwGO3ZFD8K5Fv/hrqi6R4btLvw15kN5ZW+8wyRsDtkjlZC5ZHzKquM73b95nLtUu/jn9lc28vh3N7BNrVrdot9mNJdOgEx8tvLy6yAqMlUKnPBxyWHjjxX4p+I/h+w0xbbTtLuPDMXiIW6XK7p2kK4ilke3fC7/kIQKdrF92cRgAl8BfCOfwj8Jb7SbGDw+njW8tbiCbUpbc3MUnmMcI29QfL2BAV2lQw3FH5Dc1H8FvFX/CPW1leXOiahb22p6jdR6Nd3Mv2Lyrm32R8xxIFaKQu4WONB+8YqYyaPCnxh8Q2vg3QdY1WwufEGteKJr57HTrXCwwxWxcsqCKBpQxO1AreYMKHaRBuFegeG/iLrHiTx3qGhaX4V8iy06GzuLy71G++zzQrcRJIIzAI2PmgM427sZjILLkUAYi/CbVZPipY+JL/WZbm0tksmikhunint3giZHiAkSZ3hlLEsvnpnzH3+YQGMX/AAqrXP8An603/koH/CV/6x/+PX+59z/W+33f9qspfjbqmlPf29zon269TU9ZgdJtTVY4FsII5nWJktVLKQzBd67sgbmOfl2pPjlBP4i0yx0vQZZrG7utJtJLi5uhDJG+oRtLGRGquGCxr82XX5jgZHzUAc/4V+CniPRYNVs5b3SJbY+Fr/w7ZzLLIHlea5kmSWRPLxGMSYIDPjHBOeNGX4WeL/7d8A3UOoaJHB4dh0yGSWEGK42QKy3MYk8oySq4Y4G+NMEhoyTvr3SigDzX4GfDK1+HnhO2hvLPTW8SN5ovNQtgXaUNJlVDsoYKFWP5QAMqTjOSfSqKKACiiigArF8b6VPr3gvX9Is3iS51DT7i0iaUkIHkjZQWIBOMkZwDW1XP/ELULrSPAPiXUtPl8m9s9MubiCTaG2SJEzKcEEHBA4IIoA8gsfgp4gs/Buu6Ius2017qOjW1lBqs9xM9xaNGVMlkvGPsbkNgrtID4ZJMDFrU/hBqh8D2Gk6cttJew3t1qCR3+prLZ2ksilVVIPsXkyRfMz7PKjKMW2MNxNHhL423T6boVhrGk/aNalvdG065nS5Ajdb+281LgYjGG+Vt0QUAEjDkVFD8TfEnjS7+GUehxRaDY+KHvmuHiuEluEFsXVlUyQMgGAHHyEsflzGAWYAz9O+HGuXfxw1O9gtrbS7LS73R7ldTitntllihsmjlt7VACPKckI6+ZhAqgh+lW9O+BEn/AAlmnTarBok/hu18Qapqv9noXC+RPHCLeMJsC/K0I3JnbgAfMCRRpnxV8Q6f/wAJFrHiGH7Vt8Tf8Ivp+k2UgNukoxlmYW5nbAUkMu8uXIESYFdLpnxT1/WPEui6DpngiWDUb3STqtzHq18bM2QWZ4mVl8lmYbkXaQMkSKSqjOACLxj8OfEOo/Efw1q+hT6JY6Lo01l5KQxC2uIreIyCaAMsTM6sr4CiSOMDKlCfnrJk+DF9Z2GuWOlLon2K58TQa5HbsGhjvbVTk6fcKsbBYkJJT/WKT/AlW9W+K2qaL4717Rm0r7bOus6ZpFrDLqKpbp9qildJAy23mLwil1YyYLHacD5s/Uv2iYI/DdlqumeG5bhn0n+1rqG4vBD5SfbBabI2VH8w+buOSE+UA9TtABL4N+B8lp4h8NXXjSTTfENlpPh/+zhHcb5MXP2iRxhHG1okjlMa7j/CpCrgYoaJ4K1nS/2gLB4baW70mDVtX1ua+EE0SRC8tolEZZ0EbkOAB5buTySqbSK7/wCNPiLW/Dtr4Qbw5LElzqHiOzsJY5doSaKQPmNmKOUBKrllUsO3pXFXP7RMC6CNUtfDcskf9hJrBSS9CEOb8WbxcIeA2WD9wBlVzwAe9UUUUAFFFFABRRRQB4h4v+EOq+IPH+qavJJpEuk3uu6PqL21wzsXt7WCSOZGXYVJbeMDJBGckdKPDfwh1Wwj+GN5q0mkalq3hd54bzzWdhNbuzmEpKyFiYMqUQqADnDJjJ1fE/xostD8Valo8VhFqMdta30kdxa3D4+0WtsJ5IJC0QRTjIPlvIVO3cq5wM/Tfjn9ss0ibw75etT3ulWdtbi+3W7f2hD50LPN5YZdqh9wEbYIXBIJIAJfAXwjn8I/CW+0mxg8Pp41vLW4gm1KW3NzFJ5jHCNvUHy9gQFdpUMNxR+Q3NR/BbxV/wAI9bWV5c6JqFvbanqN1Ho13cy/YvKubfZHzHEgVopC7hY40H7xipjJrq/A/jHXdT/ZoufFd9febr6aZqNwt15Ma4kiaYRnYFC8bF4xg45zWT4X+Nt03h7T7PU9J+1eJmm0ewVhchLe5kvrcSxyu4jzHwshZVjYA7QCwOQAaC/CbVZPipY+JL/WZbm0tksmikhunint3giZHiAkSZ3hlLEsvnpnzH3+YQGMX/Cqtc/5+tN/5KB/wlf+sf8A49f7n3P9b7fd/wBqs+T9omAWFhqMXhuVtOfSY9WvGa9Cywob37G6RpsIkIf5gSybl67TxXYeGfihJ4g+IN/4ftPDWpHTbW9utOfVVV3jjngVS3m/J5aKxLhcSMxIXcq7xQBwnhX4KeI9Fg1WzlvdIltj4Wv/AA7ZzLLIHlea5kmSWRPLxGMSYIDPjHBOeNGX4WeL/wC3fAN1DqGiRweHYdMhklhBiuNkCstzGJPKMkquGOBvjTBIaMk7690ooA81+Bnwytfh54Ttobyz01vEjeaLzULYF2lDSZVQ7KGChVj+UADKk4zkn0qiigAooooAKKKKAPnXXfgXrmq6jqE00+iSwT6nr9/Gkzu237bbolsSPLIDJIgY/wB3AKkmug0X4XeJLbxrpGt6tf6bqksMOmiW+ubi5a5tGt7eSOeOAqV3rM77iXYKdzbonPWXSfjLqM/wr1D4gan4Uis9EhRhbRx6n509zJ5qxL8vlKEj3lgWLFhtJCEEZi1n416lplnp5n8F3MF7cf2mzxX1xLaqY7KETGSIvBvdZEPylkQhgQR3oAqaB8D5NK+CWpeG7Z9NsfGN/DJHcavb7281TMGERkIDiJkREZQMcsdrHO41z4Ra7N8MovDWk3Omjzr25u7m21B47iOAyRuqfZZBahYVVm3lUgQ5dwrp1boLz4zaXHr3ha0tLT7Vaa39hVykjfaLJ7tWaASoEMQyApI84PglgjAZOh8Ftc1bWbXxfDrmoy6jJpXiO80y3mlijjfyYggUN5aqpPJJOO/0oA5+w+Guv/8ACYeGdZ1H+yLqextbKDULy/nOoPOYITuaGOWAPBIZWyHSZQcB2RmJB5/S/gZr9r4V8XWL+I5U1jVLVrVb5Lo+XfA3LTb7iMRK4kYExlmkmO2WQcqApq/Dr4oeMNXk+F66il9cLqqau144itFGqGBXMSxYYFChUL8wjBPcjJr0r4TeOtX8Y3fiaLVdElso9N1a6sYplMQRVjKARSASuxmG4klR5fHDUATfBvwbfeDNK8QW+oRabb/2jrNxqUFtpzs8NvFIqBYgSifd2kcKBjH0Hf0UUAFFFFABWF44u/D9j4Xvbnxito2gps+0i7g86Ll1C7kwc/OVxx1wa3a4f41+F7/xp8MtZ0DRzAt9d+T5ZncqnyTRuckA9lPagDem8J+HJ9Gg0ibQNIk0m3cyQ2T2UZgjc7vmWMrtB+ZuQP4j6mluLPQfD9vLrMljYWKadYGFrqO3VWgtIxv8sFRkRrjOwcccCvn7xv4D8S6B4UTUTP5jxXOti30i0M0ot4b23ZIoo2RDnyyu4ZVVy+Mr1Pr9v4f1O7+BUXhyVBFrE3hsaeyzPwk5tfLIZhnox5IzQBXvdU+GY0O30u+h0D+xoNOXXoLSaxX7PHbOxAnVCm0EtIQABuJc8c1etvGHgm2Oq6xBcWltdPcQWl8/2RorqWUqBCjoUErkq3y8HjOOAceSax8CtdvdNe1hv4QX8IWuks1xcyTbbyK5imKLkfLCfKwMdM5213fjLwx4r8Vwafd3Fno1nc6Tr1jqtraRzszXCQgh1km2gAkuduE4C4Oc5ABfudX+G39mvq8thpktq014Z510hpDHKQEuvOAjJjZlwH34LL1yKevgvwl41vfC3iqzBax01YpNNigtY7ePERfyju8oTbFLZCBxGdqnaR15RfhrrreGdWsNRtLC+ttd8Q3esahpyX81uVjkA8tFnQfNgopIKYOR025PZ+GPBmonwrosHizXNTm1m1tVgnlsL6W3jcgkj5UIDEAhS5GW25NAHd0UUUAFFFFABRRRQAVV1YWjaVejUoVnsTC4uImi80PHtO5SgB3AjI24OemDVqigDkvCth4K17wYB4c0rRp/DGoO0hgisUS3ndW2lmjKgEhoxyR/CPQVsWfhzQ7L+z/sWjabb/2d5n2LyrVE+y+Z/rPLwPk3ZOduM96+fbX4K+Nbfwz4a06LVLSGexsntg6XDgafOdRFx9qi4+djF8hHynjrit34h/Crxhqnj2eTwr4hn03wjq7pJq1rHdtEQzfJOY0CkEsig89WJ7UAeyy+HNDlsL6xl0bTXsr6Y3N3btaoY7iUkEySLjDMSqnccnIHpR/ZmjaR/wATKLTbS3ks7L7Ms0FqPMjtk+YRJtG7YMZCDjPQV5rc/DPVn+L1vrsWoyw6DbfZGs47acRtaJDG6Nb7Sh3RPnkKy/fOQdoqp4N+EL6R8G9U0a/gtJvF1/ZXUUl2ZmkXzGJMOHIyqqVhPA4ZSetAHqEeh+H9Tkj1Y6Np8txcPBei4mslErSRriKRty7g6KxCk/MuSOK5/wAX/Czwx4o0zS9LurKKz0nT3Z0s7K2giRgzq7KG8svGGK8+UyFtxyTxjzXRfhN4v0/xJpeqi8tFmtbrQy0i3L7/ALPb2ZhvEHy9Hbbx/EBzij4I+Gtd0b4t6h/aQnu4bPSbi1u9UZZFW8unv2kVzvUZcxjB27gAo+bkUAe6a3omla9apa65pljqVsjiRYryBJkVwCAwVgRnBIz7mua8cfDXw/4ysNK0/VIfK03TsLHa20MKKYwUPlhzGZIlxGq4iZCRkE9MdrRQAUUUUAFFFFABRRRQByWn2HgrxRqerala6Vo2oahb3EumX109ihlEioI5Imdlyw2NtPJBU46VLrekeDtE8P6pc6vpWiWujmGIXpltIxHJHCAIlcbfmCYUIuDjgKOleS2fwf8AEreLPEtz9utNNstUuNbka4glZ5LiO8jVIY3TC4EbAydTzwPWs+f4N+K9R8D+LtN1Iaab+/tdGh0/ddNIsb2cYilkLFBtLKGIwD94g+tAHsFnrXg23sdP8O2kFtDa6lFIsGlR6c6K0TSbHLwbPkjLsQS4CnJ681sQ+E/DkGjT6RDoGkR6TcOJJrJLKMQSONvzNGF2k/KvJH8I9BXBat8MZ5fiZe67o32TTLZ/C76TaXEWfNtrskqkqqMcLFhQc54xXGWfwU15/B+laVfXrfNrNjc6jbC+PlG3hhaOZoiiKVeTcMg5J2Als0Aey6loXhVrqy0+/wBB02Z7m1+xQo2mrIn2eIiQQlthVI1IVlViBkDAyK1YdE0qDWZ9Xg0yxj1a4QRzXqQIJ5EG35WkA3EfKvBP8I9BXmHxL+GF3qmo6JJ4PhsbC3s9M1WylUOYsm4t3SEAAHIEkjsfTcSM1x7/AA18T+HvDV4t3ewHSIrrRLuTTopJZEuzBCsd5GwRCQJJNrZCtnYCQOwB9H0V51+z1p2paV8HPDlrrcE8F+EmkeOf74V5pHXd3B2spweR0OK9FoAKKKKACiiigAooooAz7bRNKtNGbSLXTLGHSWR4zZRwIsBR8718sDbg7jkY5yc9aqjwn4cFra2o0DSBbWqTR28X2OPZCkoIlVBtwocEhgPvZOc14/4X+E/iHStD8Upq8663qF/ayWqxz3pS3vWadpFuJdqb0kTOQdzHkgEYBEyfDDxXH4cnsLy+ttVvhrNnqF1eTXMitrVtGPmt5gd3lheMY3A7RwCSaAPWpfCfhyW6sLqXQNIe509I47OVrOMvbJGcosZ25QKeQBjHatDT9NsdO+0/2fZW1p9pma5n8iJY/NlbG6RsD5mOBljycV4/oPwmu5vGHh++8VRWl1pWneHxZfZFuZpUW6852Aw5JdFjkKgseoGAMDFvw78M9Wh+J+ua5r2oyXenXc128arONs9vMiILaaMpkqgHHz4GwYUZNAHW+H7nwTcaL4e1bQLHT304TSW+kzWmnHEDyMyyeWFTMQYqwZvlB7nmuyrwjQ/hFq2k+D/BekwLp632geJlv5rxJWU3Vp5jMzY28MR5Q2EkfuxzWFL8GvHDeHfEdj/a9s91eWSW3mm5cf2hONRNx9ql4+RhEdmPmPPXFAH0pRXFfCzw3qfhew1+y1KWJrSXWbq502KKQssFo5BjjAIG3B3HaOBmu1oAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArB8f6lc6P4D8SanYOEvLLTbm5hYqGCukTMpweDyBxW9UF9aW9/ZXFnewpPa3EbRSxSDKujDDKR3BBIoA+e7n4g/EHSfhjqfiudTLYtodlcQXF/BCjC9nlVGMKxcNEEk3DfzkLxgkV1njXxF4h8Lmx0uHxPaajc6l4h0/S/N+zxC6sIp1Jbeq/ISdhKkoOGPXgj1FtH059E/sd7K3bSvIFr9kKAx+UF2hNvTGOMVmx+DPDcWlXGmR6Hp66fcSrNLAIV2vIuNrEdyNq4PtQB5hp/jfW5vDmt3OreIlsYdC8R3ujvPBYpLeaiEwII40I2eYzPggJyFHT5jXp/gCXX5vBukyeMIoItfaEG7SH7obJxnHAbGNwHAbOOMVFceA/CtzYWllceH9NktLR3kt4mgUrE7nLMo7EnkmtvS9Os9JsIrLTbaO2tIs7Iolwq5JJwPqSfxoAtUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABUF9d29hZXF5ezJBa28bSyyyHCoijLMT2AAJqesHx/ptzrHgPxJplgge8vdNubaFSwUM7xMqjJ4HJHNAGvY3dvf2VveWUyT2txGssUsZyrowyrA9wQQanr5ssPhl47W+0tZ3vY7C3n0CF4odVaNFtYbTy71QquBy6p05OMjvVPUPh78Vr/wAO2yXN3fHVLfw+tpG0eq+X/pa6iWBO1wGP2U43HOehO6gD6fqlqeq2GlfZP7SvILX7XcJaW/muF82Z87Y1z1Y4OB7V4RrfgX4jXGnNYW+oXyaVBrupNDDDehrj7FJGBbOHMik7GMnyu+QWUkMFxVjxV8PvG1/8QdCurm5l1rTrHUtGuo7trhYlhjt1cXRaHIBkdyJMgHg4BHSgD3LT9Rs9R+0/YbmKf7NM1tNsbPlyLjch9xkUz+1bD+2v7I+2Qf2p9n+1/Zd48zyd23zNvXbu4z614bqvgz4gw+D9f0nTI5ZjceIL64s5JNUczwWhh22xRvMXgN1DMSOu1j00k8BeKz4x03xK0m3WrnwidMuLw3P/AB6amEGJmTO1oycjagI3Ddt70Ae20V5r8D/DXiPw7ol3/wAJVfX0txP5I+y3MiyiF0iCyOkgkckOcEgkcqSFG7FelUAFFFFABRRRQAVBfXdvYWVxeXsyQWtvG0ssshwqIoyzE9gACanrB8f6bc6x4D8SaZYIHvL3Tbm2hUsFDO8TKoyeByRzQBYk8SaLHZ6XdPqtmttqkiRWMhlG25d/uKh/iJ7Yq5p+o2eo/afsNzFP9mma2m2Nny5FxuQ+4yK8GT4JSadpfw7u9Mt7htX03UtMudQglvd0NoiLm6MKk4G+QKzAZyRxgVT1L4c/EB57qC2uNQFguoa7NbD+12BEUltGtgCd+4gSp0J45J6nIB9H1S0zVbDVftf9m3kF19kuHtLjynDeVMmN0bY6MMjI968N/wCEQ+JZ8TaRd3Vzczwz3uhX188d+qJCLeBo7yMpuGd7sHwgKt9eKY/w08W6Po3imw8OtLCbvxRHqgkjvSTeWB5MI3OGWRTyxLIXAxvNAH0FVLWdVsNE02bUdXvILKxh2+ZPO4REywUZJ6ZJA/GvHdU8GeMVsvCNtBc6rq8tjarDdNe3i28LB5lLeYYpRJ5kcY27x5gPBAzknsvjl4QuvHHwz1bRdM2/2i3lzWweQorOjhtpxwcgMBu4yQeMZAB3tFeK3nhPxzJ8SdM1GwnubXRY5tOkjWS+3LaWkcMq3VtIm4+ZI7MuHw3Y7hivaqACiiigAooooAKKKKAOd/4Tfwx/bX9kf27p/wDanm+T9l84eZv3bdu3rndx9a6KuC/4RzUv+F8f8JN5K/2P/wAI1/Zvm7xnz/tXmbdvXG3nPSvPf+ED+JH/AAsf+yf7dvv+Fa/bftGftK+b5OfO8jdu87G/91u3Z289OKAPf6pXeq2FpqVjp91eQRX1/wCZ9lgdwHm2LufaO+AcmvLfDvhfxza/F6fVb++lbRTe300khut0U9pJHCLWBYc/K0bKxLbRnB+Y552PH/gy61b4meAvE1nA1xBpE00d5GtyY2CSJ8kigsAQrZLAcsCBhgMUAej1m6lr2laZqFlY6hqFtb3l6222hkkAeU5A+Ud+WUfiK8y+D3hfxzonie8ufFl9LNaGyeK4Z7rzlvbs3crrPGuT5aiFlXbhOo+Xjix4h8C6zdfGHU/Eujt9lEvheWytb1rgkRX5chCY8n5QmDjaVyM43c0Aer0V896F4I+I9ppNtNNc3gFnq2k3v9nPqW+WdYYAl5iQsV2yudwRmx8h4GQDL8Ovht4vfWPDp8dXmqnTrLRpo7hI9XfEt4byZkD7H3MPJkU5z1VRnjFAHv8ARRRQAUUUUAFFFFAGLYeK9A1D+y/sOsWNx/avm/YfLmDfafKz5mz+9twc46VtV81+E/hN420nT/h+YblrbUNKtdZjl82eJ4tPlnjkWB0CjLAsys33sY7dK0NC8EfEe00m2mmubwCz1bSb3+zn1LfLOsMAS8xIWK7ZXO4IzY+Q8DIBAPoSivAPh18NvF76x4dPjq81U6dZaNNHcJHq74lvDeTMgfY+5h5MinOeqqM8YrsNC8P+I4fi1e6pcxXcmiSvPIJb295iO1EjWGOOQqyEBzh41IzksWHIB6Fd6rYWmpWOn3V5BFfX/mfZYHcB5ti7n2jvgHJq7XnHj/wZdat8TPAXiazga4g0iaaO8jW5MbBJE+SRQWAIVslgOWBAwwGKx/g94X8c6J4nvLnxZfSzWhsniuGe685b27N3K6zxrk+WohZV24TqPl44APUtT1Ww0r7J/aV5Ba/a7hLS381wvmzPnbGuerHBwParteG/EDwN4v1v4rafqaK17olvrGlX1qftapHZwQeZ9oUxkjc7MyuGAJxxkdKwvEXhX4m3I8czy3S6PZXWnyTRNFqLeUs8V4JVZGLl0DQBxnEa84KgAGgD6PorwDwrD4k8V/D7xRNAdbD3vi24urMRXKZ+yKyEIGaRQYdysmI3HPQ4zn1/wBZ6hYeDdJttagig1NIQbmKK4edVkJJYB3JY8n1IHQEgA0AdBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVh+OtUuND8EeIdWsghurDTri6iEgyu9ImZcjuMgVuVU1bT7XV9KvdN1CLzrK8he3nj3Fd8bqVYZBBGQTyCDQB5T4a+NdldeG7I6pYXX/CRPJplm1nCqgTz3sIkiZGLbVRhvPzMCNuDyRlLn4/eHItHGpRWGpT250dNYO1UBCm7FoY+WHzLIT7EDIJ4rrU+Fvg5IZ449H2eb9jPmLdTCRGtE2W7Rvv3Rsi8bkIJBOScmotS+EngfUdMstPuNBiS0tLX7FGlvPLBuh3iTZIY3UyDzFD/ADlvmy3UkkAZ4b+Iy+INZ8QWlj4e1c2eiXc9ldX21Chki3ZWNQ29ydo4UE/OucZrQ+HfjWDxvp017Z2UtrDHsGJJ4nbcy7trKjEowBXIbB+b61p6X4X0nSbXWLfTbeW1j1a6mvbwxXEiu80oAd1fduQnAxsIxjIxR4c8L6T4dkvpdLt5Rc3zrJdXNxcS3M8xVQq7pZWZyFAwBnAycAZNAG1RRRQAUUUUAFFFFABRRRQAUUUUAeM+GfjLHHr/AIj07xbCYIrXVNWgsrqCPKNDZIkjowBLbwjFs4APQc8VoaX8bdFvhYodN1GC6utR06wEDhCUF7CZYJSQxG0qDkA7hjkV0yfDXwiupm/OjRSXJury8bzZZJEaW7QR3BZGYqQ6qAVI2jsBUVr8LfB1rpUmnwaPtieaC4803UzXCSQKFhKTl/NTy1G1QrAKCwGAxyAc14e+Ndp4kvtGs9B8Naze3Wp2MmoIimFRFEk8sJLszgD5ovX+JR1OK6jS/HltqXjq98MQafcpPaOySSzSRx5CorF1jZhIyZdVDBSDnPTmrHhb4feGPCt5a3Wg6Z9kntrJtPib7RLJtgaYzMmGYg/vGLZPPOM44q1B4P0aLxGmvNBc3GqR+b5Mt3ez3C2/mkb/ACUkdlizgD5AvHHTigDoKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAP/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_41_2719=[""].join("\n");
var outline_f2_41_2719=null;
